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Abstract:
The synthesis of glycosylated small molecule compound libraries remains a difficult
challenge in the field of organic chemistry. Leading techniques are hindered by the requirement
of optimization based on substrate, and the generation of non-classical glycoside products. The
development of a platform which takes advanced glycoside intermediates and utilizes reactive
handles on the aglycone for rapid diversification to final products has been completed in this
research. Use of amino sugars, derived from known antibiotics, as the carbohydrate component
of final compounds was intended to exploit known binding interactions with biomacromolecules.
Final compounds indeed showed ability to inhibit bacterial protein synthesis in vitro and limit
growth in culture, suggesting binding interactions were retained.
Development of new generations of therapeutics based on current classes of antibiotics
remains a primary means of new drug discovery. The aminoglycoside family of antibiotics is no
exception to this, as current members of this class show promise of improved pharmacological
properties with diversification to their structures. Studies have been conducted but have not
addressed novel alkylation patterns on the amino sugar component of these compounds. In this
work we have shown the development of a synthetic methodology to access mono-, di-, and
mixed- alkyl kanosamine sugars. Elaboration to glycosides and subsequent diversification
efforts have led to the finding of novel bacterial protein synthesis inhibitors.
New catalytic methodologies can lead to powerful synthetic transformations which would
be inaccessible or of great difficulty otherwise. In particular, asymmetric hydrogenation
reactions, while simple in terms of chemical transformation, yield enantiomerically pure
compounds which are of great importance to drug discovery efforts. In this work, the use of
prochiral starting materials and an Iridium based catalytic system using bidentate chiral
phosphine ligands has been shown to yield a wide range of 2-substituted 1,4-benzodioxanes
with excellent enantioselectivities. Compound bearing this chemical motif are known to be
privileged structures in medicinal chemistry and have great potential for further development to
lead compounds.
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Chapter 1
Post Glycosylation Diversification

1

Disclaimer page
Cannone, Z.; Shaqra, A. M.; Lorenc, C.; Henowitz, L.; Keshipeddy, S.; Robinson, V. L.;
Zweifach, A.; Wright, D.; Peczuh, M. W. Post-Glycosylation Diversification (PGD): An Approach
for Assembling Collections of Glycosylated Small Molecules. ACS Comb. Sci. 2019, 21 (3),
192–197

My work on the above manuscript consists of the synthesis of PGD intermediates, including
sugar donors, and functionalized aglycones. My efforts also included the generation of glycosyl
libraries based on the para-bromobenzyl alcohol PGD intermediate. Further work focused on
the synthesis of fluorescent labeled probes, based on macrolide and lincosamide core
structures, for competitive binding experiments with our library compounds. Biological assays
and co transcription/translation assays were conducted by collaborating researchers. This work
is the basis for the following thesis chapter;
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1.1. Introduction to antibiotics
Antibiotics have revolutionized human health through the treatment and prevention of
bacterial infections. It is evident, particularly in recent years, that bacterial infections still remain
a major public health issue, however. Commercialization and routine administration of
antibiotics have led to diminishing efficacies, and the emergence of multi drug resistant (MDR)
strains of common bacteria.1 These factors have created an imminent crisis in our healthcare
system.2
Adding to the issue of drug resistance is the growing prevalence of nosocomial
infections in the U.S. and abroad. In the U.S. alone the CDC estimates there to be 1.7 million
hospital associated infections caused by microorganisms per year.47 Of those infections, nearly
100,000 directly cause or contribute to the death of patients. Aside from the obvious direct
impact on human mortality, the economic burden that has arisen due to MDR bacteria is
estimated at $20 billion per year.47 To address this looming problem, there exists a need for
developing novel antibiotic compounds that can operate by new mechanisms of action and or
possess compositions which are intrinsically impervious to bacterial resistance mechanisms.
Bacteria have been on earth for great lengths of time and owing to this fact is their innate
ability to protect themselves from environmental factors, as well as rapidly evolve in the
presence of external pressures.1 The first line of defense in the bacterial world, and a defining
characteristic of microorganisms, is the cell wall. Bacteria can be differentiated into two broad
categories; Gram-positive and Gram-negative. The former containing a cell wall composed of a
thick layer of polysaccharide, peptidoglycan, followed by an inner plasma membrane. The latter
containing a significantly thinner layer of peptidoglycan sandwiched between an inner plasma
membrane in addition to an outer membrane composed of lipopolysaccharide and proteins.3
Despite the thick polysaccharide membrane of Gram-positive bacteria, they tend to display
greater receptiveness to antibiotics due to the lack of the protective outer membrane found in
3

their Gram-negative counterparts. Despite differences in cell wall compositions, both types of
bacteria are known to develop drug resistance due to other means of defense. Common forms
of resistance mechanisms in bacteria include; reducing permeability and increasing efflux, direct
modification of the antibiotic compound, and mutation of the active/binding site of the antibiotic.1
Decreasing the uptake of antibiotic compounds to their intercellular target is a primary
defense mechanism for bacteria. Many compounds, particularly those that are hydrophilic, pass
the cell membranes and enter the cell through passage proteins known as porins.1,4 Numerous
types of porins have been described, and their effect on intercellular concentration of antibiotics
can be significant. Resistance due to porin proteins stems from changes in the levels of porin
expression, modification in the type of porins expressed, and impairment of porin function in the
presence of antibiotics.1 While important in its own right, porin related resistance is often
accompanied by increased expression of efflux proteins.1 Efflux pumps consist of several
families of proteins capable of actively extruding toxic compounds from the intercellular space of
bacteria. In conjunction with porin modification, this can knock the effective concentration of an
antibiotic to sub-therapeutic levels. A well-studied example of efflux mediated resistance is that
of macrolides. Macrolide efflux is mediated by genetic regions termed “MEGA-elements”,
Macrolide Efflux Genetic Assembly, as well as related regions of genetic information coding for
macrolide specific efflux pumps.5 Development of subsequent generation macrolides was
guided in part to circumvent rampant efflux of first and second-generation compounds of the
class; i.e. erythromycin, azithromycin, clarithromycin. Ketolide antibiotics, where the cladinose
sugar of the parent macrolide has been substituted for a ketone group and the formation of a
cyclic carbamate group added to the macrolide ring is the product of such studies (Figure 1.1).
Due to their structural modifications, these compounds are poor substrates for macrolide efflux
pumps.6

4

Figure 1.1. 1st generation macrolides to 3rd generation ketolide

Direct modification of an antibiotic is one of the most successful strategies employed by
bacteria to evade toxicity.1 As the mechanism of action for small molecules is defined by a
binding interaction at a cellular target, modification of the structure has profound and permanent
effect on its efficacy. Known modifying enzymes are numerous, and act to catalyze many
reactions including; acetylation, phosphorylation, adenylation, and hydrolysis.1 Perhaps the
most well-known example of this type of resistance mechanism is penicillin resistance. Penicillin
was groundbreaking after its serendipitous discovery and subsequent commercialization in the
early 1940s.7 However, bacteria were quick to develop resistance through the action of βlactamase enzymes which catalyzed the cleavage of the characteristic β-lactam ring of
penicillin. Penicillin resistant S. aureus infections became clinically relevant soon after
widespread introduction of penicillin to the general population.8 The mechanism underlying this
resistance was found to be a plasmid coding for the enzyme that was easily transmitted
between S. aureus strains. This drove the development of new generations of β-lactams, which
have all seen subsequent resistance develop due to evolution of β-lactamase enzymes.9
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Modification of the cellular target is another valuable adaptation bacteria employ to
protect themselves from antibiotics, and is one of the most common means of resistance.1
Modification of the target site is irrespective of the compound class and functionality of the
antibiotic and therefore is a broad and powerful way bacteria confer resistance. As in direct
modification of the antibiotic itself, modifying the cellular target acts to diminish binding affinity to
a sub therapeutic level. Changes to the cellular target can take place through actions such as
point mutations in genes encoding the cellular target, and alterations to the cellular target via
enzymes. Of particular importance is enzymatic methylation to the target site.1,10 A relevant
example of this includes enzymes encoded by the erm (erythromycin ribosomal methylation)
genes. These enzymes have the ability to mono or di-methylate key adenosine residues within
the bacterial ribosome.1,10 Specifically, modification of A2058, located in domain V of the
23rRNA of the 50S ribosomal subunit, confers a high degree of macrolide resistance. Moreover,
because of target site overlap between macrolides, lincosamides, and streptogramins, the
expression of erm genes, and A2058 methylation, results in broad resistance spanning multiple
classes of antibiotics.1,10
It is easy for one to see that there exists a critical need for the development of new
antibacterial compounds. However, this feat has been elusive due to a variety of factors, one of
which is the pharmaceutical industry’s aversion to using resources and starting campaigns to
develop new antibiotics. This aversion stems from the differing paradigm that exists between the
usage of antibiotics and that of other pharmaceuticals. The window of usage for antibiotics is
narrow, and over prescription diminishes the efficacy of the compound in the broad population.
More so, due to the current state of bacterial resistance that we face, many new and novel
antibacterial therapies are only prescribed as a last resort against MDR infections. This creates
a very poor economic environment for profiting off a new drug in an industry bogged by
astronomical costs of research and development, and commercialization though regulatory
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agencies. For these reasons, many well established companies have shied away from antibiotic
development in leu of developing compounds for other diseases which present a better return
on investment. Governmental agencies have taken note, and created incentives companies can
use to offset the economic downside of antibiotic development.11 However, it has become more
common for university labs, and small start ups to take on the early stage development of
antibiotic compounds.
1.2. Classes of antibiotics
All antibiotics have the common property of inhibiting the growth and/or killing bacteria.
How they do so is a defining characteristic of each class. Such mechanisms include inhibitions
of cell wall synthesis, DNA replication, protein synthesis, and critical enzymes.12 As previously
stated, the cell wall is the first line of defense for bacteria, and therefore a logical site of attack
for antibacterials. As bacteria grow and replicate, their cell walls are continuously being
maintained and recycled. This action requires the use of enzymes. In particular is the enzyme
transpeptidase. This enzyme is responsible for catalyzing the cross linking of peptidyl moieties
to adjacent glycan chains to form structurally active peptidoglycan which constitutes the cell
walls of both Gram-positive and Gram-negative bacteria.12 The β-lactam class of antibiotics,
penicillins, owe their activity to inhibition of this critical enzyme. By mimicking the structure of the
D-ala-D-ala terminus of the peptide chain, which is the natural substrate for transpeptidase, the
β-lactam forms a covalent and irreversible bond with the enzyme, thus rendering it inactive
(Figure 1.2).12 While cross linking of glycan chains is severely reduced, enzymes which
catalyze the hydrolysis of peptide linkers remain unphased in the presence of β-lactams. Under
these conditions, cell walls rapidly lose their stability and bacteria die as a consequence.
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Figure 1.2. Penicillin vs D-ala-D-ala structure

DNA replication is one of the most basic and important cellular functions for proliferation.
Not surprisingly, antibacterial compounds also target this core process. DNA, being the store of
a cell’s genetic information, is a densely packed and coiled structure within the cell when not
actively being transcribed. Accessing DNA for transcription is a highly complex process
requiring many events, one of which being the management of the coiling/supercoiling of DNA
strands. This is the main function of a class of enzymes, topoisomerases.12 In a rapidly
proliferating cell, such as bacteria and cancers, DNA is in a constant state of replication. In
such, the enzymes responsible for the underlying processes are highly expressed and present
themselves as key therapeutic targets. The quinolone and fluoroquinolone class of antibiotics
exploit this and act by targeting topoisomerase enzymes.13 With an affinity for bacterial
topoisomerase II and IV, quinolone-based antibiotics inhibit DNA translation and thus protein
synthesis downstream which ultimately leads to cell death. Topoisomerase II is also a major
target of chemotherapy drugs in human healthcare, ie. etoposide. Due to lack of conformational
conservation between bacterial and eukaryotic topoisomerase isoforms, quinolone-based
antibiotics are able to treat bacterial infections while leaving eukaryotic cells unaffected.13
While topoisomerase inhibitors indirectly cause protein synthesis to cease, other classes
of antibiotics take a direct approach to protein synthesis inhibition as their mechanism of action.
Just as the homology of topoisomerase enzymes are not conserved from bacteria to eukaryotic
cells, that too is the homology of the ribosome.14 The ribosome is the essential molecular
machinery responsible to translating mRNA, transcribed from DNA, to newly formed proteins.
This process is vital to cells viability and a continuous process in both bacteria and eukaryotic
8

cells. Such a major cellular process is the target of a number of antibiotics. Among the antibiotic
classes that target the ribosome are the tetracyclines, chloramphenicols, aminoglycosides,
oxazolidinones, and macrolides.12 Protein synthesis at the ribosome is a highly complex process
and can be halted at many steps, and specific mechanisms differ between various classes of
antibiotics. For example, oxazolidinones act by blocking the formation of the initiation complex
between the 50S and 30S ribosomal subunits.15
Tetracylclines owe their activity to blockage of the A site on the assembled 70S
ribosome, which prevents aminoacyl tRNAs from binding.16 Peptidyl transfer at the PTC is
blocked by chloramphenicols as well as macrolides, preventing new addition to the growing
peptide.17 Aminoglycosides interfere with the proofreading step of protein synthesis, and cause
a higher degree of error in synthesis as well as premature termination which leads to inactive
proteins.18 Aside from blockage of peptidyl transfer, macrolides also bind within the exit tunnel of
the 70S ribosome.19 Binding at this site hinders the exit of nascent peptides as they are being
synthesized and causes a blockage at the PTC. Recent studies have shown that macrolide
blockage of the exit tunnel is not absolute, but instead is selective based on the sequence of the
nascent peptide.20
Mankin and researchers have shown that depending on the peptide sequence, it has the
ability to circumvent the bound macrolide and proceed down the exit tunnel.20 This work shows
that macrolides alter the proteome of the bacteria rather than cease all protein synthesis.
Further work by the Mankin lab has shown that in the presence of saturating concentrations of
macrolides, up to 40% of cellular proteins continue to be produced.21 Altering the proteome has
the consequence of downstream effects in numerous biochemical pathways, as well as buildup
of toxic intermediates, which ultimately results in cell death.21
1.3. Carbohydrate library synthesis:
The mechanisms of action vary greatly across the differing classes of antibiotics.
However, the discovery and development of these compounds have common difficulties. When
9

discovering and developing a drug, it is often necessary to generate a large library of
compounds from which to screen for activity and identify a lead compound.22 Adding to this
challenge is that many antibiotic compounds contain carbohydrate moieties.
Carbohydrates play integral roles in biological systems and are responsible for
processes such as cell-cell recognition, adhesion, cell signaling, target recognition, and immune
response.23 Owning to the broad range of abilities carbohydrates confer is their ability to tune
physiochemical properties and the unique binding properties associate with their structures
which mediate interactions with their targets.23 Nature has made use of these properties
extensively. In fact, the addition of a carbohydrate group is one of the most prevalent post
transcriptional modifications made to lipids and proteins.24 Small molecule natural products are
very often modified with the addition of a carbohydrate group as well. Highlighting how
carbohydrates mediate physiochemical properties of small molecules are the macrolide class of
antibiotics. As mentioned previously, some members of the macrolide family contain a cladinose
sugar attached to the macrolactone ring that acts as a handle, through binding interactions, for
efflux pumps.5 Removal of this handle, as in third-generation macrolides, alleviates efflux issues
by making the molecule a poor binder to the efflux pumps.25 Illustrative of nature’s use of
carbohydrates in the macrolide antibiotic world is that of methymycin. Produced by the bacteria
Streptomyces venezuelae, the macrolide is synthesized with a glucose group glycosylated to
the 2’ hydroxyl of the macrolactones desosamine residue.26 In this state, the molecule is
biologically inactive as an antibiotic. Concurrent with excretion from the cell a hydrolase enzyme
catalyzes the cleavage of glucose, thus freeing the desosamine residue and revealing the active
form of the antibacterial compound.26
Methymycin, along with all other macrolide compounds owe their activity, in part, to the
desosamine sugar attached to their macrolactone rings. The desosamine sugar acts to “anchor”
the macrolides to their binding site through two key interactions.27,28 Firstly, there is a hydrogen
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bonding interaction between the 2’ hydroxyl and neighboring adenine residues within the
ribosome.27 In addition, a strong binding interaction is added via electrostatic interaction
between the negatively charged phosphate of the rRNA and the positively charged 3’ nitrogen,
which is protonated at physiological pH.27,28 The importance of this desosamine moiety is
highlighted by the conservation of its bound conformation within the ribosome between all
known macrolide-ribosome crystal structures.
Examples of carbohydrate’s ability to change biological properties of small molecules
and macromolecules alike, and nature’s implementation of them, are numerous. For the
reasons mentioned, glycosylated compound library synthesis has been an area of extensive
research in drug discovery efforts. Methods for the synthesis of such libraries include
glycorandomization, neo-glycorandomization, as well as classical total synthesis efforts among
others.
Leading the innovation in the field of glycosylated library synthesis has been the Thorson
group at the University of Kentucky. Two complementary approaches have been developed in
this group. One of which is an enzymatic process coined, glycorandomization.29 In this process,
natural or engineered enzymes are used for their substrate promiscuity to enact chemical
modification to a carbohydrate library. The enzymes involved in this process are; anomeric
kinases, nucleotidyltransferases, and glycosyltransferases.29 Anomeric kinases and
nucelotidyltransferases act sequentially on the carbohydrates to yield nucleotide
diphosphosugar (NDP-sugar) donor libraries. Subsequently, in the same pot, the
glycosyltransferases then couple activated donor sugars with various aglycones to give the final
desired glycosylated sugar compounds.29 This process relies heavily on the ability of the
enzymes to accept a range of sugar libraries as substrates, and then enact the final
glycosylation. Unsurprisingly, these requirements make for glycorandomization to be a
notoriously difficult process to carry out and often require optimization based on the substrates
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being used. Representing one of the best examples of glycorandomization in practice is that of
the Thorson group, where they implemented a glycorandomization strategy to synthesize 21
novel vancomycin monoglycoside derivatives (Scheme 1.1).30
Scheme 1.1. Glycorandomization of vancomycin aglycone30

An analogous chemoselective process has also been reported by the Thorson group. In
this methodology, termed neo-glycorandomization, unprotected reducing sugars act as donors
in reaction with secondary alkoxyamines.31 Proceeding through an oxy-iminium intermediate, a
subsequent ring closing step yields the corresponding neoglycosides. While
neoglycorandomization presents itself as a powerful glycodiversification strategy, it has
drawbacks in that it produces neoglycosides rather than classical linked glycosides. Further, the
requirement for secondary alkoxyamines in this reaction is crucial, as primary alkoxyamines are
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shown to give solely the open chain oximines through deprotonation of the transient iminium
intermediate (Scheme 1.2).32
Scheme 1.2. Neo-glycorandomization

While platforms exist that incorporate carbohydrates onto small molecule compound
libraries, the brute force approach of total synthesis is not lost in drug discovery efforts. In a
recent undertaking by the Myers group, a total synthetic approach was taken to synthesize
novel macrolide derivatives.33 By a convergent synthesis starting with simple building blocks, a
platform for the synthesis of 14 and 15 membered macrolides containing the amino sugar
desosamine was devised.
Making use of eight “building-block” reagents (I-VIII), most of which are commercially
available, the group was able to assemble 14-, and 15- membered synthetic macrolides with
tunable functionality by choice of building blocks employed. Impressively, both 14, and 15
membered compounds are shown to be synthesized in about 30% yield in 10 synthetic steps
(Scheme 1.3).33
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Scheme 1.3. “Building block” strategy for macrolide total synthesis33

Using the synthesis platform, over 300 fully synthetic macrolides were produced and
evaluated for antibacterial activity through MIC assays with standardized Gram-negative and
Gram-positive strains. Results from theses assays showed that a majority of the compounds
displayed antibiotic activity. The most promising compounds in initial MIC testing were then
tested against bacteria with genetically characterized resistance mechanisms to macrolides,
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including clinically isolated MDR stains of Staphylococcus aureus, Streptococcus pneumoniae,
and Enterococcus faecalis. From these assays a number of compounds were identified as
clinically promising. Most notably, two fully synthetic 14-membered ketolides displayed superior
MIC values relative to any macrolide in current clinical use against bacteria stains containing
ribosome-modifying methyltransferase (ermB), efflux (mefA), and constitutively-expressed
erythromycin ribosome methyltransferase (c-erm) genes. In addition, one of these ketolides
displayed improved activity against Gram-negative strains relative to most other macrolides.
Displaying MICs ranging from 0.03-16µg/ml-1 against these various strains the synthetic
compounds are promising leads for future generations of macrolide antibiotics, and promising
as elusive Gram-negative treatments, however further work is needed to lower MICs to a
clinically viable level.33
1.4. Fluorescent probes used in drug discovery
Aiding in the process of drug discovery is the use of fluorescent labeled probes.
Evaluation of a compounds ability to bind a target can be a challenging, yet necessary, task. In
recent years the advent of high through put assays utilizing fluorescence polarization anisotropy
techniques has lowered the barrier of determining such properties.34 Fluorescence anisotropy is
the phenomenon where light, emitted by a fluorophore, has unequal intensities along different
axes of polarization. This property of light emission can be harnessed to gain insight on
molecular level interactions between small molecules and various biological targets. In practice,
a sample containing a fluorophore is excited with polarized light and the subsequent emission
from the sample is measured for the degree of polarization/anisotropy. The small molecule
fluorophore, while unbound to a macromolecule, is in a constant fast tumbling state. The light
emission from this fluorophore is thus depolarized relative to the excitation source and is said to
have low anisotropy. Conversely, when the small molecule is bound to a macromolecule, such
as a protein, the tumbling of the fluorophore in solution is slowed. In this situation the
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polarization of light emission is conserved and is therefore in a higher state of anisotropy
(Figure 1.3).
Figure 1.3. Anisotropy

The result of being able to quantitatively measure anisotropy of a ligand allows to
compare binding interactions with a desired target. For example, competitive binding
experiments where a potential drug like compound competes with a fluorophore tagged probe
can give the apparent Kd of your potential compound to the target in competition with competitor
compound.35
Recent drug discovery efforts have utilized such properties by tagging know antibiotic
compounds with fluorophores.36,37 In one such effort, a team of researchers at Vernalis, a
pharmaceutical research company in the UK, synthesized a series of three lincomycin derived
fluorescent probes.37 Due to lincomycins binding site at the peptidyl transferase center (PTC) of
the ribosome these probes were made so as to identify novel compounds binding to the PTC
through competitive binding assays. Of the three probes made, two bore a TAMRA type
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fluorophore and one a BODIPY type fluorophore. The series was made via coupling of a
common lincomycin-amine intermediate with an NHS ester of the desired fluorophore
compound.
When modifying or adding on to a compound the binding properties will likely change.
However, in order for fluorescent labeled probes to be useful as tools for competitive binding
assays they must retain their original binding motif. To validate the lincomycin probes they had
made, binding assays were conducted using increasing amounts of test compound in 10 nM
probe solutions containing 2 µm S. carnosus or S. aureus ribosomes in buffer. For each
concentration of test compound, a fluorescent anisotropy measurement was taken using
excitation wavelength of 535 nm and emission wavelength of 580 nm. Compounds binding to
the PTC will thus interfere with binding of TAMRA-lincosamide or BODIPY-lincosamide and
cause a change in anisotropy. Using know PTC binders as positive controls (chloroamphenicol,
erythromycin, lincomycin,clindamycin) and know non-PTC binders as negative controls
(paromoycin and streptomycin), the assays showed strong evidence of competitive binding
selectively at the PTC (Figure 1.4).37
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Figure 1.4. BODIPY-, and TAMRA-lincosamide derivatives and their anisotropy studies37

Similar work in this field has been conducted by Ma and coworkers, where a series of
three BODIPY-erythromycin based fluorescent probes (IX,X,XI) were designed and
synthesized.36 The series of compounds varied the placement of the fluorophore at either the 4’
or 9’-positions of the erythromycin structure (Figure 1.5).
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Figure 1.5. BODIPY-erythromycin derivatives and their ribosome binding affinities36

Evaluation of the probes included a determination of their binding affinities to the 70 S E.
coli ribosome. Kds varied from 0.5 nM, 1.5 nM, and 30 nM for probes IX, X, and XI respectively.
Only probes with appropriate binding affinities and kinetics are useful in competitive binding
assays. Probes with high affinity allow for greater resolution and require less assay reagents,
but result in slower displacement and signal intensity.36 Due to this, probe IX demonstrated the
best binding affinity but competitive binding required up to two days incubation. Probe XI also
showed strong binding and kinetics that required overnight incubation. In contrast, probe X, with
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moderate binding (30 nM) required just 1-hour incubation time for full ligand exchange. With the
proper kinetics, probe X was successfully applied to an ultra-high throughput screen to identify a
series of novel ribosome binding ligands that competitively or allosterically displace the probe.36
1.5. Project design
Our project aims to develop a platform in which libraries of glycosylated small molecules
can be synthesized rapidly, and ideally without the need for protecting group manipulations. We
wish to guide the design of these compounds so that they will be candidates for protein
synthesis inhibition. Using knowledge of macrolide binding motifs, in particular erythromycinribosome crystal structure data, the amino sugar desosamine will be a central component of our
compounds. As previously mentioned, desosamine forms strong interactions within the
ribosome and “anchors” the macrolide to its binding site (Figure 1.6).27,28

Figure 1.6. Erythromycin bound to E. coli ribosome28

*Figure reproduced for use in this thesis with permission of publisher (Elsevier)

Aside from its anchoring effects, the sugar itself, with both polar and basic groups, plays
an important role in membrane permeability as well. Using desosamine as the sugar moiety we
then aim to attach various aglycones. The aglycones will be functionalized with reactive groups,
such as amine, azide or aryl bromide, that can be manipulated to give a series of derivatives
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(Scheme 1.4). The variation on the aglycone through diversification will affect binding
interactions within the ribosome. Evaluation of binding affinity will therefore give a structure
activity relationship (SAR) for the series of compounds made.
Scheme 1.4. Post Glycosylation Diversification (PGD)

Key to our project design is the ability to furnish libraries of glycosylated small molecules
from a common carbohydrate starting material. We term this method of carbohydrate library
synthesis, post glycosylation diversification (PGD). The classical approach to forming a novel
glycoside would be to functionalize an aglycone and then perform a glycosylation with a donor
sugar. This approach requires a late stage glycosylation to deliver candidate compounds and
introduces some challenging issues such as optimizing conditions, addressing anomeric
configuration of products, and subsequent protecting group manipulations. One can think of this
approach as “diversify then glycosylate”. With PGD, the use of an advanced intermediate
glycoside with reactive aglycone flips this narrative to “glycosylate then diversify” and allows for
much simpler and faster assembly of a library of derivatives. With this method, one can screen
an initial library, and guided by the assay results, make minor structural changes to compounds
that show activity in hopes of further optimization. Iterations of compounds based on SAR data
in this fashion can be powerful in identifying potential lead compounds.
Evaluation of our compounds for biological activity will be central to our efforts. To do so
we envision using an in vitro co transcription translation assay to evaluate levels of protein
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synthesis in the presence of our compounds. Using a commercially available assay system from
New England Biolabs we will be able to quantitatively measure protein synthesis based on the
production of EmGFP.39 In this system, E. coli ribosomes are incubated with DNA vector
containing the emGFP gene. Fluorescence of the system is then measured and compared to
the fluorescence from a control with no inhibitor compound present. The ratio of fluorescent
values is then used to determine percentage of protein synthesis inhibition in each experiment.
Complimentary to the transcription/translation assay will be a competitive binding assay.
Results from the in vitro transcription assay will tell us whether protein synthesis is being
inhibited but will not confirm the binding site of the inhibitory compounds. By design, we
hypothesize that our compounds will bind to the ribosome.36,37 Utilizing desosamine, we hope
the conserved nature of the sugars binding in the ribosome exit tunnel is maintained. To
investigate whether this is the case we will synthesize fluorescent labeled probes known to bind
to the ribosome at the exit tunnel and the peptidyl transferase center (PTC). Using these probes
in competitive binding assays with our inhibitory compounds we will monitor the fluorescence
anisotropy of the system to confirm binding at the specified sites.
1.6. Results and discussion
Our first step in forming PGD compounds was isolation of desosamine itself. As we had
a readily available supply of erythromycin, hydrolysis of this natural product became the source
of our sugar (Scheme 1.5). Treatment of erythromycin with ethanolic 6 M HCL followed by
workup and recrystallization gave desosamine as its hydrochloride salt (1.1) in 50% yield.
Formation of glycosyl donor from this point was done using well established procedures.40,41
Desosamine was converted to pyrimidyl glycoside (1.2) via a Mitsonobu reaction with
mercaptopyrimidine. Protection of the C2 hydroxyl group as the methyl carbamate followed and
gave compound 1.3 in 49% yield over the two-step sequence.
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Scheme 1.5. Synthesis of thioglycoside donor from erythromycin40,41

Following the formation of glycosyl donor 1.3, proof of concept glycosylations were
performed using simple alkyl alcohols to determine reactivity and selectivity (Table 1.1). Using a
known glycosylation procedure using silver triflate as a thioglycoside activator, products (1.41.7) were prepared in satisfactory yields following carbamate deprotection.42 To our delight,
glycosylation reactions proceeded selectively to give the β glycosides. This finding simplified
subsequent synthetic steps, and is consistent with a neighboring group participation effect by
the C2 carbamate.
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Table 1.1. Proof of concept alkyl and macrolide glycosylations

Following successful glycosylations with alkyl acceptors, we then attempted to use
macrolide acceptors, previously synthesized in our lab, to form synthetic desosamine containing
macrolides. Under the same silver triflate activating conditions, synthetic macrolides 1.8 and 1.9
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were formed in decent yield. Anomeric selectivity was mostly conserved, varying only slightly in
the case of 1.9.
In an attempt to reveal whether these compounds were of promise as bacterial
inhibitors, minimum inhibitory concentration (MIC) assays we performed against various strains
of s. aureus, k. pneumoniae, and e. coli. MIC values were determined to be >100µg/ml for s.
aureus and >200µg/ml for k. pneumoniae and e. coli. While these values are far from clinically
viable, they suggest the synthetic desosamine compounds do possess a certain degree of
activity and that desosamine may be acting in the same “anchoring” fashion as it does with
nature macrolides.
Having proof of concept, our aim then became to generate a series of glycosides with
reactive handles that could be used to generate libraries. To this end, we sought to incorporate
azide, amine, and aryl bromide functional groups. Glycosylations of donor 1.3 with acceptors,
amino ethanol, m-bromobenzyl, and p-bromobenzyl were conducted using silver triflate as
activator. After glycosylation, carbamate deprotection was accomplished by solvolysis in
methanol-water to yield PDG intermediates 1.10-1.12. In addition, amino ethyl glycoside 1.12
was converted to the azido ethyl PGD intermediate 1.13 by reduction over Pd/C. Yields for the
glycosylation/deprotection sequences are summarized in Scheme 1.6. We saw these
intermediates as valuable in terms of diversification through cycloaddition,
acylation/sulfonylation, and Pd coupling reactions.
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Scheme 1.6. Glycosylation to PGD intermediates

We began our diversification efforts on azidoethyl and aminoethyl precursors. Azidoethyl
PGD precursor 1.12 was diversified via simple cycloaddition click reactions using
different alkynes. Using established procedures, we coupled 1.12 to substituted alkynes in the
presence of Cu(II) and catalytic ascorbic acid in aqueous alcohol.43 Use of aromatic containing
phenyl acetylene gave triazole 1.14. In addition, propyargylic biphenyl compounds gave rise to
biphenyl derivatives 1.15 and 1.16.
Amide and sulfonamide analogues were also prepared from aminoethyl glycoside 1.13
via acylation reactions. Use of an amino ethyl PDG intermediate was guided by simple access
to this compound from the azido intermediate and was thought to be a simple means of
generating structurally diverse library compounds. Treatment of the amines with acid chlorides
in the presence of a base gave rise to amide products 1.17-1.19, in varying yields. Sulfonamide
1.20 was prepared from amine 1.13 with phenylsulfonyl chloride in a similar manner (Table 1.2).
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Table 1.2. Desosamine PGD cycloaddition derivatives
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Table 1.3. Desosamine PGD aminoethyl derivatives

Compounds 1.14-1.20 were then tested for MICs against S. aureus, S. pyogene, C.
glabrata, K. pneumoniae, P. aeruginosa, E. coli, B. subtilus, C. albicans, B. anthracis, E.
faecalis, and B. cereus. With results less than satisfying, all of the compounds returned MIC
values >500 µM. While troublesome, it was speculated that the polar nature of these
compounds was disfavored for the desired inhibitory properties we aimed for.
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Palladium coupling had presented itself as an attractive means of diversification from the
outset. By allowing for the incorporation of heteroaromatic and aromatic functionality, they are a
prominent transformation in medicinal chemistry efforts. After identifying a general set of
conditions,44 in which PGD intermediate (1.10 or 1.11) is reacted with boronic acid in the
presence of Cs2CO3 and Pd(Cl)2(PPh3)3 in a dioxane/water mixture at elevated temperature, a
series of meta substituted compounds 1.21-1.26 were first synthesized (Table 1.4).
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Table 1.4. Desosamine PGD palladium coupling meta derivatives

Meta-substituted compounds were then evaluated for MIC activity. Results for the MIC
assays are summarized in Table 1.5. As can be seen, the activities for this series is drastically
enhanced across the spectrum when compared to the previous series. In particular, compounds
1.21 and 1.23 showed highly promising activity against s. aureus 29213, with MICs of 50 µg/ml
and 25 µg/ml, respectively.
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Table 1.5. MIC data to meta PGD derivatives (µM)

The promising MIC results for this series of compounds, combined with the less than
impressive results for the previous two series (amide/sulfonimide/cycloaddions) suggested that
nonpolar functionality was favored as a diversification to the aglycone of our PGD intermediates.
This result is proposed to be due to hydrophobic and/or pi stacking type interactions with the
region of the ribosome where our compounds are binding. These findings led us to expand our
Pd coupling efforts and generate a para-substituted series of compounds. Using PGD
intermediate 1.11, with bromo functionality, under the same Pd coupling conditions, compounds
1.27-1.32 were synthesized in varying yields (Table 1.6).
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Table 1.6. Desosamine PGD palladium coupling para derivatives
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Table 1.7. MIC data for para PGD derivatives (µM)

As can be seen (Table 1.7), MIC values were once again promising for the Pd coupling
products with para-substitution pattern. Combined with previous data, it became clear that the
best performing compounds bore a mesityl group off of the aglycone. The reason for the mesityl
functionalities activity was unknown, but we aimed to exploit this by further derivation of the
compounds. One line of thought was to install a hydroxy group on the aglycone, which would
act to mimic the C13 hydroxyl of erythromycin and hopefully participate in hydrogen bonding
interactions with the ribosome. Synthesis of this compound required an aglycone which had the
required functionality for yielding the free hydroxyl post glycosylation. To this end, the synthesis
of glycosyl acceptor 1.37 commenced from isophthalic acid (Scheme 1.7).
Treatment with NBS in concentrated sulfuric acid yielded the meta bromo derivative 1.33
in excellent yield. Conversion to the bis methyl ester 1.34 proceeded in high yield with methanol
and acid catalyst. Selective mono reduction using one equivalent of reducing agent gave the
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hydroxymethyl intermediate 1.35 in good yield. Hydroxyl protection with TBSCl followed by
reduction of the remaining ester yielded the glycosyl acceptor 1.37 in 44% yield from isophthalic
acid over five synthetic steps.
Scheme 1.7. Synthesis of hydroxymethyl acceptor

Also, of interest to us was the variation of the linker length between the carbohydrate
and the aglycone functionality. We envisioned a series of compounds, derived from phenol, and
phenethyl alcohol acceptors, which would yield valuable SAR data along with the hydroxymethyl
analog (Scheme 1.8). Glycosylations took place in like fashion to the previous series and were
followed by carbamate deprotection. Pd coupling with mesityl boronic acid then yielded the
mesityl derivatives 1.38-1.40 in varying yields.
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Scheme 1.8. Synthesis of modified aglycon mesityl derivatives

MIC assays were then conducted for the series of mesityl compounds against various
bacteria strains (Table 1.8). Results for the newly synthesized compounds (1.38-1.40) closely
matched that of the parent compound 1.23. However, phenethyl compound 1.39 displayed
improved activity against certain strains. These findings suggested that the added flexibility
afforded by the extra methylene group linking carbohydrate to aglycone allowed for improved
binding contacts within the ribosome.
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Table 1.8. MIC data for modified aglycone mesityl derivatives (µM)

With promising MIC results, it was our hope to utilize a complimentary in vitro
transcription/translation assay in an effort to quantify the level of protein synthesis inhibition. The
PURExpress cell free system from New England Biolabs presented itself as an ideal test for our
compounds. In this system, fluorescence of nascent EmGFP would be measured in the
presence of inhibitory compound and compared to that of control experiments in the absence of
inhibitor (negative control) and in the presence of known inhibitor (positive control). Compounds
were assayed at a concentration of 25 µg/ml, and the best results for the series of desosamine
compounds are shown in Figure 1.7. Pyrimidyl compound 1.24 demonstrated inhibition of
EmGFP signal by about 35% relative to negative control. Best results were found with
compound 1.40, the hydroxy methyl derivative of parent compound 1.23, where signal reduction
of around 70% was observed. Erythromycin, used as a positive control at 1µg/ml, reduced the
fluorescence signal by 99% suggesting close to complete inhibition of protein synthesis.

36

Figure 1.7. Co-transcription/translation assay results

Results in MIC and translation inhibition assays suggested that our compounds
displayed antibiotic activity, and it was our hypothesis from the onset that the compounds were
acting via binding interactions with the bacterial ribosome. Efforts then turned to target
confirmation in an attempt to validate this proposed mechanism. By use of fluorescent labeled
probes which bind to the bacterial ribosome, we aimed to conduct competitive binding studies
with our series of compounds. With the requirement that the labeled compound retain binding to
the desired binding site, as well as maintain a certain Kd such that it could be competitively
unbound, it became obvious that a novel compound for these studies would require too much
effort in addition to synthetic operations. For these reasons, we began a synthesis of known
compounds which had been shown to work in competitive binding studies to identify ribosome
binding compounds.
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First in our efforts was the synthesis of an erythromycin-based probe tagged with a
BODIPY fluorophore. Synthesis began in similar manner to known BODIPY erythromycin
compound, with the formation of erythromycin oxime 1.41 via reaction of hydroxylamine with
erythromycin (Scheme 1.9).36 Initial attempts to reduce the oxime to an imine intermediate, as
had been previously reported, were met with much difficulty. Eventually, we found conditions
that allowed the formation of erythromylamine 1.42 in a single step from the oxime. This
reaction proceeded in modest yield but afforded adequate product for fluorescent tagging.
Coupling of the amine with an NHS ester of a BODIPY fluorophore provided the erythromycinBODIPY compound 1.43 in 72% yield.
Scheme 1.9. Synthesis of erythromycin-BODIPY probe
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It was our understanding that the novel desosamine compounds we had synthesized
may not have retained absolute fidelity of macrolide binding site in the ribosome. Due to this, we
envisioned the synthesis of a complementary probe based on the lincosamide antibiotic,
clindamycin. Initially we proposed tagging the lincosamide with a BODIPY fluorophore coupled
to the proline moiety. This sequence began with the hydrazinolysis of clindamycin to yield the
free amine intermediate 1.44. Difficulties with this transformation were very extensive, and led to
the formation of an unreported clindamycin derivative (1.45) resulting from hydrazine insertion to
the carbonyl followed by and E2 elimination of the chlorine atom (Scheme 1.10).
Scheme 1.10. Initially proposed lincosamide probe and E2 elimination product

Synthesis of the free amine was eventually realized by use of lincomycin starting
material, however, subsequent amide coupling presented new challenges. For these reasons,

39

and for simplicity, we resorted to the synthesis of a known clindamycin-BODIPY compound.37
Synthesis of this compound commenced with nucleophilic substitution of the chlorine with
sodium azide (scheme 1.11). Acetylation the gave the peracetyl intermediate 1.47 in good yield.
Staudinger reduction then gave the amine 1.48 in 79% yield. Zemplén conditions provided the
deprotected sugar which then underwent amide coupling with NHS ester BODIPY compound to
give the desired clindamycin-BODIPY compound 1.50 in 85% isolated yield.
Scheme 1.11. Synthesis of lincosamide-BODIPY probe
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Efforts to use these probes in competitive binding studies were conducted via
collaboration. Experiments are being conducted to optimize assay conditions and results are
expected to be reported due time.
1.7. Conclusion
The goal of this project was to develop method to access glycosylated small molecule
compound libraries. To do so, we looked at how these libraries are currently being assembled
and devised a platform which flipped the conventional synthetic ideology. By changing the
established “diversify then glycosylate” strategy to a more streamlined “glycosylate then
diversify” route we have shown that they synthesis of small molecule glycosides is possible in a
fashion which allows quick diversification of a core motif to final compounds. Showcasing this
methodology, we utilized the amino sugar desosamine, found on naturally occurring antibiotics,
to generate a moderate sized library of compounds which displayed retained antibiotic activity.
By design, the compounds were assembled in such a way that provided initial SAR data which
allowed for subsequent improvement of lead compounds.
Envisioned to compliment this study was the use of fluorescence polarization assays to
confirm binding sites. Use of desosamine was theorized to allow for binding of the subsequent
glycosides at the natural binding site of the ribosome for the sugar. While activity was observed
for various glycosides, confirmation of the binding site, and perhaps further structural data for
this interaction, would greatly aid in optimization efforts.
As a general synthetic platform for glycoside libraries, it would be logical to extend the
methodology to other sugars beyond desosamine. By exploiting other known sugar binding
interactions, novel bioactive glycosides may be identified using the PGD platform.
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1.8. Experimental

Compound 1.2: In flame dried glassware under N2 atmosphere, DIAD (3.31 mL, 0.0168 mmol)
was added dropwise to a solution of Bu3P (4.15 mL, 0.0168 mmol) in toluene (75 mL) at -30 oC.
The resulting solution was stirred for 20 mins while maintaining temperature. A solution of
desosamine in 75 mL toluene was added in one portion to the reaction. The mixture was stirred
at -30 oC for 45 min. Solid 2-mercaptopyridine (1.87 g, 0.0168 mmol) was added and cooling
bath removed. The reaction was allowed to stir at rt for 16hrs. The reaction was filtered through
a pad of celite and concentrated in vacu to yield a thick yellow syrup which was purified by
chromatography (90:10:1, DCM,MeOH,TEA) to yield a crude product containing
tributylphosphine oxide. The crude product was dissolved in 90 ml EtOAc and extracted with 2
M HCl (4 x 10 ml). The HCl solution was made basic (pH 12) with 6 M NaOH and the resulting
aqueous solution was saturated with NaCl (s) and extracted with EtOAc (4 x 20 mL). The
organic fractions were washed with brine (25 mL), dried over Na2SO4, and concentrated to give
the desired crude compound. Chromatography (90:10:1, DCM:MeOH:TEA) gave the pure
product (788 mg, 21%); 1H NMR (400MHz, CDCl3) δ ppm 8.39 (d, J = 4.5Hz, 1H), 7.51 (dt, J =
1.4/7.9 Hz, 1H), 7.28 (d, J = 7.9 Hz, 1H), 7.02 (dd, J = 5.1/6.7 Hz, 1H), 5.34 (d, J = 9.6 Hz, 1H),
3.72 (m, 1H), 3.57 (t, J =9.7 Hz, 1H), 3.07 (q, J = 7.6/15.1 Hz, 1H), 2.86 (m, 1H), 2.46 (s, 6H),
1.96 (dd, J = 1.8/13.0 Hz, 1H), 1.40 (dd, J = 12.0/23.5 Hz, 1H), 1.25 (d, J = 6.1 Hz, 3H); 13C
NMR (100MHz, CDCl3) δ ppm 157.2, 149.5, 136.4, 123.3, 120.4, 85.4, 73.9, 68.9, 67.4, 45.9,
40.4, 29.4, 21.6, 8.9; LRMS (ESI+) m/z calcd. for C12H19N3O2S [M+H]+ 269.12, found 269.3
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Compound 1.3: Desosamine thioglycoside (750 mg, 2.79 mmol) was dissolved in THF (15 mL)
and saturated NaHCO3 aq. (15 mL). Methyl chloroformate (0.276 mL, 3.35 mmol) was added
dropwise and the reaction mixture stirred at rt 1hr. Upon completion by TLC, the reaction was
diluted with EtOAc (60 mL) and the aqueous fraction extracted with EtOAc (3 x 10 mL). The
combined organic layers were pooled and washed with brine, dried over Na2SO4, and
concentrated to give a crude oil which was purified by chromatography (90:10:1
DCM:MeOH:TEA) to give 580 mg (64%) of the desired product as a thick yellow oil; 1H NMR
(400Mhz, CDCl3) δ ppm 8.34 (d, J = 4.5 Hz, 1H), 7.43 (dt, J = 2.1/7.9/9.5 Hz, 1H), 7.13 (d, J =
7.9 Hz, 1H), 6.94 (qd, J =0.9/4.7/5.7 Hz, 1H), 5.55 (d, J = 10.1 Hz, 1H), 4.75 (t, J = 10.1 Hz,
1H), 3.69 (s, 3H), 2.86 (m, 1H), 2.25 (s, 6H), 1.80 (qd, J = 1.4/4.2/5.8 Hz, 1H), 1.41 (q, J =
12.3/24.2 Hz, 1H), 1.20 (d, J = 6.1 Hz, 3H); 13C (100Mhz, CDCl3) δ ppm 156.7, 155.1, 149.4,
136.3, 122.9, 120.3, 82.9, 73.5, 72.7, 64.7, 54.9, 40.7, 31.2, 21.3; LRMS (ESI+) m/z calcd. for
C14H21N3O4S [M+H]+ 327.12, found 327.2
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GP1: Representative procedure for the desosamine glycosylation reactions
A representative procedure is given for the synthesis of desosamine glycosides: Compound 1.11
protected: AgOTf (0.055 g, 0.212 mmol, 3.0 eq.) was added to a suspension of 4Å molecular
sieves (0.150 g) in dry DCM (1 mL) at 0 °C in darkness (wrapping with aluminum foil). A solution
of desosamine donor 1.3 (0.023 g, 0.071 mmol, 1.0 eq.) and p-bromobenzyl alcohol (0.141 mmol,
2.0 eq.) in dry DCM (1 mL) were then added to the AgOTf solution. The mixture was stirred for 2
h at 0 °C and then quenched by the addition of saturated NaHCO3 (0.5 mL). The reaction mixture
was then diluted with EtOAc (10 mL) and filtered through a pad of celite; the filter cake was
washed with additional EtOAc (1 x 5 mL). The filtrate was then washed with water (1 x 5 mL) and
brine (1 x 5 mL). The organic layer was dried over Na2SO4, and then concentrated in-vacuo and
the residue was purified by flash-chromatography to give compound 1.11 protected (71%) as a
light yellow oil.

Rf 0.5 (75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 7.42 (d, J= 9.1 Hz, 2H), 7.17
(d, J = 9.1 Hz, 2H), 4.82 (d, J = 12.1 Hz, 1H), 4.67 (dd, J= 7.6/10.6 Hz, 1H), 4.54 (d, J= 12.5 Hz,
1H), 4.40 (d, J = 7.6 Hz, 1H), 3.76 (s, 3H), 3.54 (sep, J = 7.2/12.5/17.5 Hz, 1H), 2.76 (td, J =
3.8/11.4/15.2 Hz, 1H), 2.29 (s, 6H), 1.77 (dd, J = 3.0/12.5 H, 1H), 1.27 (d, J = 6.0, 3H) ); 13C
NMR (100MHz, CDCl3) δ ppm 136.7, 131.4, 129.1, 121.4, 101.2, 74.9, 69.6, 69.4, 62.9, 54.9,
40.6, 30.7, 21.0; HRMS (DART-TOF) m/z calcd. for C17H24BrNO5 [M+H]+ 402.0908, found
402.0886.
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GP2: Representative procedure for carbamate deprotection
A representative procedure is given for the synthesis of carbamate deprotected desosamine
glycosides: Compound 1.11: Desosamine glycoside 1.11 protected (~0.120 mmol) was taken
up in MeOH (8 mL) and solid K2CO3 (0.0005 g, 0.004 mmol, 5%) was then added. The mixture
was stirred overnight at rt and after it was concentrated in-vacuo. The residue was purified by
flash chromatography to give the product.

Title compound 1.11 was prepared according to GP2 in 92% yield as a light-yellow oil. Rf 0.45
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 7.45 (d, 2H), 7.29 (d, 2H), 4.87 (d,
1H), 4.64 (d, 1H), 4.34 (d, 1H), 3.55 (m, 1H), 3.34 (dd, 1H), 2.53 (td, 1H), 2.29 (s, 6H), 1.71 (dq,
1H), 1.28 (d, 3H); 13C NMR (100MHz, CDCl3) δ ppm 136.8, 131.4, 129.6, 121.6, 103.1, 69.9,
69.8, 69.6, 65.6, 40.3, 28., 21.3; HRMS (DART-TOF) m/z calcd. for C15H22NO3Br [M+H]+
344.0856, found 344.0868.
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Compound 1.40 protected was prepared according to GP1 in 76% yield as a yellow oil. Rf 0.55
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 7.36 (s, 1H), 7.22 (s, 1H), 7.14 (s,
1H), 4.85 (d, J = 12.4 Hz, 1H), 4.57 (d, J = 12.4 Hz, 1H), 4.62-4.76 (8H, m), 4.41 (d, J = 8.4 Hz,
1H), 3.82 (s, 3H), 3.56 (m, 1H), 2.79 (dt, J = 4.1/7.7/14.7, 1H), 2.30 (s, 6H), 1.78 (dd, J = 2.2/7.0
Hz, 1H), 1.41, (q, J= 11.9/23.6 Hz, 1H), 1.30 (d, J= 5.9 Hz, 3H), 0.95 (s, 9H), 0.11 (s, 9H);

13

C

NMR (100MHz, CDCl3) δ ppm 170.9, 155.6, 143.8, 138.6, 130.3, 129.8, 125.2, 102.1, 101.5,
75.1, 65.5, 64.4, 63.1, 55.1, 40.9, 26.2, 21.3, 21.2.
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Compound 1.40 was prepared according to GP2 in 82% isolated yield as a light-yellow oil. Rf
0.29 (75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 7.47 (s, 1H), 7.42 (s, 1H), 7.34
(s, 1H), 4.87 (d, J = 12.3 Hz, 1H), 4.65 – 4.60 (m, 3H), 4.33 (d, J = 7.3 Hz, 1H), 3.59 – 3.52 (m,
1H), 3.33 (dd, J = 7.4/10.4 Hz, 1H), 2.51 (ddd, J = 3.9/10.4/14.2 Hz, 1H), 2.27 (s, 6H), 1.69 (ddd,
J = 1.8/3.6/12.8 Hz, 1H), 1.30 – 1.25 (m, 4H);

C NMR (100MHz, CDCl3) δ ppm 143.5, 140.5,

13

130.0, 129.2, 124.9, 122.7, 103.4, 70.1, 70.0, 69.7, 65.6, 64.6, 40.5, 28.8, 21.5; HRMS (DARTTOF) m/z calcd. for C16H24NO4Br [M+H]+ 374.0967, found 374.0948.
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GP3: Representative procedure for Suzuki couple of desosamine glycosides
A representative procedure is given for the synthesis of Suzuki derivatized desosamine
glycosides: Compound 1.27: Starting material 1.11 (29.2 mg, 0.0848mmol) along with phenyl
boronic acid (20.68 mg, 0.1696mmol), Cs2CO3 (82.89 mg, 0.2544mmol), and PdCl2(PPh3)2
(11.9 mg, 0.017 mmol) was purged under high vacuum and flushed with nitrogen. 2.8 mL
Dioxane/H2O was added (2:1, 0.03M) and mixture stirred at rt under nitrogen for 15 min. The
reaction was then heated to 80 oC and followed by TLC. Once complete (4 Hr) the reaction was
quenched with saturate bicarbonate solution and extracted with EtOAc (3 x 2 mL). The organic
fractions were pooled and washed with brine, dried over Na2SO4 and concentrated. The crude
material was purified by chromatography (70:25:5, EA:Hex:TEA) to yield 1.27 (13 mg, 45%)

Rf 0.30 (75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 7.60 (q, J = 5.5/7.12 Hz, 4H),
7.51 (d, J = 8.1 Hz, 2H), 7.45 (t, J = 7.4 Hz, 2H), 7.36 (t, J = 6.6 Hz, 1H), 4.99 (d, J = 12.4 Hz,
1H), 4.76 (d, J = 12.4 Hz, 1H), 4.41 (d, J = 7.5 Hz, 1H), 3.60 (m, 1H), 3.40 (dd, J = 7.2/10.2 Hz,
1H), 2.57 (m, 1H), 2.32 (s, 6H), 1.73 (m, 1H), 1.33 (d, J = 5.7 Hz, 3H); 13C NMR (100MHz, CDCl3)
δ ppm 141.0, 140.6, 136.7, 128.8, 128.5, 127.2, 127.1, 127.1, 103.0, 70.2, 70.1, 69.7, 65.4, 40.4,
28.8, 21.3; HRMS (DART-TOF) m/z calcd. for C21H27O3N [M+H]+ 342.2058, found 342.2062.
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Compound 1.28 was prepared according to GP3 in 52% yield as a light-yellow oil. Rf 0.50
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 7.47 (d, J = 7.7 Hz, 2H), 7.13 (d, J
= 7.7 Hz, 2H), 6.95 (s, 2H), 5.01 (d, J = 11.6 Hz, 1H), 4.74 (d, J = 11.6 Hz, 1H), 4.46 (d, J = 7.4
Hz, 1H), 3.62 (m, 1H), 3.41 (m, 1H), 2.61 (m, 1H), 2.33 (s, 9H), 2.01 (s, 6H), 1.75 (m, 1H), 1.33
(d, J= 5.9 Hz, 3H);

13

C NMR (100MHz, CDCl3) δ ppm 136.0, 132.2, 132.0, 129.3, 128.6, 128.1,

128.0, 103.5, 90.7, 70.0, 69.8, 65.4, 40.4, 28.9, 21.4, 21.0, 20.8; HRMS (DART-TOF) m/z calcd.
for C24H33O3N [M+H]+ 384.2528, found 384.2497.
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Compound 1.29 was prepared according to GP3 in 41% yield as a light-yellow oil. Rf 0.20
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 8.86 (s, 1H), 8.60 (s, 1H), 7.89 (d, J
= 8.3 Hz, 1H), 7.56 (q, J = 8.3/13.5 Hz, 4H), 7.37 (q, J = 4.4 Hz, 7.21, 1H), 5.00 (d, J = 12.3 Hz,
1H), 4.76 (d, J = 12.3 Hz, 1H), 4.41 (d, J = 7.2 Hz, 1H), 3.60 (m, 1H), 2.57 (m, 1H), 2.32 (s, 6H),
1.74 (m, 1H), 1.33 (d, J = 6.2 Hz, 3H);

C NMR (100MHz, CDCl3) δ ppm 148.4, 148.3, 137.8,

13

137.1, 134.3, 128.7, 127.2, 123.6, 103.1, 70.0, 70.0, 69.8, 65.4, 40.4, 29.7, 28.8, 21.3; HRMS
(DART-TOF) m/z calcd. for C20H26O3N2 [M+H]+ 343.2011, found 343.1958.
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Compound 1.30 was prepared according to GP3 in 55% yield as a light-yellow oil. Rf 0.18
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 8.67 (m, 2H), 7.64 (d, J= 7.8 Hz,
2H), 7.56 (d, J = 7.8 Hz, 2H), 7.52 (d, J = 5.4 Hz, 2H), 5.01 (d, J = 12.4 Hz, 1H), 4.77 (d, J = 12.4
Hz, 1H), 4.42 (d, J = 7.4 Hz, 1H), 3.61 (m, 1H), 3.39 (dd, J = 6.8/9.9 Hz, 1H), 2.56 (m, 1H), 2.32
(s, 6H), 1.73 (m, 1H), 1.33 (d, J = 7.8 Hz, 3H);

C NMR (100MHz, CDCl3) δ ppm 150.2, 138.9,

13

137.4, 128.7, 127.1, 121.6, 121.7, 103.3, 70.0, 69.8, 65.4, 40.4, 29.7, 28.7, 21.4; HRMS (DARTTOF) m/z calcd. for C20H26O3N2 [M+H]+ 343.2011, found 343.1958.
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Compound 1.31 was prepared according to GP3 in 42% yield as a light-yellow oil. Rf 0.30
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 7.52 (d, J= 8.3 Hz, 2H), 7.47 (d, J=
8.3 Hz, 1H), 7.31 (d, J= 8.3 Hz, 1H), 7.24 (d, 8.3 Hz, 2H), 4.99 (d, J= 11.4 Hz, 1H), 4.89 (d, J =
11.4 Hz, 0.4H), 4.73 (d, J = 11.4 Hz, 1H), 4.65 (d, J = 11.4 Hz, 0.4H), 4.43 (d, J = 7.4 Hz, 1H),
4.35 (d, J = 7.4 Hz, 0.4H), 3.6 (m, 1.6H), 3.37 (m, 1.8H), 2.56 (m, 1.6H), 2.41 (s, 3H), 2.31 (s,
6H), 2.28 (s, 3H), 1.74 (m, 2H), 1.33 (m, 10H);

C NMR (100MHz, CDCl3) δ ppm 137.2, 131.5,

13

129.8, 119.6, 129.1, 128.4, 103.4, 103.1, 70.3, 70.0, 69.9, 69.8, 69.6, 65.4, 40.3, 29.7, 28.7, 21.4,
11.6, 10.9, 1.0; HRMS (DART-TOF) m/z calcd. for C20H28N2O4 [M+H]+ 361.2116, found 361.2102.
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Compound 1.32 was prepared according to GP3 in 37% yield as a light-yellow oil. Rf 0.25
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400 MHz, CDCl3) δ ppm 7.6-7.4 (m, 8H), 7.1 (d, 2H), 5.45 (t,
1H), 4.93 (d, 1H), 4.64 (d, 1H), 4.39 (d, 1H), 3.92 (dt, 1H), 3.5-3.7 (m, 3H), 2.63 (m, 1H), 2.34 (s,
6H), 2.05 (m, 2H), 1.5-1.8 (m, 2H), 1.1-1.5 (m, 4H);

C NMR (100MHz, CDCl3) δ ppm 141.0,

13

140.6, 136.7, 128.8, 128.5, 127.2, 127.1, 127.1, 103.0, 96.3, 70.2, 70.1, 69.7, 65.4, 62.0, 40.4,
30.4, 28.8, 25.2, 21.3, 18.8; HRMS (DART-TOF) m/z calcd. for C26H35NO5 [M+H]+ 442.2515,
found 442.2604.
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Compound 1.40 was prepared according to GP3 in 45% yield as a light yellow oil. Rf 0.46
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 7.45 (s, 1H), 7.05 (s, 2H), 6.92 (s,
2H), 4.97 (d, J = 12.0 Hz, 1H), 4.73 – 4.67 (m, 3H), 4.39 (d, J = 7.3 Hz, 1H), 3.62 – 3.54 (m, 1H),
3.41 (dd, J = 7.3/10.2 Hz, 1H), 2.72 (ddd, J = 4.0/10.3/14.1 Hz, 1H), 2.40 (s, 6H), 2.32 (s, 3H),
1.99 (s, 3H), 1.98 (s, 3H), 1.82 (ddd, J = 2.0/3.912.9 Hz, 1H), 1.37 – 1.31 (m, 1H); 1.29 (d, J = 6.2
Hz, 3H); 13C NMR (100MHz, CDCl3) δ ppm 141.6, 138.8, 138.3, 126.8, 36.1, 136.0, 128.2, 127.5,
124.9, 103.1, 70.8, 70.2, 69.7, 65.5, 40.5, 29.8, 21.4, 21.2, 21.0; HRMS (DART-TOF) m/z calcd.
for C25H35NO4 [M+H]+ 414.2644, found 414.2640.
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Compound 1.43: Compound 1.42 (8.6 mg, 0.01 mmol) and BODIPY-NHS ester (5 mg, 0.012
mmol) were dissolved in THF (0.5 mL, dry). The reaction stirred at rt overnight while shielded from
light. Upon completion, the THF was distilled off and the residue purified by column
chromatography (0-10% MeOH:CH2Cl2) to yield title compound 1.43 (4.5 mg, 72%) as a red solid;
H (400Mhz, CD3OD): δ ppm 7.43 (s, 1H), 6.99 (d, J = 4.6 Hz, 1H), 6.36 (d, J = 3.8 Hz, 1H), 6.23

1

(s, 1H), 5.50 (s, 1H), 5.08 (b.s., 1H), 4.97 (dd, J = 2.9/10.1 Hz, 1H), 4.05-4.16 (multiple peaks,
2H), 3.97 (b.s., 1H), 3.75 (m, 8H), 3.61 (dd, J = 3.5/9.8 Hz, 1H), 3.56 (b.s., 1H), 3.35-3.40 (multiple
peaks, 7H), 3.25 (t, J = 7.3 Hz, 3H), 3.02-3.11 (multiple peaks, 3H), 2.86 (s, 2H), 2.52-2.65
(multiple peaks, 20H), 2.30 (s, 5H), 1.89 (m, 13H), 1.58-1.68 (m, 3H), 1.19-1.33 (multiple peaks,
26H), 1.09-1.19 (multiple peaks, 13H), 1.02 (d, J = 6.7 Hz, 4H), 0.85-0.94 (multiple peaks, 6H);
C NMR (100Mhz, CD3OD) δ ppm 172.8, 159.9, 157.0, 144.4, 135.1, 133.6, 132.3, 131.7, 131.6,

13

128.6, 128.5, 128.1, 126.5, 124.3, 119.9, 116.5, 88.3, 77.5, 75.1, 73.0, 10.0, 69.3, 69.2, 67.7,
67.3, 66.3, 64.3, 57.7, 40.7, 35.6, 35.4, 34.3, 32.0, 29.6, 24.3, 21.3, 20.2, 20.0, 18.2, 17.7, 15.9,
11.9, 10.1, 9.8, 7.8, 1.4; HRMS (DART-TOF) m/z calcd. for C51H83BF2N4O13 [M+H]+ 1009.60521,
found 1009.60529
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Compound 1.50: Compound 1.49 (3.7mg, 0.01 mmol) and BODIPY TMR-X succinimide ester
(5 mg, 0.0082 mmol) were dissolved in DMF (0.55 mL, dry) and Et3N (1.9 mg, 0.019 mmol) was
added. The reaction stirred at rt overnight while shielded from light. Upon completion, the DMF
was distilled off and the residue purified by column chromatography (0-10% MeOH:CHCl3) to
yield title compound 1.50 (6.9mg, 85%) as a purple solid; 1H NMR (400Mhz, CDCl3) δ ppm 8.07
(d, J = 8.9 Hz, 1H), 7.77 (d, J = 8.3 Hz, 2H), 7.19 (s, 2H), 7.01 (s, 1H), 6.85-6.92 (multiple
peaks, 3H), 6.45 (d, J = 4.2 Hz, 1H), 6.05 (t, J = 4.87 Hz, 1H), 5.72 (d, J = 7.5 Hz, 1H), 5.195.24 (multiple peaks, 3H), 4.30 (quint., J = 7.6/14.2 Hz, 1H), 4.10 (t, J = 9.15 Hz, 1H), 4.02 (dd,
J = 5.3/10.0 Hz, 1H), 3.72-3.80 (multiple peaks, 4H), 3.63 (d, J = 2.6 Hz, 1H), 3.39-3.46
(multiple peaks, 2H), 3.00-3.21 (multiple peaks, 3H), 2.89 (dd, J = 4.0/10.7 Hz, 1H), 2.59-2.77
(multiple peaks, 3H), 2.45 (s, 3H), 2.32 (s, 3H), 2.16-2.27 (multiple peaks, 3H), 2.13 (s, 3H),
2.10 (s, 3H), 1.70-2.06 (multiple peaks, 10H), 1.28-1.61 (multiple peaks, 8H), 1.12-1.26 (multiple
peaks, 10H), 1.07 (d, J = 6.69 Hz, 4H), 0.77-0.85 (multiple peaks, 6H); 13C (100Mhz, CDCl3) δ
ppm 177.0, 173.6, 172.0, 160.8, 159.9, 140.5, 135.3, 134.8, 131.0, 128.2, 125.8, 123.1, 118.6,
114.1, 89.2, 72.0, 71.4, 69.5, 69.0, 68.9, 63.2, 55.7, 53.2, 46.7, 42.4, 39.6, 38.3, 38.0, 36.6,
36.3, 36.0, 30.0, 29.4, 26.6, 25.5, 21.9, 20.5, 16.8, 14.9, 16.6, 9.9; HRMS (DART-TOF) m/z
calcd. for C45H65BF2N6O8 [M+H]+ 899.4725, found 899.4513.
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Chapter 2
A Versatile Method for the Preparation of Alkylated Kanosamine Sugars
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2.1. Introduction to amines
Amine groups are ubiquitous in biology and biologically active compounds.1 This
versatile chemical group is found in neurotransmitters, alkaloids, and proteins, as well as many
other classes of compounds. Owning to natures broad use of amines are the advantageous
properties which they confer. In proteins, amines are typically in a protonated, ammonium, state.
This facilitates many processes such as the binding to anionic DNA fragments by DNA binding
proteins.2 Ammonium groups also form salt bridges with other chemical groups, including
carboxylate groups, which aid in protein function.3
Properties of amines on small molecules offer similar effects. Basic amine groups can
become protonated and positively charged. The ionic nature of such compounds allows for the
formation of salts, which can not only aid in synthetic efforts, but also allows solubility in
aqueous solution.1 Amines on small molecules also participate in hydrogen bonding
interactions, as well as electrostatic interactions. The effect of these interactions is crucial for
many binding events which confer biological activity to the compounds. Therefore, it is not
surprising that amines are highly prevalent in pharmaceutical compounds and discovery efforts
for such compounds.
2.2. Synthetic utility of amines
As a synthetic handle, the reactivity of amines is broad. They can be used to form
amides with activated carboxylic acids, imines with carbonyl compounds, as reagents in
multicomponent reactions, transformed to nitroso groups by oxidation, or to biorthogonal azide
groups among many other transformations. An illustrative example of amine reactivity in the
field of drug discovery is that of azithromycin.
Erythromycin, the first 14-membered macrolide, has been in clinical use since the early
1950s. Improvement upon this naturally derived compound via semisynthesis and isolation of
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other natural macrolides led to the clinical application of spiramycin, roxithromycin,
dirithromycin, and clarithromycin, which all exhibit improved pharmacological properties.4
Expansion upon the 14 membered macrocylic ring, and insertion of a basic nitrogen, to yield a
15 membered macrolide, azithromycin, was a breakthrough in the field of antibiotics in the
1980s.4
Synthesis of this blockbuster drug commenced with the reaction of erythromycin with
hydroxyl amine, forming the erythromycin oxime intermediate (XII, Scheme 2.1). Following this
initial step is a key Beckmann rearrangement reaction. This reaction is characterized by the
migration of an alkyl group which positions the nitrogen in the macrolide ring and leads to the
formation of an imino-ether intermediate XIII. Hydrogenation cleaves this ether functionality and
yields the free amine intermediate (not shown). Following is the final step in the synthesis, a
mono alkylation of the free amine, via reductive amination, to the N-methyl compound,
azithromycin.
Scheme 2.1. Azithromycin semisynthesis form erythromycin
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Key to the activity of azithromycin is the simple final step of amine methylation. This is
but one case showing how alkylation of amines is a powerful diversification strategy and can
potentiate biological activity of the compound drastically. Perhaps one of the best examples of
amine alkylation modulating biological activity is that of the neurotransmitter serotonin (XIV).
Serotonin is amongst the most well-known neurotransmitters in popular culture and plays a role
in numerous physiological processes including cognition, memory, learning, and emotional
states.5
Nature has made use of an amine methylation strategy to diversify this integral
neurotransmitter to its dimethyl analog, psilocin (XV, Figure 2.1). Psilocin, and its
phosphorylated counterpart psilocybin (XVI), are the active components of psychedelic
mushrooms, whose use is documented as far back as an estimated 10,000 years.7 Exhibiting
effects similar to that of notorious psychedelics DMT (XVII) and LSD (XVIII), these compounds
are theorized to have had significant implications in the development of human culture.6
Both psilocin and psilocybin were first isolated, and named, by Swiss chemist Albert Hofmann,
famous for the discovery of LSD. Hofmann was later successful in devising synthetic routes to
these chemicals.8
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Figure 2.1. Serotonin dimethylation and its psychedelic analogs

With the power to influence activity in such drastic fashion, methodologies for the
alkylation of amines has seen a great deal of effort in their development over the years. One of
the simplest techniques used for alkylation of amines is the nucleophilic reaction of an alkyl
halide with an amine or ammonia (Scheme 2.2).9 Problematic in these reactions is that the
primary and/or secondary amine product can in turn react with the alkyl halide producing
unwanted higher order products.9 For this reason, this method is mostly used in the synthesis of
tertiary amines. Furthermore, in industrial applications, amines are generally alkylated using
alcohols as the alkylating agent, as the use of alkyl halides is not advantageous on scale.
Scheme 2.2: Alkylation with alkyl halides

Reactions of amines with aryl halides, nucleophilic aryl substitution, are very sluggish
and require activated aryl rings in the cases where they do succeed. In such cases, Pd
catalyzed reactions, such as Buckwald-Hartwig coupling, are best (Scheme 2.3).9,10
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Scheme 2.3. Aryl amines via Buckwald-Hartwig coupling

Reductive amination, as in previously mentioned synthesis of azithromycin, converts a
carbonyl to an alkyl amine through an imine intermediate. The Escweiler-Clark reaction, and
analogous reactions with borohydride reducing agents, are powerful and robust methods of
forming amines by reduction processes.11 Limiting the utility, however, is that these reactions
typically give rise to tertiary amines as products.9 In the case of azithromycin, this was desired,
but this is not always the case. When one desires a mono alkylated amine, the procedures are
limited as N-alkylation tends to be an unselective synthetic operation.
Techniques developed for mono alkylation include the Delepine reaction, and the
Gabriel synthesis (Scheme 2.4). The previous being a reaction between benzyl or alkyl halides
with the commercially available reagent, hexamethylenetetramine XIX. This reaction produces a
quaternary ammonium salt XX which is then subjected to acidic conditions to liberate the
primary amine XXI.9,12
The latter process again invokes the use of alkyl halides, this time in reaction with a
phthalimide salt XXII. The intermediate N-alkyl phthalimide XXIII, is then treated with hydrazine
which facilitates a hydrazinolysis to give the primary amine and phthalhydrazide.9,13
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Scheme 2.4. Techniques for the mono alkylation of amines

2.3. Aminoglycosides
As stated, amines are ubiquitous in biology and biologically relevant molecules, and
amine containing compounds are prevalent in pharmaceutical compounds. Highly illustrative of
this are the aminoglycoside (AG) class of antibiotics. The AGs are a family of related
compounds which display Gram-negative antibacterial activities.14 Characteristic to this class,
they contain amino modified sugars in their structure as well as a deoxystreptamine ring bearing
two primary amines. However, the first in class clinical compound for this class, streptomycin,
lacks the deoxystreptomine ring in place of a furanose ring (Figure 2.2).
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Figure 2.2. Representative compounds of the aminoglycoside family of antibiotics

In clinical practice, AG antibiotics, which had not been considered an option for some
time, have seen a resurgence in their utilization given the emergence of infections caused by
MDR bacteria (See chapter one for more on MDR). Clinical use has been hindered by common
side effects such as nephro- and ototoxicity.15 While AGs remain active against many clinical
isolates of MDR bacteria, their toxicity limits their utility. The observed retention of activity gives
promise that these compounds hold potential for new generations with improved
pharmacodynamic properties to alleviate such issues. A member of the AG class, and a target
of research in our lab, which has been given new life in light of resistant bacteria are the
kanamycins (Figure 2.3).

71

Figure 2.3. Structures of Kanamycin A and B

2.4. Mechanism of action
AGs, including Kanamycins A and B, are a potent class of antibiotics that act via protein
synthesis inhibition. This mechanism of action requires binding to the ribosome as the key factor
to their potency. Just as the structures of AGs vary, so too do the specifics of their binding
interactions. In general, AGs derive their activity by interacting with 16s rRNA of the decoding Asite of the bacterial ribosome. Crystal structures of various AGs in complex with oligonucleotides
mimicking the A-site topology show that AG binding enforces that A1492 and A1493 take up a
“bulged-out” conformation that leads to a loss in translational fidelity (Figure 2.4).16,18
Additionally, the neamine (rings A and B) portion of the AGs are conserved in their binding
orientation over the class of compounds. Other carbohydrate rings of AGs are found to be less
ordered in their binding orientations, yet still confer much needed interactions. Due to their
polycationic nature, AGs also owe much of their binding properties to electrostatic interactions
which are in part derived from these rings structures (C, D, E, etc..).17,18
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Figure 2.4. Aminoglycoside binding to 16s rRNA18

*Figure reproduced for use in this thesis with permission of publisher (Portland Press)

2.5. Resistance mechanisms and diversification efforts
Resistance mechanisms to AGs are predominantly due to aminoglycoside modifying
enzymes (AMEs).19 This is in contrast to primary resistance mechanisms to other classes of
antibiotics, such as the macrolides, where ribosomal base mutation and methylation dominate
resistance. AMEs act on the AGs and facilitate acetylation, phosphorylation, or nucleotide
addition to their structure. These modifications irreversibly render the compounds inactive
against the bacteria (Figure 2.5).
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Figure 2.5. Sites of modification by AMEs on kanamycin B19

*Figure reproduced for use in this thesis with permission of publisher (Future Science)

Based on these molecular level understanding of resistance and binding, many studies
have been conducted to develop derivatives of the kanamycins.
Analysis of crystal structure data lead a team of researchers to identify the C4’ position
of ring A of the neamine moiety to be a position which would benefit from chemical
modification.20 Efforts to do so by direct modification of Kanamycin B were unsuccessful and the
researchers were forced to take a glycosylation approach to access the desired compounds. In
their route, they first disconnected ring A from kanamycin B to yield a glycosyl acceptor
containing rings B and C. Protecting group modification and epimerization led to a thioglycoside
glycosyl donor based on Ring A which now bore a protected C4- amino group. NIS activated
glycosylation conditions gave rise to a protected C4-amino Kanamycin intermediate.
Subsequent modification and deprotection steps yielded a small series of C-4-amine/amide
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derivative of kanamycin B (Table 2.1). Compounds were then subjected to MIC assays against
standard and resistant strains of Gram-positive and Gram-negative bacteria, with kanamycin A
and B as controls. Remarkably, antibiotic activity was retained across the series, showing at
times even better activity than the parent compounds themselves. Of note, is that compounds
XXVI and XXIX displayed enhanced activity against strains with known resistance mechanisms.
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Table 2.1. C4-modified kanamycin derivatives and their MIC activity20

In a different approach, a series of conformationally constrained Kanamycin A
derivatives were studied by the Li research group.21 By bridging the C2’-OH of the neamine ring
(A) with the 5’-OH of the central deoxystreptamine ring (B) constrained rotation between the two
rings was achieved (Table 2.2). The methodology resulted in the formation of 8-, 9-, 10-, and
11-membered ethers of Kanamycin A. This modification has the ability limit conformational
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freedom and pre-configure the molecule for binding to the rRNA target. Also, of advantage is
that these sites would be masked from deactivation by AMEs. MIC activity for the series was
found to vary with the length of the chain linking the two rings, though no analog performed
better than Kanamycin A itself.
Table 2.2. Conformationally constrained kanamycin derivatives and their MIC activity

In addition to the Neamine core (rings A and B), the Kanamycins bear a 3-deoxy-3amino glucose unit (kanosamine, ring C in Figure 2.3) that aides in recognition via electrostatic
and hydrogen bonding interactions.17 This ring is integral to binding with the ribosome, and a
site of acetylation by AMEs.4 Modification of this motif was the central aspect of work employing
a glycodiversification approach by Chang and coworkers.22 A library of Kanamycin B derivatives
varying the placement and number of the amino groups on the C ring were synthesized utilizing
a neamine glycosyl acceptor and a modified C ring thioglycoside donor sugar. Activation using
NIS and TfOH gave glycoside products with varying anomeric selectivity and modest yields.
77

Subsequent deprotections gave final products (XXXV-L) which were then evaluated by MIC
assays against standard e. coli and s. aureus strains (Table 2.3). No compound in the series
performed better than kanamycin B itself, however activity was retained in most cases. Results
also reinforced the placement of the amino group at the natural C3 position.
Table 2.3. Kanosamine modified kanamycin derivatives and their MIC activity22

The examples given show that the kanamycins are applicable to broad diversification
strategies, where their antibacterial activity is retained and/or improved. Drawing from the
observed conservation of binding confirmation of the neamine core, and the preferred natural 3amino confirmation of the kanosamine sugar we began to wonder if alkyl modification to this
functional group could yield positive results. While several studies on AG derivatives have been
78

conducted, a study using N-alkylated kanosamines has yet to be reported. Here we present a
methodology for accessing various N-alkyl kanosamine derivatives, including mono, di-, and
mixed compounds, and attempts at their incorporation into kanamycin B analogs
2.6. Project design
In the course of our PGD studies we became interested in changing the sugar itself,
which led us to the synthesis of alkylated kanosamines. Kanosamine analogs were attractive
targets because of their additional functionality relative to desosamine. We envisioned starting
with N,N-dimethyl kanosamine, whose structure formally adds a hydroxyl group at C6 relative to
desosamine ( as well as C4 hydroxyl). The C6 hydroxyl group could ultimately be an additional
site of diversification (Figure 2.6).
Figure 2.6. Proposed C6 acetylation of PGD compounds

Initial synthesis of the N,N-dimethyl analog led us to believe that we could improve upon
our synthetic route as well as access other alkylation patterns on the amine. Herein, we
describe our efforts at optimizing the synthesis of the N,N-dimethyl analog and subsequent
reaction scope studies to access novel mono-, di-, and mixed alkyl derivatives of kanosamine.
2.7. Results and discussion
In our efforts to synthesize the N,N-dimethyl compound we recognized the utility of known
triflate 2.2, itself obtained from the epimerized product of 2.1, as a useful intermediate. Treatment
of 2.2 with an excess of dimethylamine in a pressure vessel, followed by acid catalyzed acetonide
deprotection, gave dimethyl kanosamine 2.4 in 96% yield over two steps (Scheme 2.5).
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Optimization of the amine equivalents, triflate concentration, and volume of the pressure vessel
were all required to obtain this yield. The challenges encountered when using other amine
partners required a different route if additional analogs were to be obtained. We turned, therefore,
to a reductive amination approach in place of triflate displacement. Reductive amination using 2.6
as the amine presented itself as a robust and facile method. Synthesis of 2.6 followed a previously
established synthetic route to kanosamine.23
Scheme 2.5. Synthesis of dimethyl kanosamine through key triflate intermediate

*a, b, c, d: See experimental for conditions

Epimerization of diacetone D-glucose 2.1, through an oxidation-reduction sequence, gave
the C3-epimerized allo-configured product (not shown) in 86% yield over two steps. Its treatment
with triflic anhydride and pyridine then converted it to triflate 2.2. Without further purification, this
compound was then subjected to nucleophilic displacement using sodium azide to give
intermediate 2.5 (96% over two steps) followed by reduction with LiAlH4 yielding amine 2.6,
diacetone D-kanosamine, as a single diastereomer in 86% yield. To test the reductive amination,
amine 2.6 was reacted with three equivalents of both formaldehyde and sodium
cyanoborohydride. TLC indicated complete consumption of the starting material after two hours.
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Workup and purification of the crude material via column chromatography gave N,N-dimethyl
kanosamine diacetonide 2.3 in near quantitative yield. This represented a significant improvement
on the previous route using pressure vessel.
Following on the heels of the successful preparation of 2.3 by reductive amination, we
aimed to extend the methodology to other N-alkylated derivatives. The scope was tested using a
series of aldehydes and ketones (Table 2.4). To our delight, the reactions proceeded in very good
yields (91-97%), similar to the initial reaction with formaldehyde. Di-alkylation products were
observed in the case of small aldehydes such as formaldehyde and acetaldehyde (entries 1 and
2), which gave products 2.3 and 2.7. Longer chain aldehydes primarily gave mono-alkylation.
Table 2.4. mono and di alkylations of diacetonide substrate

81

Propionaldehyde (entry 3) gave 2.8 whereas butyraldehyde (entries 4 and 5) gave both
mono- (2.9) and di-alkylated (2.10) products in separate runs, where di-alkylated product was the
only exception to the trend. The methodology was further extended to aromatic aldehydes such
as benzaldehyde or vanillin, yielding products 2.11 and 2.12. Reactivity with ketones proceeded
to give mono-alkylation products (entries 8-10), giving products 2.13-2.15.
The observed mono alkylations are most likely due to steric interactions between the substrate
and aldehydes/ketones that prevents di-alkylation. Due to the required iminium intermediate in
the mechanism, the congested amine disfavors di-alkylation for bulky carbonyls.
We next considered exploiting the mono-alkylation selectivity to prepare disubstituted
analogs containing two different alkyl groups. The logic was to do serial alkylations in one pot first with a large aldehyde or ketone, and then a small one to give the mixed di-alkyl product. To
test the approach, amine 2.6 was reacted with 1.5 equivalents of propionaldehyde under the
established reaction conditions, monitored by TLC. Upon consumption of starting material and
formation of a less polar spot, excess formaldehyde was added. After a short period, a new spot
appeared on TLC, accompanied with the disappearance of the mono-alkylated product. Work up
and purification gave N-methyl,N-propyl derivative 2.16 in high yield (97%) with no evidence of
N,N-dimethyl or N-propyl side products. The scope of this methodology to form mixed alkyl
derivatives was then extended as summarized in Table 2.5. Other carbonyl partners such as
butyraldehyde, benzaldehyde, vanillin, cyclohexanone, and acetone were utilized in the reaction
sequence with formaldehyde to deliver products 2.17-2.21 in 91-97% yield (entries 2-6).
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Table 2.5. Mixed alkylations of diacetonide substrate

Deprotection of purified alkylated acetonide intermediates (2.3, 2.7-2.21) was
accomplished by treatment with 2 M HCl. Evaporation of the acidic aqueous solution upon
completion gave rise to the corresponding hydrochloride salts 2.4, 2.22-2.37 in quantitative yields
(Scheme 2.6)
Scheme 2.6. Acid catalyzed diacetonide cleavage
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In a case of interesting reactivity, in early experiments with dimethyl compound (2.3),
acetonide deprotection proceeded to give a mono deprotected product (Scheme 2.7). We
attribute this reactivity to the use of less equivalents of HCl and a shorter reaction length. This
was the only observed mono deprotection in the series and was not observed again even with
the dimethyl compound. Following acetonide deprotection, acetylation gave compound 2.38,
which was confirmed by NMR and mass spec studies.
Scheme 2.7. Mono deprotection of dimethyl diacetonide substrate

A telescoped sequence would eliminate the need for isolating the protected acetonide
intermediate, and facilitate the formation of a pyranose suitable for further manipulation, starting
from our key intermediate 2.6. To illustrate the strategy, 2.6 was alkylated with vanillin, then
acetaldehyde, to form the dialkyl diacetonide intermediate LI (Scheme 2.8). Addition of HCl to the
reaction mixture at this point served two purposes. It quenched the residual borohydride from the
reductive amination and it also facilitated acetonide deprotection, giving lactol LII, which was not
isolated. Workup to remove unreacted aldehyde was followed by acetylation and purification by
chromatography to deliver 2.39 in 80% yield. Remarkably, the sequence included four reactions
with only one chromatography.
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Scheme 2.8. One pot mixed alkylation procedure to dialkyl peracetyl kanosamine

Synthetic efforts to make alkyl kanosamine derivatives has promise in leading to novel
antibiotic compounds. To this end, it was our desire to incorporate these newly formed sugars
into novel Kanamycin derivatives. Our efforts began with the formation of a suitable acceptor
(2.42) derived from neomycin sulfate by a known process,22,24 and the formation of thioglycoside
donor (2.44) of our kanosamine sugars (Scheme 2.9).
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Scheme 2.9. Synthesis of neamine glycosyl acceptor and dimethyl kanosamine thioglycoside
donor22,24

Attempts at glycosylation began by using previously established conditions to form
kanamycin derivatives.22 using NIS and TfOH activators. These conditions were chosen due to
their applicability to neamine acceptor and selectivity for the desired alpha anomeric
configuration. Under these conditions we were unable to see product formation. Reactions
resulted in re-isolation and/or degradation of starting materials.

Thinking the activator may be the cause of the lack of reactivity we then tried
glycosylations with a Me2S2-Tf2O thioglycoside activator.25 The choice of this system was guided
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by the need for a mild thioglycoside activator to alleviate degradation, and the ability to influence
the anomeric configuration based on solvent ratios. Results with this activating system did not
show significant improvement. However, trace amounts of non-isolatable product were identified
via mass spectrometry. Having difficulty finding conditions for the desired reactivity we then set
our efforts on getting the bond formation using more classical, less selective, methods. To
determine whether the bond could be formed via glycosylation we used Koenigs-Knorr type
conditions with the anomeric bromide (2.45, shown below) or thioglycoside (2.44) reacting with
neamine based acceptor under AgOTf activating conditions. Under these conditions, we again
only observed trace product formation at best and were unable to isolate any desired compound

We suspended our efforts to glycosylate our alkyl kanosamine compounds with
neamine acceptor at this point. Use of the NIS/TfOH system by Chang and co-workers to yield
kanamycin derivatives was carried out using benzyl protected azido sugars. It is our thinking
that the acetate protected amino sugars we were trying to utilize have a negative electronic
consequence on the reactivity which led us to observe no product formation. Furthermore, the
presence of the amino functionality can lead to a protonated intermediate under glycosylation
conditions which will disfavor oxocarbenium formation. In conjunction with the non-ideal donor,
the neamine based acceptor bears two secondary hydroxyls on a somewhat crowded
cyclohexyl (deoxystreptamine) ring. This makes for a weak nucleophilic partner for
glycosylation, and taken together could be the reason for lake of observed reactivity.

In lieu of direct glycosylation of alkyl kanosamine sugars to neamine acceptor, we
have theorized alternative methods for this coupling (Figure 2.7). One method to achieve this
would be an azide-alkyne click chemistry approach. By conversion of the kanosamine sugar to a
1-azido glycoside and functionalizing neamine with an alkyne we would set the compound up for
an azide-alkyne cycloaddition. This route would require deprotection of azido groups on
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neamine and would have to be carried out in aqueous alcohol solvent to address solubility
issues of substrates.

Alternatively, an alkene-thiol radial coupling is envisioned as a means of linking the
two compounds. Also considered a “click” type of chemistry, this reactivity would require the
formation of a 1-thiol sugar, which has been shown to form readily though a thiourea
intermediate in work by Shavva and coworkers.26 Rather than formation of a propargyl neamine
derivative, an olefinic derivative would be needed. This functionalization is accessible in similar
fashion to the propargyl neamine.

Lastly, it is proposed that a mitsonobu approach could be used to enact the desired
transformation. This route would be possible by formation of a peracetyl kanosamine lactol, and
a thiol functionalized neamine derivative. Treatment with azodicarboxylate reagent and
triphenylphosphine in theory would facilitate the desired bond formation.

The alternative coupling strategies postulated rely on functionalized neamine
derivatives at the C6 position of the deoxystrepamine ring (Ring C). Selective alkylation of C6 of
deoxystreptamine is shown to be possible, and we believe use of our neamine acceptor (2.42)
would give rise to the desired selectivity in alkylation at this position.27

88

Figure 2.7. Possible coupling techniques between neamine and kanosamines
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With the formation of kanamycin derivatives on the back burner we then turned our
attention to applying our PGD methodology to the kanosamine derivatives formed in this
study.28 Conversion of N,N-dimethyl lactol to the peracetate (2.43) with acetic anhydride was
followed by formation of the anomeric bromide (2.45), in 56% yield over the two steps, which
served as the donor for glycosylation reactions (Scheme 2.10).

Scheme 2.10. Kanosamine lactol to anomeric bromide glycosyl donor

Using Ag2CO3 activating conditions glycosides 2.46-2.49 were furnished in moderate
yields (46-55%) (Table 2.6).

Table 2.6. Glycosylations of dimethyl kanosmaine anomeric bromide

A: Donor, Acceptor (4 eq.), Ag2CO3 (3 eq.), 4Å mol sieves
B: Donor, Acceptor (4 eq.), Ag2CO3 (3 eq.), I2, 4Å mol sieves
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The new glycosides contained latent reactivity handles that were exploited in post
glycosylation diversification reactions. As a proof of concept, we conducted Suzuki couplings on
bromobenzyl glycosides 2.48 and 2.49 to prepare, after de-acetylation, compounds 2.50 and
2.51 in 82% and 72% yields, respectively (Scheme 2.11).

Scheme 2.11. Palladium coupling diversifications on kanosamine PGD intermediates

Chloroethyl glycoside 2.47 was converted to the azido ethyl compound 2.52 by
substitution, and was then subjected to a click reaction with phenyl acetylene to give, after deacetylation, compound 2.53 in 73% yield over two steps (Scheme 2.12).

Scheme 2.12. Cycloaddition diversification on kanosamine PGD intermediate

As in our previous PGD efforts, we proposed the use of a cell free, in vitro
transcription-translation assay that monitors the fluorescence of EmGFP to evaluate new
compounds 2.50, 2.51, and 2.53.28 Compounds 2.51 and 2.53 exhibited inhibition of
approximately 70% relative to negative control of protein synthesis in the absence of inhibitor
(Figure 2.8). The m-mesityl compound 2.50 reduced protein synthesis by ~40%.
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Figure 2.8. Co-transcription/translation assay results for kanosamine PGD compounds

These results show that the PGD methodology identified new protein synthesis
inhibitors that are amenable to modification to improve pharmacological properties. While the
PGD derivatives tested are limited to the dimethyl kanosamine sugar for simplicity in our proof
of concept reactions, we are optimistic that the sugars with varying alkylation patterns presented
in this study are promising candidates for subsequent series of PGD compounds.

2.8. Conclusion

In conclusion, we have presented a method for the preparation of alkylated
kanosamine sugars from diacetone D-glucose. The robust and versatile method allows mono,
di- and mix alkyl patterns to be accessed in a single pot fashion. In addition, the method was
further developed to take the diacetonide starting material to a peracetylated pyranose, with a
single purification, over a four-step process. While efforts to incorporate the sugars yielded from
this process into Kanamycin B derivatives fell short, they have been shown to be applicable to a
diversification platform (PGD) which has identified novel inhibitors of bacterial protein synthesis.
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2.9. Experimental
Preparation of diacetone kanosamine substrate

Compound 2.2: Diacetone d-allofuranose (664 mg, 2.55 mmol) was dissolved in dry DCM (7.6
mL, 0.04 M). Pyridine (0.41 mL, 5.15 mmol) was added and the solution cooled to -30 oC. Triflic
anhydride (864 mg, 3.06 mmol) was added dropwise over 15 min and stirring was continued at 30 oC for 30 min. The reaction was then quenched with MeOH (1 mL), warmed to rt, diluted with
DCM (5 mL) washed with H2O (2 x 5 mL), dried over Na2SO4 and concentrated to a clear, slight
yellow oil (2.2 1.05 g, quantitative); 1H NMR (400MHz, CDCl3) δ ppm 5.85 (d, J = 3.7 Hz, 1H),
4.92 (t, J = 5.7 Hz, 1H), 4.79 (d, J = 4.6 Hz, 1H), 4.10-4.24 (multiple peaks, 3H), 3.92 (dd, J =
4.4/8.8 Hz, 1H), 1.60 (s, 3H), 1.46 (s, 3H), 1.40 (s, 3H), 1.37 (s, 3H); 13C NMR (100MHz,
CDCl3) δ ppm 114.4, 110.3, 104.2, 80.0, 77.8, 77.7, 75.2, 66.3, 26.8, 26.5, 26.2, 24.8; HRMS
(DART-TOF) m/z calcd for C13H19F3O8S [M+H]+ 415.0639, found 415.0776
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Compound 2.5: 2.2 (800 mg, 2.04 mmol) and NaN3 (397 mg, 6.12 mmol) was dissolved in DMF
(4 mL, 0.5 M) and allowed to stir at 50 oC overnight. Upon completion the reaction was
quenched and washed with H2O (2 x 2 mL), extracted with EtOAc (3 x 2 mL), washed with brine,
dried over Na2SO4 and concentrated to a clear to slightly yellow oil (2.5, 560 mg, 96%) which
was used unpurified in the following synthetic step; 1H NMR (400MHz, CDCl3) δ ppm 5.84 (d, J
= 3.8 Hz, 1H), 4.60 (d, J = 3.3 Hz, 1H), 4.23 (m, 1H), 4.05-4.15 (m, 3H), 3.96 (dd, J = 5.1/8.8
Hz, 1H), 1.49 (s, 3H), 1.42 (s, 3H), 1.35 (s, 3H), 1.31 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm
112.2, 109.5, 105.0, 83.4, 80.4, 73.0, 67.6, 66.3, 26.8, 26.6, 26.1, 25.1; LRMS (ESI+) m/z calcd
for C12H19N3O5 [M+Na] 308.13, found 308.10
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Compound 2.6: 2.5 (280 mg, 0.98 mmol) was dissolved in dry Et2O (12.55 mL, 0.078 M) and
cooled to 0 oC in an ice bath. Solid LiAlH4 (149 mg, 3.92 mmol) was added portion wise and the
reaction was stirred and allowed to warm to rt over 2 hr. The reaction was then cooled again in
an ice bath and quenched with H2O (2 mL), 1M NaOH (aq) (3 mL), followed by H2O again (2
mL). The mixture was filtered through celite, dried over Na2SO4 and concentrated to a slight
yellow oil (2.6, 215.9 mg, 85%); 1H NMR (400MHz, CDCl3) δ ppm 5.82 (d, J = 3.6 Hz, 1H), 4.32
(d, J = 3.6 Hz, 1H), 4.06-4.17 (m.p., 2H), 3.89-3.99 (m, 2H), 3.48 (d, J = 3.4 Hz, 1H), 1.45 (s,
3H), 1.38 (s, 3H), 1.29 (s, 3H), 1.24 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 11.4, 109.2,
104.9, 86.4, 81.4, 72.9, 68.0, 57.3, 26.8, 26.7, 26.0, 25.2; LRMS (ESI+) m/z calcd for C12H21NO5
[M+H]+ 260.14, found 260.60
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Synthesis of mono- and di- alkyl diacetonides
GP4: General procedure for mono and di alkylations
A representative procedure is given for the synthesis of mono- and di- alkyl diacetonide
compounds: Compound 2.3: 2.5 (59 mg, 0.23 mmol) formaldehyde (33% solution in MeOH, 3
eq.) was dissolved in MeOH (1.14 mL, 0.2 M). Solid NaCNBH3 (3 eq.) was added followed by
addition of glacial AcOH (pH 4-5, ~2 drops). The reaction was stirred at rt and monitored by TLC
(25% EA:Hex). Upon consumption of the starting material (~2 hrs) the reaction was quenched
with saturated NaHCO3 (aq.) (2ml), extracted with DCM (3 x 2 mL), washed with water (3 mL),
brine (3 mL), dried over Na2SO4 and concentrated to a crude oil. The crude oil was purified by
column chromatography (10-25% EA:Hex) to yield 2.3 (97%) as a colorless oil.

Rf (0.3) (25%EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.78 (d, J = 3.8 Hz, 1H), 4.77 (d, J =
3.9 Hz, 1H), 4.38 (dt, J = 5.3/9.1 Hz, 1H), 4.08 (3H, m), 3.19 (d, J = 5.6 Hz, 1H), 2.35 (s, 6H),
1.51 (s, 3H), 1.43 (s, 3H), 1.38 (s, 3H), 1.33 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 110.6,
109.3, 105.0, 81.2, 78.0, 72.5, 69.4, 67.4, 43.1; HRMS (DART-TOF) m/z calcd for C14H25NO5
[M+H]+ 288.1800, found 288.1893
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Compound 2.7 was prepared according to GP4 in 95% yield as a colorless oil; Rf (0.70) (25%
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.76 (d, J = 4.0 Hz 1H), 4.74 (d, J = 3.7 Hz, 1H),
4.27 (dt, J = 5.7/8.3 Hz, 1H), 4.11 (m, 2H), 3.99 (dd, J = 5.57.3 Hz,1H), 3.37 (d, J = 5.5 Hz,1H),
2.61 (m, 2H), 2.49 (m, 2H), 1.50 (s, 3H), 1.41 (s, 3H), 1.35 (s, 3H), 1.31 (s, 3H), 1.04 (t, J = 7.0
Hz, 6H); 13C NMR (100MHz, CDCl3) δ ppm 110.6, 108.8, 105.2, 81.6, 80.5, 72.9, 67.3, 66.6,
44.9, 26.9, 26.6, 25.9, 25.1, 13.6; HRMS (DART-TOF) m/z calcd for C16H29NO5 [M+H]+
316.2113, found 316.2128
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Compound 2.8 was prepared according to GP4 in 93% yield as a colorless oil; Rf (0.15) (25%
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.7 (d, J = 3.8 Hz, 1H), 4.55 (d, J = 4.1 Hz, 1H),
4.17 (m, 3H), 3.98 (dd, J = 5.1/8.3 Hz, 1H), 3.29 (d, J = 3.6 Hz,1H), 2.67 (m, 2H), 1.52 (m, 5H),
1.43 (s, 3H), 1.37 (s, 3H), 1.33 (s, 3H), 0.95 (t, J = 7.4 Hz, 3H); 13C NMR (100MHz, CDCl3) δ
ppm 111.3, 109.3, 105.1, 83.4, 81.2, 72.9, 68.2, 64.0, 49.8, 26.8, 26.1, 25.3, 23.1, 11.6; HRMS
(DART-TOF) m/z calcd for C15H27NO5 [M+H]+ 302.1957, found 302.2000

98

Compound 2.9 was prepared according to GP4 in 92% yield as a colorless oil; Rf (0.15) (25%
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.87 (d, J = 3.9 Hz, 1H), 4.55 (d, J = 4.2 Hz,1H),
4.17 (m, 3H), 3.96 (dd, J = 5.0/8.1 Hz, 1H), 3.29 (d, J = 4.1 Hz, 1H), 2.76 (m, 1H), 2.65 (m, 1H),
2.38 (bs,1H), 1.82 (m, 1H), 1.45-1.6 (m, 7H), 1.43 (s, 3H), 1.3-1.4 (m, 9H), 0.99 (t, J = 6.8 Hz,
2H), 0.94 (t, J = 6.8 Hz, 3H); 13C NMR (100MHz, CDCl3) δ ppm 111.3, 109.4, 105.1, 83.3, 81.1,
72.9, 68.2, 47.6, 32.0, 26.8, 26.1, 25.3, 20.2, 17.9, 13.9, 13.4; HRMS (DART-TOF) m/z calcd for
C16H29NO5 [M+H]+ 316.2113, found 316.2128
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Compound 2.10 was prepared according to GP4 in 33% yield as a colorless oil; Rf (0.80) (25%
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.78 (d, J = 3.7 Hz, 1H), 4.75 (d, J = 3.7 Hz, 1H),
4.30 (m, 1H), 4.11 (dd, J = 5.3/8.1 Hz, 2H), 3.95 (dd, J = 6.4/8.1 Hz, 1H), 3.35 (d, J = 4.6 Hz,
1H), 2.47-2.57 (m, 2H), 2.38-2.46 (m, 2H), 1.52 (s, 3H), 1.20-1.47 (m.p., 20H), 0.91 (t, J = 6.8
Hz, 6H); 13C NMR (100MHz, CDCl3) δ ppm 110.5, 108.8, 105.3, 81.9, 80.5, 72.7, 67.6, 67.0,
51.5, 30.7, 26.8, 26.6, 25.9, 25.5, 20.3, 14.1; HRMS (DART-TOF) m/z calcd for C20H37NO5
[M+H]+ 372.1776, found 372.1776

100

Compound 2.11 was prepared according to GP4 in 96% yield as a colorless oil; Rf (0.30) (25%
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 7.33-7.4 (m, 6H), 5.89 (d, J = 3.9 Hz,1H), 4.68 (s,
1H), 4.59 (d, J = 3.8 Hz, 1H), 4.25 (m, 1H), 4.15 (dt, J = 5.8/8.6 Hz, 2H), 3.97 (dd, J = 5.2/8.2
Hz, 2H), 3.85 (d, J = 13.7 Hz,1H), 3.37 (d, J = 4.0 Hz, 1H), 1.53 (s, 3H), 1.42 (s, 3H), 1.38 (s,
3H), 1.33 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 139.6, 129.0, 128.5, 128.0, 127.2, 127.0,
111.5, 109.4, 105.1, 83.4, 81.1, 72.9, 68.1, 63.3, 51.6, 26.8, 26.2, 25.3; HRMS (DART-TOF) m/z
calcd for C19H27NO5 [M+H]+ 350.1957, found 350.2034
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Compound 2.12 was prepared according to GP4 in 94% yield as a colorless oil; Rf (0.15) (25%
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 6.87 (m, 3H), 5.89 (d, J = 3.4 Hz, 1H), 4.59 (d, J =
4.1 Hz, 1H), 4.29 (dt, J = 5.8/8.8 Hz,1H), 4.16 (m, 2H), 3.99 (dd, J = 5.1/8.1 Hz, 1H), 3.86-3.9
(m, 2H), 3.88 (s, 3H), 3.7 (d, J = 13.3 Hz, 1H), 3.36 (d, J = 4.3 Hz, 1H), 1.52 (s, 3H), 1.43 (s,
3H), 1.38 (s, 3H), 1.33 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 146.6, 144.8, 131.6, 120.7,
114.3, 111.5, 110.7, 109.3, 105.1, 83.4, 81.1, 72.9, 68.1, 63.2, 55.8, 51.5, 26.8, 26.2, 25.4;
HRMS (DART-TOF) m/z calcd for C20H29NO7 [M+H]+ 396.2011, found 396.2002
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Compound 2.13 was prepared according to GP4 in 91% yield as a colorless oil; Rf (0.40) (25%
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.82 (d, J = 4.2 Hz, 1H), 4.46 (d, J = 4.6 Hz, 1H),
4.19 (m, 1H), 4.11 (m, 2H), 3.94 (dd, J = 5.4/8.4 Hz, 1H), 3.33 (d, J = 3.8 Hz, 1H), 2.93 (sep.,
18.4/11.8/5.5 Hz, 1H), 1.49 (s, 3H), 1.4 (s, 3H), 1.33 (s, 3H), 1.3 (s, 3H), 1.06 (dt, J = 6.3/5.1 Hz,
6H); 13C NMR (100MHz, CDCl3) δ ppm 111.4, 109.1, 105.01 84.5, 80.9, 72.9, 67.9, 61.3, 46.7,
26.8, 26.2, 25.3, 24.6, 22.5; HRMS (DART-TOF) m/z calcd for C15H27NO5 [M+H]+ 302.1957,
found 302.1934
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Compound 2.14 was prepared according to GP4 prepared in 96% yield as a colorless oil
(mixture of two diastereomers); Diastereomer 1:Rf = (0.30) (25% EA:Hex); 1H NMR (400MHz,
CDCl3) δ ppm 7.36 (m, 5H), 7.27 (m, 1H), 5.76 (d, J = 3.3 Hz, 1H), 4.31 (m, 2H), 4.20 (t, J = 7.9
Hz, 1H), 3.96-4.16 (m, 4H), 3.31 (d, J = 2.9 Hz, 1H), 1.48 (s, 3H), 1.46 (s, 3H), 1.43 (s, 3H), 1.24
(s, 3H), 1.22-1.62 (m, 11H); 13C NMR (100MHz, CDCl3) δ ppm 146.1, 125.5, 127.1, 126.6,
111.4, 109.2, 104.7, 84.7, 81.3, 72.8, 68.1, 61.7, 56.4, 26.8, 26.7, 26.1, 25.5, 24.2; HRMS
(DART-TOF) m/z calcd for C20H29NO5 [M+H]+ 364.2113, found 364.2127; Diastereomer 2: Rf =
(0.25) (25% EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 7.30-7.41 (m, 4H), 7.22-7.29 (m, 1H),
5.92 (s, 1H), 4.61 (s, 1H), 4.34 (m, 1H), 4.18 (t, J = 7.3 Hz, 1H), 4.08 (m, 1H), 3.96 (m, 2H), 3.12
(s, 1H), 1.25-1.54 (m.p., 20H); 13C NMR (100MHz, CDCl3) δ ppm 144.6, 128.3, 126.7, 111.4,
109.1, 105.0, 83.3, 80.8, 73.1, 67.8, 61.1, 55.4, 26.7, 26.7, 26.1, 25.4, 25.3; HRMS (DARTTOF) m/z calcd for C20H29NO5 [M+Na] 386.1932, found 386.2102
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Compound 2.15 was prepared according to GP4 in 92% yield as a colorless oil; Rf (0.45) (25%
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.85 (d, J = 3.8 Hz, 1H), 4.47 (d, J = 4.0 Hz, 1H),
4.21 (m, 1H), 4.12 (m, 2H), 3.93 (dd, J = 5.5/8.1 Hz, 1H), 3.39 (d, J = 3.9 Hz, 1H), 2.55 (m, 1H),
2.08 (m, 2H), 1.94 (m, 1H), 1.5-1.89 (m, 11H), 1.50 (s, 3H), 1.41 (s, 3H), 1.34 (s, 3H), 1.31 (s,
3H), 0.97-1.29 (m, 7H); 13C NMR (100MHz, CDCl3) δ ppm 111.4, 109.1, 104.9, 84.4, 81.0, 72.9,
67.9, 60.9, 54.4, 37.9, 34.6, 32.8, 26.7, 26.2, 26.0, 25.3, 25.0, 24.8, 24.5, 22.4; HRMS (DARTTOF) m/z calcd for C18H31NO5 [M+H]+ 342.2270, found 342.2248
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Synthesis and characterization of mixed alkyl compounds.
GP5: General procedure for mixed alkylations:
A representative procedure is given for the synthesis of mixed alkyl diacetonide compounds:
Compound 2.16: 2.5 (59 mg, 0.23 mmol) along with propanaldehyde (1.5 eq.) was dissolved in
MeOH (1.14 mL, 0.2M). Solid NaCNBH3 (3 eq.) was added followed by addition of conc. AcOH
(pH 4-5, ~2 drops). The reaction was stirred at RT and monitored by TLC (25% EA:Hex). Upon
consumption of the starting material 38% methanolic formaldehyde solution was added (0.1 mL,
in excess). Upon consumption of the intermediate by TLC the reaction was quenched with
saturated NaHCO3 (aq.) (2 mL), extracted with DCM (3 x 2 mL), washed with water (3 mL), brine
(3 mL), dried over Na2SO4 and concentrated to a crude oil. The crude oil is purified by column
chromatography (10-25% EA:Hex) to yield 2.16 (97%) as a colorless oil

Rf (0.80) (25% EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.79 (d, J = 3.9 Hz, 1H), 4.77 (d, J =
3.9 Hz, 1H), 4.36 (dt, J = 6.2/8.7 Hz, 1H), 4.12 (m, 2H), 4.02 (dd, J = 6.0/8.7 Hz, 1H), 3.29 (d, J
= 5.4 Hz, 1H), 2.48 (m, 2H), 2.31 (s, 3H), 1.52 (s, 3H), 1.51 (m, 2H) 1.43 (s, 3H), 1.38 (s, 3H),
1.33 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm110.6, 109.0, 105.2, 81.7, 79.3, 72.6, 68.6, 67.5,
57.7, 39.5, 27.0, 26.6, 25.9, 25.6, 21.0, 11.5; HRMS (DART-TOF) m/z calcd for C16H29NO5
[M+H]+ 316.2113, found 316.2206
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Compound 2.17 was prepared according to GP5 in 95% yield as a colorless oil; Rf (0.85) (25%
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.78 (d, J = 3.6 Hz, 1H), 4.77 (d, J = 2.7 Hz, 1H),
4.35 (dt, J = 6.0 Hz, 1H), 4.11 (m, 2H), 4.01 (dd, J = 5.8 Hz, 1H), 3.29 (s, 1H), 2.51 (m, 2H),
2.30 (s, 3H), 1.51 (s, 3H), 1.42 (s, 3H), 1.37 (s, 3H), 1.33 (s, 3H), 1.25-1.53 (m, 6H), 0.92 (t, J =
6.9 Hz, 3H); 13C NMR (100MHz, CDCl3) δ ppm 110.6, 109.1, 105.1, 81.6, 79.2, 27.7, 68.5, 55.6,
39.5, 30.0, 26.9, 26.7, 25.9, 25.6, 20.2, 14.0; HRMS (DART-TOF) m/z calcd for C11H23NO5
[M+H]+ 250.1644, found 250.1618
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Compound 2.18 was prepared according to GP5 in 93% yield as a colorless oil; Rf (0.75) (25%
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 7.42 (d, J = 7.3 Hz, 2H), 7.33 (t, J = 6.9 Hz, 2H),
7.27 (m, 1H), 5.86 (d, J = 3.9 Hz, 1H), 5.05 (dd, J = 16.4/24.0 Hz, 1H), 4.85 (d, J = 3.9 Hz, 1H),
4.45 (m, 1H), 4.16 (m, 3H), 4.01 (dd, J = 6.5/9.9 Hz, 1H), 3.84 (d, J = 14.3 Hz, 1H), 3.67 (d, J =
13.8 Hz, 1H), 3.42 (d, J = 4.7 Hz, 1H), 2.42 (m, 2H), 2.32 (s, 3H), 1.52 (s, 3H), 1.45 (s, 3H), 1.45
(s, 3H), 1.35 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 139.0, 136.5, 128.3, 128.2, 128.0,
127.0, 115.5, 110.7, 109.1, 105.2, 81.9, 79.3, 72.6, 68.5, 67.8, 60.9, 60.1, 39.3, 33.4, 28.8,
28.0, 26.9, 26.6, 25.9, 25.7; HRMS (DART-TOF) m/z calcd for C20H29NO5 [M+H]+ 364.2113,
found 364.2242
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Compound 2.19 was prepared according to GP5 in 92% yield as a colorless oil; Rf (0.20) (25%
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 7.01 (s, 1H), 6.88 (m, 2H), 5.83 (d, J = 4.4 Hz, 1H),
4.83 (s, 1H), 4.45 (m, 1H), 4.14 (m, 2H), 4.03 (dd, J = 5.6/8.6 Hz, 1H), 3.9 (s, 3H), 3.77 (d, J =
13.3 Hz, 1H), 3.61 (d, J = 13.3 Hz,1H), 3.42 (d, J = 4.9 Hz, 1H), 2.3 (s, 3H), 1.5 (s, 3H), 1.43 (s,
3H), 1.41 (s, 3H) 1.34 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 146.6, 121.1, 113.9, 110.8,
105.0, 81.8, 79.3, 72.7, 68.0, 67.7, 30.0, 55.9, 39.2, 26.9, 26.6, 26.0, 25.7; HRMS (DART-TOF)
m/z calcd for C21H31NO7 [M+H]+ 410.2168, found 410.2248
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Compound 2.20 was prepared according to GP5 in 91% yield as a colorless oil; Rf (0.60) (25%
EA:Hex); 1H NMR (400MHz, CDCl3) δ 5.80 (d, J = 3.7 Hz, 1H), 4.78 (d, J = 3.9 Hz, 1H), 4.28 (q,
J = 5.7/13.4 Hz, 1H), 4.14 (dd, J = 4.6/7.3 Hz, 1H), 4.09 (dd, J = 5.9/13.4 Hz, 1H), 4.01 (dd, J –
6.1/8.2 Hz, 1H), 3.36 (d, J = 4.8 Hz, 1H), 2.92 (sep., J = 6.2/12.7/18.1 Hz, 1H), 2.28 (s, 3H),
1.51 (s, 3H), 1.41 (s, 3H), 1.36 (s, 3H), 1.31 (s, 3H), 1.08 (t, J = 6.6 Hz, 6H); 13C NMR (100MHz,
CDCl3) δ ppm 110.5, 108.6, 105.1, 81.9, 81.7, 73.3, 66.9, 64.6, 55.2, 34.4, 26.9, 26.6, 25.9,
25.7, 19.8, 18.4; HRMS (DART-TOF) m/z calcd for C16H29NO5 [M+H]+ 316.2113, found
316.2206
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Compound 2.21 was prepared according to GP5 in 92% yield as a colorless oil; Rf (0.80)
(EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.79 (d, J = 3.8 Hz, 1H), 4.77 (b.s., 1H), 4.28 (q, J =
6.0/13.3 Hz, 1H), 4.14 (dd, J = 4.8/7.3 Hz, 1H), 4.08 (dd, J = 6.2/8.1 Hz, 1H), 3.99 (dd, J =
6.3/8.2 Hz, 1H), 3.39 (d, J = 3.2 Hz, 1H), 2.43 (b.s., 1H), 2.31 (s, 3H), 1.55-1.95 (m, 6H), 1.50
(s, 3H), 1.40 (s, 3H), 1.35 (s, 3H), 1.30 (s, 3H), 1.02-1.28 (m, 5H); 13C NMR (100MHz, CDCl3) δ
ppm 110.5, 108.7, 82.1, 81.9, 73.3, 66.9, 65.6, 64.5, 35.2, 29.2, 26.8, 26.6, 26.0, 25.2; HRMS
(DART-TOF) m/z calcd for C19H33NO5 [M+H]+ 356.2426, found 356.2535
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Synthesis and characterization of pyranose sugars
GP6: General Procedure for acetonide deprotection
A representative procedure is given for the synthesis of mixed alkyl diacetonide compounds:
Compound 2.4: 2.3 (30 mg) was dissolved in 2M HCl (~2 mL) and allowed to stir at RT
overnight. Upon completion (TLC showing a single spot at baseline with 1:1 EA:Hex), the
aqueous solution was extracted with EtOAc (2 x 1 mL) to remove any residual organic soluble
impurities. The aqueous solution was then concentrated under vacuum to yield 2.24 as its
hydrochloride salt in quantitative yield.

Rf (0.00) (EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.19 (d, J = 3.7 Hz, 1H), 4.65 (d, J = 7.3 Hz,
1H), 3.3-4.08 (28H, m), 2.92-3.03 (26H, m); 13C NMR (100MHz, D2O) δ ppm 96.1, 91.4, 76.5,
71.5, 70.1, 68.2, 67.5, 65.8, 63.6, 63.4, 60.1, 59.9, 41.5, 40.9; HRMS (DART-TOF) m/z calcd for
C8H17NO5 [M+H]+ 208.1174 , found 208.1224
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Compound 2.22 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.21 (d, J = 4.0 Hz, 1H), 4.67 (d, J = 8.0 Hz, 1H),
3.13-4.0 (20H, m); 13C NMR (100MHz, D2O) δ ppm 96.0, 91.1, 76.8, 71.2, 70.5, 68.1, 65.9, 65.8,
60.1, 60.0, 57.8, 55.1; HRMS (DART-TOF) m/z calcd for C6H13NO5 [M+H]+ 180.0861, found
180.0947
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Compound 2.23 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.20 (d, J = 3.6 Hz, 1H), 4.68 (d, J = 6.1 Hz, 1H), 3.24.02 (29H, m), 1.34 (t, J = 7.2 Hz, 17H); 13C NMR (100MHz, D2O) δ ppm 96.2, 91.5, 76.6, 71.6,
68.4, 67.4, 65.8, 64.9, 63.7, 63.5, 62.1, 60.1, 59.9, 48.6, 48.4, 48.1, 10.0; HRMS (DART-TOF)
m/z calcd for C10H21NO5 [M+H]+ 236.1487, found 236.1532
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Compound 2.24 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.21 (d, J = 3.5 Hz, 1H), 4.66 (d, J = 7.8 Hz, 1H),
3.08-3.88 (18H, m), 1.7 (sep., J = 6.9/14.8/22.3 Hz, 4H), 0.94 (t, J = 7.4 Hz, 6H); 13C NMR
(100MHz, D2O) δ ppm 96.1, 91.3, 76.7, 71.4, 69.2, 66.9, 64.6, 64.5, 63.1, 47.1, 47.1, 19.2, 10.2;
HRMS m/z calcd for C9H19NO5 [M+H]+ 222.1331 , found 222.1397
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Compound 2.25 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.20 (d, J = 3.6 Hz, 1H), 4.65 (d, J = 7.3 Hz, 1H),
3.12-3.88 (18H, m), 1.66 (dt, J = 7.1/14.8 Hz, 5H), 1.36 (sep., J = 7.1/14.8/23.1 Hz, 5H), 0.87 (t,
J = 7.7 Hz, 7H); 13C NMR (100MHz, D2O) δ ppm 96.2, 91.4, 76.7, 71.4, 69.2, 66.8, 64.6, 64.5,
63.1, 45.3, 45.2, 27.5, 19.1, 12.7; HRMS (DART-TOF) m/z calcd for C10H21NO5 [M+H]+
236.1487, found 236.1473
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Compound 2.26 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.22 (d, J = 3.5 Hz, 1H), 4.68 (d, 1H), 3.19-4.02 (m,
32H), 1.74 (m, 10H), 1.35 (m, 10H), 0.89 (t, J = 7.7 Hz, 16H); 13C NMR (100MHz, D2O) δ ppm
96.3, 91.6, 76.6, 71.6, 68.4, 65.9, 65.8, 63.7, 63.5, 63.1, 60.1, 59.9, 53.7, 53.6, 26.7, 19.3, 12.7;
HRMS (DART-TOF) m/z calcd for C14H29NO5 [M+H]+ 292.2113 , found 292.2168
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Compound 2.27 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 7.36-7.51 (m, 18H), 5.21 (d, J = 3.9 Hz, 1H), 4.62 (d,
J = 7.8 Hz, 1H), 4.34-4.45 (m, 7H), 3.19-4.05 (m, 23H); 13C NMR (100MHz, D2O) δ ppm 130.0,
129.77, 129.7, 129.3, 96.2, 91.3, 76.7, 69.5, 67.2, 64.9, 64.7, 62.7, 60.1, 60.0, 59.9, 49.6, 49.5;
HRMS (DART-TOF) m/z calcd for C13H19NO5 [M+H]+ 270.1331 , found 270.1412
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Compound 2.28 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 7.00 (s, 2H), 6.85 (m, 5H), 5.17 (d, J = 3.1 Hz, 1H),
4.58 (d, J = 8.0 Hz, 1H), 4.25 (s, 5H), 3.12-3.97 (m, 26H), 1.97 (s, 3H); 13C NMR (100MHz, D2O)
δ ppm 147.6, 146.0, 123.5, 122.9, 115.8, 114.0, 96.1, 91.3, 76.8, 71.4, 69.6, 67.3, 64.9, 62.5,
60.1, 59.9, 59.7, 55.9, 49.6, 20.3; HRMS (DART-TOF) m/z calcd for C14H21NO7 [M+H]+
316.1385 , found 316.1454
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Compound 2.29 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.18 (d, J = 3.9 Hz, 1H), 4.65 (d, J = 7.5 Hz, 1H),
3.22-3.93 (m, 24H), 2.02 (s, 2H), 1.31 (d, J = 7.6 Hz, 22H); 13C NMR (100MHz, D2O) δ ppm
96.1, 91.2, 76.7, 71.5, 70.7, 69.6, 66.1, 66.0, 61.8, 60.1, 60.0, 59.2, 57.8, 52.5, 18.8; HRMS
(DART-TOF) m/z calcd for C9H19NO5 [M+H]+ 222.1331, found 222.1340

120

Compound 2.30 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.18 (d, J = 3.8 Hz, 1H), 4.64 (d, J = 7.3 Hz, 1H),
3.26-3.99 (m, 24H), 2.09 (d, J = 11.0 Hz, 7H), 1.78 (d, J = 11.7 Hz, 7H), 1.59 (d, J = 12.5 Hz,
3H), 1.05-1.42 (m, 18H); 13C NMR (100MHz, D2O) δ ppm 96.1, 91.3, 76.7, 71.4, 70.63, 68.2,
66.0, 65.9, 61.4, 60.1, 59.9, 59.0, 58.9, 29.4, 24.4, 24.0; HRMS (DART-TOF) m/z calcd for
C12H23NO5 [M+H]+ 262.1644, found 262.1652
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Compound 2.31 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.19 (d, J = 2.3 Hz, 0.18H), 5.13 (d, J = 3.6 Hz, 1H),
4.85 (q, J = 6.7/14.1 Hz, 3H), 4.47 (d, J = 7.5 Hz, 1H), 3.57-3.86 (m.p., 11H), 3.34-3.42 (m.p.,
3H), 3.13-3.26 (m.p., 1.3H), 3.02 (t, J = 10.2 Hz, 1.3H), 1.66 (dd, J = 1.4/6.9 Hz, 7.3H); 13C NMR
(100MHz, D2O) δ ppm 136.0, 135.9, 129.7, 129.4, 127.8, 127.7, 95.9, 91.0, 76.6, 71.2, 70.1,
67.7, 66.3, 66.1, 62.0, 59.9, 59.8, 59.6, 59.5, 19.4, 19.1; HRMS (DART-TOF) m/z calcd for
C14H21NO5 [M+H]+ 284.1487, found 284.1451
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Compound 2.32 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 6.02 (d, J = 4.0 Hz, 0.3H), 5.89 (d, J = 4.0 Hz, 1H),
5.22 (dd, J = 3.5/7.8 Hz, 3H), 5.03 (m, 4H), 3.39-4.21 (m.p., 100H), 3.18 (m, 11H), 2.97 (m,
33H), 1.76 (m, 23H), 0.90-0.99 (m.p., 35H); 13C NMR (100MHz, D2O) δ ppm 96.2, 96.1, 96.0,
91.1, 91.3, 77.6, 76.6, 76.4, 75.1, 72.4, 71.5, 71.4, 70.6, 69.1, 68.4, 68.0, 67.4, 66.0, 65.8, 65.5,
65.4, 64.9, 64.6, 63.6, 63.5, 63.4, 63.3, 63.2, 60.0, 60.0, 59.8, 58.3, 58.1, 53.5, 49.7, 48.4, 40.1,
38.4, 38.3, 38.2, 28.2, 18.0, 9.9; HRMS (DART-TOF) m/z calcd for C10H21NO5 [M+H]+ 236.1487,
found 236.1481
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Compound 2.33 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.02 (dd, 3.3/8.4 Hz, 1H), 3.20 (m, 3H), 1.71 (m, 7H),
1.33 (sex., (7.2/14.3/21.8 Hz, 7H), 0.87 (t, 7.1 Hz, 10H); 13C NMR (100MHz, D2O) δ ppm 96.2,
91.6, 91.3, 76.6, 71.5, 68.4, 68.1, 66.0, 64.8, 64.6, 63.5, 63.2, 60.0, 59.8, 38.3, 38.2, 37.8, 26.4,
19.1, 12.7; HRMS (DART-TOF) m/z calcd for C10H21NO5 [M+H]+ 250.1644 , found 250.1618

124

Compound 2.34 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 7.48 (s, 12H), 5.19 (d, J = 5.9 Hz, 1H), 4.48 (m, 3H),
3.18-4.13 (m, 21H), 3.03 (s, 7H); 13C NMR (100MHz, D2O) δ ppm 131.0, 130.2, 129.4, 96.2,
91.6, 77.6, 76.5, 75.2, 75.5, 71.5, 70.7, 69.2, 68.2, 66.2, 64.0, 63.7, 63.4, 63.1, 60.8, 60.1, 59.9,
58.7, 53.5, 49.7, 48.5, 40.2, 38.0, 37.8, 37.5, 33.8, 28.3; HRMS (DART-TOF) m/z calcd for
C14H21NO5 [M+H]+ 284.1487, found 284.1544
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Compound 2.35 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.17 (m, 2H), 6.8-6.98 (m, 4H), 5.17 (m, 1H), 4.274.63 (m, 6H), 3.21-4.06 (m, 23H), 2.98 (m, 6H); 13C NMR (100MHz, D2O) δ ppm 147.7, 146.3,
124.6, 121.5, 121.5, 115.8, 115.7, 114.9, 114.7, 114.7, 96.2, 9.6, 76.5, 71.6, 68.4, 67.9, 66.1,
65.7, 65.5, 63.6, 63.0, 62.7, 60.9, 60.0, 59.9, 59.8, 56.0, 37.6, 37.5, 37.1; HRMS (DART-TOF)
m/z calcd for C15H23NO7 [M+H]+ 330.1542, found 330.1606
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Compound 2.36 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.22 (dd, J = 3.4/10.7 Hz, 1H), 4.68 (d, J = 3.8 Hz,
1H), 3.42-4.20 (m, 23H), 2.89 (s, 6H), 2.89 (s, 3H), 2.62 (s, 3H), 1.37 (dd, J = 6.3/13.2 Hz, 19H);
C NMR (100MHz, D2O) δ ppm 96.2, 96.1, 91.7, 91.3, 76.6, 76.3, 71.6, 71.4, 68.5, 68.4, 67.2,
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66.0, 65.8, 64.5, 64.4, 63.8, 63.8, 63.6, 63.5, 60.2, 60.1, 60.0, 59.9, 59., 33.66, 33.6, 33.4, 33.2,
20.4, 18.5, 18.4, 17.6, 17.5, 17.5, 17.4; HRMS (DART-TOF) m/z calcd for C10H21NO5 [M+H]+
236.1487, found 236.1627
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Compound 2.37 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00)
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.22 (dd, J = 3.5/9.2 Hz, 1H), 3.27-4.16 (m, 18H),
2.87 (d, J = 4.0 Hz, 6H), 2.06-2.28 (m, 6H), 2.03 (s, 2H), 1.75-1.9 (m, 5H), 1.6 (d, J = 12.8 Hz,
3H), 1.03-1.5 (m, 13H); 13C NMR (100MHz, D2O) δ ppm 96.3, 96.1, 91.7, 91.3, 76.6, 76.4, 71.6,
71.4, 68.5, 68.3, 67.0, 67.0, 66.7, 66.6, 66.1, 65.7, 64.3, 64.2, 63.7, 63.6, 63.5, 60.2, 60.1, 59.9,
33.4, 33.3, 33.2, 32.9, 29.4, 28.9, 28.8, 28.8, 27.9, 27.9, 27.8, 27.8, 24.5, 224.3, 24.0, 20.4;
HRMS (DART-TOF) m/z calcd for C13H25NO5 [M+H]+ 276.1800, found 276.1890
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Synthesis and characterization of one pot mixed alkylation

Compound 2.39: 2.6 (330 mg, 1.27mmol) along with vanillin (289.84 mg, 1.90 mmol, 1.5 eq.)
were dissolved in MeOH (6.35 mL, 0.2M). Solid NaCNBH3 (3 eq.) was added followed by the
addition of conc. AcOH (pH 4-5, ~8 drops). The reaction was stirred at rt and monitored by TLC
(25% EA:Hex). Upon consumption of the starting material acetaldehyde was added (0.25 mL, in
excess). Upon consumption of the intermediate, conc. HCl was added (1.5 mL) to bring the
solution to 2M in HCl and allowed to stir at rt overnight. Upon completion (TLC showing a single
spot at baseline with 1:1 EA:Hex), the aqueous solution was extracted with EtOAc (2 x 4 mL) to
remove any residual organic soluble impurities. The aqueous solution was then concentrated
under vacuum to yield the corresponding crude alkyl kanosamine hydrochloride salt. The crude
salt was then taken up in pyridine (5 mL) and an equal volume of acetic anhydride added (5
mL). Upon stirring overnight, the solution was quenched with water (1 mL), washed with sat.
bicarbonate (aq.) (3 x 4 mL), washed with water (2 x 3 mL), washed with brine, dried over
Na2SO4 and concentrated to a crude oil. The crude oil is purified by column chromatography
(10-25% EA:Hex) to yield 2.39 (562 mg, 80% over 4 steps, 57:43 α:β) as a yellow oil; 1H NMR
(400MHz, CDCl3) δ ppm 6.92 (dd, 2.2/8.1 Hz, 1.76H), 6.87 (d, 3.3 Hz, 1.8H) 6.79 (t, J = 7.6 Hz,
1.84H), 6.27 (d, 3.5 Hz, 1H), 5.62 (d, 7.6 Hz, 0.74H), 5.07-5.22 (m, 3.55H), 3.94-4.20 (m, 6.7H),
3.80 (t, J = 6.6 Hz, 6.35H), 3.54-3.75 (m.p., 3.5H), 3.37 (t, J = 10.6 Hz, 1H), 3.18 (t, J = 10.1 Hz,
0.74H), 2.59 (m, 3.8H), 2.28 (s, 6H), 2.59 (m, 3.8H); 13C NMR (100MHz, CDCl3) δ ppm 170.6,
169.5, 169.2, 169.0, 168.9, 150.9, 138.7, 138.5, 122.1, 121.0, 120.9, 112.9, 112.8, 93.1, 89.5,
74.1, 70.8, 69.1, 69.6, 66.3, 65.9, 62.4, 62.2, 62.0, 60.3, 58.0, 55.9, 21.0, 20.9, 20.8, 20.8, 20.7,
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20.6, 14.3, 14.3, 14.1; HRMS (DART-TOF) m/z calcd for C24H33NO11 [M+H]+ 512.2121, found
512.2140
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Synthesis and characterization of PGD and neamine compounds

Compound 2.43: 4 (840 mg, 3.45 mmol), was dissolved in pyridine (6 mL) and an equal volume
of acetic anhydride (6 mL) was then added. The solution was allowed to stir at rt overnight and
then quenched with water (1 mL), washed with sat. bicarbonate (aq.) (3 x 3mL), washed with
water (2 x 3mL), washed with brine (3 mL), dried over Na2SO4 and concentrated to a crude oil.
The crude oil was purified by column chromatography (15-40% EA:Hex) to yield 2.43 (1191 mg,
92%) yellow oil; 1H NMR (400MHz, CDCl3) δ ppm 6.16 (d, J = 3.18 Hz, 1H), 5.56 (d, J = 7.7 Hz,
0.83H), 4.88-5.05 (m, 4H), 4.06-4.16 (m, 2H), 3.90-4.06 (m, 4H), 3.65 (m, 0.83H), 3.05 (t, J =
10.85 Hz, 1H), 2.84 (t, J = 10.41 Hz, 0.87H), 2.27 (s, 12H), 1.92-2.02 (m, 23H); 13C NMR
(100MHz, CDCl3) δ ppm 170.5, 169.4, 169.2, 169.2, 169.0, 168.8, 92.9, 89.4, 73.9, 70.6, 68.2,
67.0, 65.6, 62.1, 62.0, 41.1, 41.0, 20.8, 20.7, 20.6; LRMS (ESI+) m/z calcd for C16H25NO9
[M+H]+ 376.16, found 376.5
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Compound 2.44: 2.43 (227 mg, 0.61 mmol), and 2-mercaptopyridine (101 mg, 0.91 mmol, 1.5
eq.) were dissolved in DCM (4 mL, dry). 4 Å mol sieves (0.1 g) were added and the solution
stirred for 30min. The solution was then cooled to 0 oC and BF3.Et2O (0.34 mL, 3.02mmol, 5 eq.)
was added dropwise. The solution was stirred at 0 oC for 20 minutes and then warmed to rt and
stirred overnight. Upon completion, the reaction was quenched and washed with sat.
bicarbonate (aq.) (2 x 2 mL), washed with water (2 x 2 mL), washed with brine, dried over
Na2SO4 and concentrated to a crude oil. The crude product was purified by column
chromatography (10-40% EA:Hex) to yield 2.44 (152 mg, 59%) as a semi solid oil; 1H NMR
(400MHz, CDCl3) δ ppm 8.39 (bs, 0.6H), 7.47 (dt, J = 1.4/8.1 Hz, 0.66H), 7.17 (d, J = 7.8 Hz,
0.61H), 7.00 (t, J = 5.5 Hz, 0.64H), 6.19 (d, J = 3.6 Hz, 1H), 5.62 (d, J = 10.4 Hz, 0.65H), 4.925.08 (3H, mp), 3.93, 4.08 (4H, mp), 3.72 (m, 0.68H), 3.08 (t, J = 10.5 Hz, 1H), 2.94 (t, J = 1.1
Hz, 0.63H), 2.32 (s, 3H), 2.30 (s, 6H), 1.93-2.05 (mp, 17H); 13C NMR (100MHz, CDCl3) δ ppm
170.6, 169.5, 169.4, 169.3, 169.2, 168.6, 156.1, 149.4, 136.4, 122.2, 120.5, 89.4, 83.0, 77.0,
70.6, 68.9, 67.6, 67.6, 65.2, 65.5, 62.5, 62.4, 62.2, 60.2, 41.2, 41.1, 21.1, 20.9, 20.8, 20.8, 20.6,
14.1; LRMS (ESI+) m/z calcd C19H26N2O7S [M+H]+ 427.15, found 427.50
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Compound 2.45: 2.43 (428 mg, 1.28 mmol) was dissolved in DCM (2.5 mL, dry). The solution
was cooled to 0 oC and a solution of HBr in AcOH (1.1 mL, 33 wt %HBr, 3.5 eq.) was added
dropwise. The cooling bath was removed and reaction stirred for 4hrs at rt. Upon completion the
reaction was pour over ice, and the organic fraction washed with sat. bicarbonate solution (4 x 2
mL), washed with water (2 mL), washed with brine, dried over Na2SO4 and concentrated to a
crude oil of 2.45 (300 mg, 60%). A portion of the product was purified by column
chromatography (10-30% EA:Hex) for characterization; 1H NMR (400MHz, CDCl3) δ 6.52 (d, J =
3.8 Hz, 1H), 4.94 (t, J = 10.8 Hz, 1H), 4.74 (dd, J = 3.9/10.8 Hz, 1H), 4.15 (dd, J = 4.5/12.5 Hz,
1H), 4.04-4.10 (m, 1H), 3.11 (t, J = 10.4 Hz, 1H), 2.27 (s, 6H), 2.01 (s, 3H), 1.97 (s, 3H), 1.96 (s,
3H); 13C NMR (100MHz, CDCl3) δ 170.2, 169.3, 169.1, 89.8, 72.9, 69.1, 64.5, 62.9, 61.5, 41.2,
20.8, 20.6, 20.5; LRMS (ESI+) m/z calcd C14H22BrNO7 [M+H]+ 397.0559, found 397.935
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Compound 2.46: 2.45 (99 mg, 0.25 mmol), Ag2CO3 (207 mg, 3 eq.), chloroethanol (68 µL, 4
eq.), 4 Å mol sieves, and a small I2 crystal were charged to a reaction vial covered in foil. DCM
(2.5 mL, dry) was added and the mixture stirred at rt overnight. Upon completion the reaction
was quenched with sat. bicarbonate (aq.) and the organic fraction washed with sat. Na2S2O3
(aq.) (2 x 1mL), water (2 mL), brine (2 mL), dried over Na2SO4 and concentrated to a crude oil.
Crude product was then purified by column chromatography (10-30% EA:Hex) to yield 2.46 (46
mg, 49%) as a yellow oil; 1H NMR (400MHz, CDCl3) δ ppm 6.22 (d, J = 3.9 Hz, 0.16H), 5.81
(oct. J = 4.9/10.4/16.4/21.4 Hz, 1H), 5.10-5.27 (multiple peaks, 2H), 4.96 (m, 2H), 4.41 (d, J =
7.7 Hz, 1H), 4.28 (dd, J = 4.3/12.8 Hz, 1H), 4.09 (m, 5H), 3.54 (oct., J = 2.7/5.1/7.9/9.6 Hz, 1H),
3.09 (t, J = 11.2 Hz, 0.16H), 2.80 (t, J = 9.8 Hz, 1H), 2.30 (s, 7H), 1.98-2.05 (m.p.,12H); 13C
NMR (100MHz, CDCl3) δ ppm 170.7, 169.4, 169.2, 133.6, 117.1, 100.7, 89.5, 73.1, 70.7, 69.4,
67.7, 66.3, 65.6, 62.4, 62.2, 73.1, 70.7, 69.4, 67.7, 66.3, 65.6, 62.4, 62.2, 60.3, 41.2, 21.1, 21.0,
20.7; LRMS (ESI+) m/z calcd C17H27NO8 [M+Na] 396.174, found 396.215
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Compound 2.47: 2.45 (97 mg, 0.25 mmol), Ag2CO3 (207 mg, 3 eq.), chloroethanol (67 µL, 4
eq.), 4 Å mol sieves, and a small I2 crystal were charged to a reaction vial covered in foil. DCM
(2.5 mL, dry) was added and the mixture stirred at rt overnight. Upon completion the reaction
was quenched with sat. bicarbonate (aq.) and the organic fraction washed with sat. Na2S2O3
(aq.) (2 x 1 mL), water (2 mL), brine (2 mL), dried over Na2SO4 and concentrated to a crude oil.
Crude product was then purified by column chromatography (10-30% EA:Hex) to yield 2.47 (45
mg, 46%) as a yellow oil; 1H NMR (400MHz, CDCl3) δ ppm 6.26 (s, J = 3.8 Hz, 1H), 5.51 (d, J =
7.7 Hz, 0.24H), 5.08-5.16 (m, 2H), 4.93-5.07 (m, 7H), 4.00-4.23 (m, 20H), 3.69-3.79 (m, 4H),
3.57-3.66 (m, 8.74H), 3.14 (t, J = 10.9 Hz, 1H), 2.86 (t, J = 10.7 Hz, 3H), 2.36 (s, 26H), 2.17 (s,
3H); 13C NMR (100MHz, CDCl3) δ ppm 170.7, 169.4, 169.3, 102.3, 89.5, 73.2, 70.7, 69.6, 69.2,
67.7, 66.9, 66.2, 65.6, 62.5, 62.5, 62.2, 42.6, 41.2, 42.1, 20.9, 20.7; LRMS (ESI+) m/z calcd
C16H26ClNO8 [M+Na] 418.135, found 418.035
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Compound 2.48: 2.45 (107 mg, 0.27 mmol), p-bromo benzyl alcohol (187 mg, 1 mmol, 4 eq.),
and 4 Å mol sieves were dissolved in DCM (2.7 mL, dry). The mixture was stirred for 30 min
followed by the addition of solid Ag2CO3 (224 mg, 0.813 mmol, 3 eq.). The vial was covered in
foil and the reaction stirred overnight. Upon completion the reaction was quenched and washed
with sat. bicarbonate (aq.) (2 x1 mL), water (2 x1 mL), brine (2 mL), dried over Na2SO4 and
concentrated to a crude oil. Crude product was purified by column chromatography (10-30%
EA:Hex) to yield 2.48 (75 mg, 55%) as a colorless oil; 1H NMR (400MHz, CDCl3) δ ppm 7.48 (d,
J = 8.4 Hz, 2H), 7.18 (d, J = 8.1 Hz, 2H), 5.06 (q, J = 7.6/10.4 Hz, 1H), 5.02 (t, J = 9.9 Hz, 1H),
4.83 (d, J= 12.5 Hz, 1H), 4.56 (d, J = 12.4 Hz, 1H), 4.45 (d, J = 7.4 Hz, 1H), 4.1-4.24 (m, 1H),
3.59 (oct., J = 2.5/5.3/7.8/9.5 Hz, 1H), 2.83 (t, J = 10.3 Hz, 1H), 2.36 (s, 6H), 2.10 (s, 3H), 2.06
(s, 3H), 2.05 (s, 3H); 13C NMR (100MHz, CDCl3) δ 169.4, 169.2, 136.1, 131.5, 129.2, 121.7,
100.5, 73.2, 69.5, 69.4, 67.0, 66.3, 62.6, 41.2, 21.1, 20.8; LRMS (ESI+) m/z calcd C21H28BrNO8
[M+Na] 524.099, found 523.939
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Compound 2.49: 2.45 (100 mg, 0.25 mmol), p-bromo benzyl alcohol (142 mg, 0.76 mmol, 4
eq.), and 4 Å mol sieves were dissolved in DCM (1.7 mL, dry). The mixture was stirred for 30
min followed by the addition of solid Ag2CO3 (209 mg, 0.76 mmol, 3 eq.). The vial was covered
in foil and the reaction stirred overnight. Upon completion the reaction was quenched and
washed with sat. bicarbonate (aq.) (2 x1 mL), water (2 x1 mL), brine (2 mL), dried over Na2SO4
and concentrated to a crude oil. Crude product was purified by column chromatography (1030% EA:Hex) to yield 2.49 (35 mg, 48%) as a colorless oil; 1H NMR (400MHz, CDCl3) δ ppm
7.41-7.49 (m.p., 2H), 7.23 (m.p., 2H), 6.28 (d, J = 3.8 Hz, 0.05H), 4.99-5.10 (m.p., 2H), 4.85 (d,
J = 12.8 Hz, 1H), 4.59 (d, J = 12.8 Hz, 1H), 4.46 (d, J = 7.8 Hz, 1H), 4.12-4.25 (m.p., 2H), 3.59
(oct., 2.6/5.2/7.8/9.6 Hz, 1H), 2.84 (t, J = 9.9 Hz, 1H), 2.37 (s, 6H), 2.12 (s, 3H), 2.09 (s, 3H),
2.06 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 100.6, 73.2, 69.4, 69.3, 67.0, 66.3, 62.6, 41.2,
29.6, 21.2, 21.0, 20.8; LRMS (ESI+) m/z calcd C21H28BrNO8 [M+Na] 524.099, found 524.175
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Compound 2.51 protected was prepared according to GP3 in 50% yield as mixture of
rotamers; 1H NMR (400MHz, CDCl3) δ ppm 7.49 (d, J = 8.5 Hz, 1H), 7.35 (d, J = 7.5 Hz, 1.3H),
7.18 (d, J = 8.5 Hz, 1H), 7.13 (d, J = 7.9 Hz, 1.3H), 6.96 (s, J = 1.2 Hz, 1H), 4.98-5.14 (m, 2H),
4.94 (d, J = 12.2 Hz, 0.66H), 4.84 (d, J = 12.4 Hz, 0.47H), 4.67 (d, J = 12.2 Hz, 0.66H), 4.534.60 (m, 1H), 4.46 (d, J = 7.5 Hz, 0.53H), 4.17-4.28 (m, 2H), 3.62 (m, 1H), 2.86 (q, J = 9.9/22.9
Hz, 1H), 2.39 (s, 3H), 2.37 (s, 3H), 2.35 (s, 3H), 1.99-2.14 (m.p.,15H); 13C NMR (100MHz,
CDCl3) δ ppm 170.5, 169.3, 135.9, 131.5, 129.3, 129.2, 128.0, 127.6, 100.8, 100.5, 73.2, 73.2,
70.4, 69.5, 69.4, 67.2, 66.4, 66.3, 62.7, 62.6, 41.2, 21.1, 21.0, 21.0, 20.8, 20.7; LRMS (ESI+)
m/z calcd C30H39NO8 [M+Na] 564.267, found 564.214
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Compound 2.51: 2.51 protected (8mg, 0.015 mmol) was dissolved in MeOH (0.2 mL), and 5.2
µL of NaOMe solution was added (0.5M in MeOH). Upon consumption of starting material by
TLC the reaction was quenched with acidic Amberlite resin (0.1 g). The mixture was filtered and
the resin washed with MeOH. The MeOH was then pooled and concentrated to yield 2.51 (5
mg, 82% as mixture of rotamers) as a colorless oil; 1H NMR (400MHz, CDCl3) δ 7.47 (d, J = 8.5
Hz, 0.67H), 7.38 (d, J = 9.0 Hz, 1H), 7.21 (d, J = 9.0 Hz, 0.63H), 7.12 (d, J = 8.5 Hz, 1H), 6.92
(s, 1H), 4.95 (d, J = 12.0 Hz, 0.48H), 4.84 (d, J = 12.5 Hz, 0.33H), 4.67 (d, J = 11.5 Hz, 0.5H),
4.57 (d, J = 11.5 Hz, 0.37H), 4.49 (d, J = 7.0 Hz, 0.5H), 4.39 (d, J = 8.5 Hz, 0.33H), 3.87-3.97
(m, 0.8H), 3.74-3.85 (m, 0.85H), 3.56-3.71 (m, 1H), 3.32- 3.43 (m, 1.5H), 2.49 (d, J = 4.3 Hz,
4H), 2.30 (s, 2H), 1.97 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 135.9, 135.2, 131.7, 129.7,
129.5, 128.1, 128.0, 103.7, 103.4, 71.6, 70.3, 70.2, 69.9, 66.2, 63.1, 41.6, 21.0, 20.7, 1.0; LRMS
(ESI+) m/z calcd C24H33NO5 [M+H]+ 416.24, found 416.50
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Compound 2.50 protected was prepared according to GP3 in 72% yield as a yellow oil; 1H
NMR (400MHz, CDCl3) δ ppm 7.41 (t, J = 7.4 Hz, 1H), 7.09 (m, 2H), 6.95 (s, 2H), 4.98-5.12
(m.p., 2H), 4.93 (d, J = 12.9 Hz, 1H), 4.67 (d, J = 12.9 Hz, 1H), 4.48 (d, J = 8.0 Hz, 1H), 4.104.23 (m.p., 3H), 3.57 (oct., J = 2.8/5.2/7.8/9.6 Hz, 1H), 2.83 (t, J = 10.4 Hz, 1H), 2.36 (s, 6H),
2.34 (s, 3H), 2.06 (s, 6H), 2.01 (s, 6H), 1.94 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 170.8,
169.4, 169.2, 141.2, 138.6, 137.1, 136.6, 135.7, 128.8, 128.6, 128.5, 128.0, 125.9, 100.3, 73.2,
70.2, 69.4, 67.1, 66.3, 62.7, 41.2, 21.0, 21.0, 20.7; LRMS (ESI+) m/z calcd C24H33NO5 [M+Na]
564.267, found 564.064
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Compound 2.52: 2.47 (44mg, 0.11mmol) was dissolved in DMF (0.5 mL). NaN3 (22 mg, 3 eq.)
was added and the reaction was heated and stirred at 100 oC under N2 atmosphere. Upon
consumption of starting material by TLC, the reaction was quenched with water (1 mL) and
extracted with DCM (3 x 1 mL). The organic fractions were pooled and washed with water (2
mL), brine (2 mL), dried over Na2SO4 and concentrated. The crude oil was purified by column
chromatography (10-30% EA:Hex) to yield 2.52 (18 mg, 42%) yellow oil; 1H NMR (400MHz,
CDCl3) δ ppm 4.95-5.02 (m.p., 2H), 4.67 (s, 0.4H), 4.48 (d, J = 7.5 Hz, 1H), 4.08-4.2 (m, 2H),
3.98 (m, 1H), 3.64-3.69 (m,1H), 3.6 (m, 1H), 3.40-3.50 (m, 1H), 3.29 (m, 1H), 2.84 (t, J = 10.2
Hz, 1H), 2.35 (s, 6H), 2.07 (s, 3H), 2.06 (s, 3H), 2.04 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm
170.7, 169.4, 169.3, 101.9, 73.2, 69.2, 68.0, 67.1, 66.3, 62.6, 50.6, 41.2, 21.1, 21.0, 20.8; LRMS
(ESI+) m/z calcd C6H26N4O8 [M+Na] 425.175, found 425.103
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Compound 2.53 protected: 2.52 (15 mg, 0.04 mmol) was dissolved in BuOH:H2O (1:1, 0.16
mL). CuSO4.5H2O (0.1 mg, 1mol %) and added along with sodium ascorbate (3.3 µL 1M aq.
Solution, 0.1 eq.). Phenyl acetylene (8.6 µL, 2 eq.) was then added and the reaction stirred at rt.
Upon completion the reaction was diluted with water (1 mL), extracted with EtOAc (2 x 2 mL),
organic fractions pooled and washed with brine (1 mL), dried over Na2SO4 and concentrated.
Purification by chromatography (70:25:5; Hex:EA:TEA) gave 2.53 protected (9.5 mg, 47%) as a
clear oil; 1H NMR (400MHz, CDCl3) δ ppm 7.86 (m.p. 3H), 7.40 (t, J = 8.0 Hz, 2H), 7.30 (t, J =
7.6 Hz, 1H), 4.91-5.02 (m, 2H), 4.67 (dt, J = 3.6/6.9/15.0 Hz, 1H), 4.45-4.53 (m, 1H), 4.33 (d, J =
7.9 Hz, 1H), 4.20-4.27 (m, 1H), 4.17 (dd, J = 5.3/12.1 Hz, 1H), 4.09 (dd, J = 2.0/12.2 Hz, 1H),
3.85 (dt, J = 2.3/9.2 Hz, 1H), 3.56 (oct., J = 2.5/5.4/7.7/9.8 Hz, 1H), 2.77 (t, J = 10.4 Hz, 1H),
2.30 (s, 6H), 2.05 (s, 3H), 2.02 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 170.7, 169.5, 169.4,
130.6, 128.8, 128.0, 125.7, 121.5, 101.7, 73.3, 69.1, 67.5, 66.8, 66.0, 62.4, 50.1, 41.2, 29.6,
21.0, 20.9, 20.7
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Compound 2.53: 2.53 protected (9.5 mg) was dissolved in MeOH (0.2 mL) followed by the
addition of NaOMe (846 µL, 25% solution in MeOH, 0.2 eq.). Upon consumptions of starting
material the reaction was quenched with Amberlite resin. The mixture was filtered and the resin
washed with MeOH. The MeOH was then pooled and concentrated to yield 2.53 (4.3 mg, 62%)
as a colorless oil; 1H NMR (400Mhz, CDCl3) δ ppm 8.45 (s, 1H), 7.84 (d, J = 7.3 Hz, 2H), 7.45
(t, J = 7.3 Hz, 2H), 7.36 (t, J = 7.6 Hz, 1H), 4.72 (t, J = 4.6 Hz, 2H), 4.40 (d, J = 7.8 Hz, 1H),
4.29-4.36 (m, 1H), 4.06-4.14 (m, 1H), 3.88 (dd, J = 2.4/12.1 Hz, 1H), 3.69 (dd, J= 5.6/11.8 Hz,
1H), 3.34-3.57 (m, 2H), 2.66 (s, 6H); 13C NMR (100MHz, CDCl3) δ ppm 128.5, 127.8, 125.2,
121.9, 104.0, 77.7, 70.4, 68.9, 67.7, 65.1, 61.1, 50.3, 40.7; LRMS (ESI+) m/z calcd C18H26N4O5
[M+H]+ 379.193, found 379.30
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Compound 2.40: Neamine hydrochloride (300 mg, 0.064 mmol) was dissolved in 8 mL H2O.
The freshly prepared TfN3 solution (8 mL) was then added along with MeOH (24 mL) and a
solution of CuSO4 (9.9 mg, 0.062 mmol, in 2 mL of 3:3:4 MeOH:H2O:TEA). The resulting
solution was stirred to 2 hrs and monitored by TLC. Upon completion the reaction was
quenched with solid NaHCO3 (800 mg). The organics were then distilled off and the resulting
aqueous mixture extracted with EtOAc (3 x 5 mL). The pooled organics were washed with
water, brine, dried over Na2SO4 and concentrated to a crude oil which was purified by
chromatography (25-50%EA:Hex) to yield 2.40 (166 mg, 61%) as a white solid; 1H NMR
(400Mhz, CDCl3) δ ppm 5.66 (d, J = 4.0 Hz, 1H), 4.19 (ddd, J = 2.4 Hz, 1H), 3.88 (dd, J = 9.1
Hz, 1H), 3.34-3.57 (m, 7H), 3.28 (t, J = 8.9 Hz, 1H), 3.14 (dd, J = 3.6 Hz, 1H), 2.26 (dt, J = 3.9
Hz, 1H), 1.43 (q, J = 12.3 Hz, 1H); 13C NMR (100Mhz, CDCl3) δ ppm 98.3, 79.6, 76.5, 71.8,
71.3, 70.8, 63.3., 60.4, 59.5, 31.8; HRMS (DART-TOF) m/z calcd for C12H18N12O6 [M+H]+
449.1359, found 449.1429
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Compound 2.41: To a solution of 2.40 (300 mg, 0.704mmol) and p-toluenesulfonic acid
monohydrate (67 mg, 0.352mmol) in dry ACN (2.6 mL, 0.27M) was added cyclohexone dimethyl
ketal (0.482 mL, 3.168 mmol) and the solution stirred overnight at rt. The reaction was
quenched with TEA (0.1 mL) and concentrated to a crude residue. The residue was then taken
up in EtOAc (5 mL), washed with water (3 mL), brine (3 mL), dried over Na2SO4 and
concentrated to a crude oil. The oil was purified by column (25-50% EA:Hex) to yield both
unreacted starting material (90 mg) as well as the 2.41 (152 mg, 43%, 61% BRMS) as a white
solid; 1H NMR (400Mhz, CDCl3) δ ppm 5.56 (d, J = 3.6 Hz, 1H), 4.02 (ddd, J = 2.4 Hz, 1H), 3.95
(t, J = 9.4 Hz, 1H), 3.83 (t, J = 9.4 Hz, 1H), 3.38-3.7 (m, 8H), 3.26 (dd, J = 3.4 Hz, 1H), 2.33 (dt,
J = 5.1 Hz, 1H), 1.32-1.78 (m, 16H); 13C NMR (100Mhz, CDCl3) δ ppm 113.8, 96.3, 79.3, 79.2,
77.0, 71.3, 71.1, 71.1, 62.6, 60.8, 57.1, 51.2, 36.2, 36.0, 33.7, 24.8, 23.7; HRMS (DART-TOF)
m/z calcd for C18H26N12O6 [M+H]+ 529.1985, found 529.2064
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Compound 2.42: Crude starting material (Diacetlyated 2.41, not shown) (200 mg) was
dissolved in dioxane/H2O (1:1, 1.8 mL). Glacial acetic acid (1.35 mL) was added and the
reaction refluxed at 65 oC overnight. Upon completion the reaction was quenched with sat.
NaHCO3 (aq.) (to basic pH), and extracted with EtOAc (3 x 4 mL). The pooled organics were
washed with sat. NaHCO3 (aq.) (4 mL), water (4 mL), brine (4 mL), dried over Na2SO4 and
concentrated to a crude oil. The oil was purified by chromatography (25-50%EA:Hex) to yield
2.42 (127 mg, 83% over two steps) as a white solid; 1H NMR (400Mhz, CDCl3) δ ppm 5.47 (t, J
= 9.7 Hz, 1H, t), 5.40 (d, J = 3.7 Hz, 1H), 5.05 (t, J = 9.7 Hz, 1H, t), 4.36 (m, 1H), 3.93 (bs, 1H),
3.62 (dd, J = 3.8 Hz, 1H), 3.2-5.9 (m, 9H), 2.35 (m, 2H), 2.09 (s, 3H), 2.05 (s, 3H), 1.54 (q, J =
9.7 Hz, 1H); 13C NMR (100Mhz, CDCl3) δ ppm 98.5, 82.6, 76.0, 75.5, 71.1, 69.4, 69.3, 61.6,
59.7, 58.6, 50.8, 30.8, 20.7, 20.6; HRMS (DART-TOF) m/z calcd for C16H22N12O8 [M+H]+
533.1570, found 533.1612
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Chapter 3

Iridium Catalyzed Hydrogenations to Access 2-substituted 1,4-benzodioxanes
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3.1. Introduction to catalysis

Defined as a substance that increases the rate of reaction without itself being
consumed, the field of chemistry would be unrecognizable without catalysts. Catalytic species
exist in many fields of study, including biological, inorganic, and organic chemistry. Biology has
made extensive use of catalysis in the form of proteins and enzymes which regulate and control
biological processes.1 So essential is catalysis to biological function, it is hard to imagine a
biological pathway that does not depend of some form of catalysis. Inorganic chemistry relies
heavily on catalysis as well. Illustrating the importance of catalyst development in inorganic
chemistry is the electrolysis of water.2 An attractive source of alternative energy production,
sustainable water splitting (to hydrogen and oxygen) remains a holy grail in the field. The
development and use of catalysts in synthetic organic chemistry has allowed novel bond
formations and access to selective confirmations otherwise inaccessible. Owning to the
powerful transformations that are allowed with catalysis, we have seen major strides in synthetic
methodologies in a short time frame. Of particular importance in the field of catalysis has been
the addition of hydrogen to an organic compound; catalytic hydrogenation.

3.2. Development of hydrogenation reactions

Hydrogenation is the earliest reported forms of catalysis in the field of synthetic
chemistry.3 In particular, the Pt catalyzed addition of hydrogen to oxygen being one of the first
know examples. This reaction was the basis of the commercialization of a lamp in the 1820s,
known as Dobereiners lamp. Named after the chemist who invented it, Johnan Wolfgang
Dobereiner, Zinc metal is reacted with dilute sulfuric acid producing hydrogen gas. The gas is
then funneled to a platinum sponge which catalyzes its reaction with atmospheric oxygen
yielding water and an illuminating flame in the process (Scheme 3.1).4
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Scheme 3.1. Hydrogenation of molecular oxygen

Marking a revolution in hydrogenation methodology was Paul Sabatier, who in the late
1800s discovered the first catalytic addition of hydrogen to yield hydrocarbons. The reaction,
now known as the Sabatier process reacts hydrogen with carbondioxide in the presence of Ni
catalyst to give methane gas and water (Scheme 3.2). The process is carried out at elevated
temperature and pressure (~40 oC), and is also known to be catalyzed by ruthenium on
aluminum oxide.5 This work later earned Sabatier a shared Nobel prize in chemistry in 1912.
The relevance of this process persists to this day, and its application is currently being applied
to space station technology in order to regenerate water from exhaled CO2 from astronaut
respiration.6

Scheme 3.2. Hydrogenation of carbon dioxide

What is arguable one of the most important catalytic hydrogenations to date, and
analogous to the aforementioned Dobereiner process, is the catalytic reaction of hydrogen gas
with nitrogen gas. Known as the Haber process, the fixation of nitrogen to form ammonia is
carried out by iron-based catalysts at elevated temperature and pressure (Scheme 3.3).7 The
process is historically of great importance in the agriculture sector, as it is used to produce
fertilizers. The fertilizers from this process, along with advancements in pesticides, have
quadrupled the productivity of agricultural land.8 Having such drastic impact on food production,
the process is thought to be a key factor in the human population explosion in the 20th century.9
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For his development of the process and its subsequent impact on human culture, Fritz Haber
was later awarded a Nobel prize in chemistry.

Scheme 3.3. Hydrogenation of molecular nitrogen

The examples given represent the earliest development of hydrogenation reactions,
and are limited to the addition of hydrogen to the simplest of substrates. Subsequent develop of
catalytic methodology in the following decades has led to the field of homogeneous catalysis
and the hydrogenation of much more complex organic compounds. In addition to complex
substrates, the ability to selectively reduce compounds to yield enantiomerically pure products
has been realized.

3.3. Homogeneous catalysis

Homogeneous catalysts are catalysts which dissolve in the reaction solvent along with
substrates. This property allows for a higher level of control over the reaction conditions and has
opened to door to asymmetric methodologies as well. Pioneering the field of homogeneous
catalysis was English chemist, Sir Geoffrey Wilkinson. His development of a coordination
complex between rhodium and triphenylphosphine in the 1960s marked a great advance in the
field.10 The complex, Wilkinsons catalyst, bears three triphenylphosphine ligands on a central
rhodium atom with a single chlorine atom attached to the metal center. Synthesis of which is
carried out by reacting rhodium (III) chloride with triphenylphosphine in refluxing ethanol.10,11

The catalyst is best known for its use in the hydrogenation of alkenes to give saturated
alkanes. Mechanistically, the catalyst undergoes a loss of one of its phosphine ligands and an
oxidative addition with molecular hydrogen follows. Complexation with alkene substrate is then
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accompanied by a hydride transfer and lastly a reductive elimination to yield the saturated
alkane and regeneration of the active catalyst (Figure 3.1).12

Figure 3.1. Mechanism for the hydrogenation of olefins by Wilkinsons catalyst12

While best known for use in hydrogenations, Wilkinsons catalyst is also shown to
catalyze other reactions such as hydroacylation, hydroboration, and hydrosilylation of alkenes.13
This catalyst, and its transformations, marked a large leap forward in the field of catalysis, and
the introduction of the use of phosphine ligands to transition metal complexes for the application
of catalysis.

Expanding the power of homogeneous catalysis was the development of asymmetric
methodologies. By use of chiral induction using enantiomerically pure ligands complexed to the
transition metals it is possible to influence facial selectivity and yield an enantiomerically
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enriched/pure product. This work was first developed by American chemist William Knowles in
the late 1960s when he developed the first asymmetric hydrogenation catalyst by replacing the
achiral triphenylphosphine ligands in Wilkinsons catalysts with chiral methyl-, phenyl-, isopropylphosphine ligands.14 The catalyst was effective at achieving a 15% ee on their test substrate
(Figure 3.2).

Figure 3.2. First asymmetric hydrogenation reaction14

Following these findings, the field of chiral metal centered ligands has since exploded
and has led to great advancements in synthetic chemistry. With the modest early selectivity of
15%ee subsequent ligands quickly drove selectivity to the high 90 ranges within a short period
of years.15

The applicability of these methodologies was immediate, and the first industrial
application of asymmetric hydrogenation was conducted by Knowles while working for
Monsanto, in the late 1970s, in the production to Parkinsons drug, L-DOPA.15,16 From achiral
starting material (LIII), Knowles made use of rhodium complexed with a chiral bidentate
phosphine ligand, (R,R-DIPAMP). Under hydrogen atmosphere, the reaction carried through
with excellent enantioselectivity to the biologically active isomer (Figure 3.3). For his
contribution to asymmetric catalysis and the synthesis of L-DOPA, Knowles later shared the
Nobel Prize in chemistry.15
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Figure 3.3. Asymmetric synthesis of L-DOPA15

From the above examples, one can see that the addition of the simplest atom,
hydrogen, can be a most powerful tool in chemical synthesis. With many early examples being
deemed worthy of a Nobel Prize. Doing so in an asymmetric fashion only adds to this power.
The utility of such reactivity has been used in the synthesis of many privileged structures in
medicinal chemistry, as shown in the L-DOPA example. One other such motif is that of 2substituted 1,4-benzodioxanes.

3.4. 2-substituted 1,4-benzodioxanes

The idea of privileged structures in medicinal chemistry has become an attractive
concept for drug discovery.17 Privileged structures are chemical scaffolds which through
diversification tend to show biological activity for a range of different biological targets. Along
with activity, such structures tend to display favorable pharmacological properties as well.17
These properties taken together, lead to compounds which are drug-like and amenable to
optimization efforts to enhance properties. Illustrative of this concept is that of 2-substituted 1,4benzodioxanes.

There are numerous examples of compounds with core benzodioxane structure that
have varying targets/activities (Figure 3.4). Of clinical importance it that of doxazosin (LIV), a
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chiral 1,4-benzodioxane based compound prescribed for hypertension and prostate
hypertrophy.18

Figure 3.4. Examples of chiral 2-substituted 1,4-benzodioxanes

Naturally, a great deal of effort has been expended at accessing this motif
synthetically, as its derivatives are promising medicinal candidates. Important to note, is that
one can observe the substituents at the 2-position varies greatly amongst the known
compounds. In particular, there are 2- alkyl, aryl, heteroaryl, and carboxyl compounds. This
variation at the chiral center presents itself as a truly difficult synthetic hurdle as most reactions
do not tolerate such broad substrate scope.

With such prized structures, work on their synthetic accessibility began in the early
2000s in the lab of Stephen Buckwald. In their approach, functionalized aryl halides are treated
with palladium to catalyze intramolecular etherification reactions (Figure 3.5).19 Employing an
achiral di-tert-butylphosphinobiaryl ligand, these reactions proceeded without enantioselectivity
to give rise to a number of unsubstituted benzodioxanes. Use of enantiomerically enriched
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alcohols as starting materials was found to be tolerated by the methodology and chiral products
were yielded without loss of optical purity.

Figure 3.5. Intramolecular etherification route to chiral 1,4-benzodioxanes19

Marking the first enantioselective process to access these chiral benzodioxanes was
the work by Larry Overmann and coworkers (Figure 3.6). By use of a phenolic (E)-allylic
trichloroacetimidate starting material (LV), in the presence of Colbalt Oxazoline Palladacycle
(COP) catalyst, the group was able to synthetically yield chiral 2-vinyl 1,4 benzodixoanes in the
80-90% ee range where the aryl group tolerated nominal substitutions.20 Significantly limiting
this methodology is the requirement of a difficult substrate and limited scope of only generating
a 2-vinyl 1,4-benzodioxane.

Figure 3.6. First enantioselective synthesis of chiral 1,4-benzodioxanes20
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Building on the president set by the Overman lab, a new palladium catalyzed
methodology was reported in 2015 by the Cai group (Figure 3.7).21 In their approach, Pd(OAc)
was complexed with a chiral spirodiphosphine monoxide ligand to form the active catalytic
species. The starting substrate being an aryl halide with a symmetric 1,3-propane diol moiety
(LVI). The reaction acts to form an O-aryl bond, with enantioselectivity, to give the 2hydroxymethyl 1,4-benzodioxanes in varying yield and high ee. While marking the first
enantioselective synthesis of chiral 1,4-benzodioxanes, the methodology is limited to the 2hydroxymethyl derivative and tolerates only simple aryl derivation.

Figure 3.7. Palladium catalyzed bidentate phosphine route to chiral 1,4-benzodioxanes21

Another intramolecular methodology which was being developed concurrently to that
of the Cai group was an intramolecular alkene aryloxyarylation reaction by the Tang group
(Figure 3.8).22 In this reaction, an olefinic starting material (LVII) is reacted with Palladium in the
presence of chiral phosphine ligand, of the (R)-AntPhos family, as well as an arylbromide. Chiral
induction lead to the aryloxyarylation taking place selectively to give chiral tertiary 1,4benzodioxane products in moderate to good yields and fairly decent selectivity. While an
elegant means of generating such compounds, the methodology is limited as it can only give
C2-tertiary products, and the substituents off this chiral center are limited.
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Figure 3.8. Palladium catalyzed route to chiral, tertiary 1,4-benzodioxanes22

The previous methodologies make use of palladium catalysts to facilitate
intramolecular cyclizations to form the heterocyclic core of the benzodioxanes. As alluded to in
the introduction, and of importance to our efforts, is that of asymmetric hydrogenation. To this
end, recent years have seen the report of two complimentary processes which make use of this
route.23,24

The group of Xumu Zhang first reported on a rhodium catalyzed asymmetric
hydrogenation using ZhoaPhos ligands (Table 3.1).23 Substrates for these transformations were
prochiral 2-substitiuted 1,4-benzodioxines. The transformations took place at 1 mol% Rh and
ligand loading with 10-30 atm H2 at rt. Both yields, and selectivity for the reactions were
excellent. However, the choice of rhodium, which is a metal center known to act via substrate
coordination, as well as ZhoaPhos, whose thiourea functionality takes part in hydrogen bonding
interactions with the substrate, the substrate scope is limited to compounds with polar functional
groups at C2.23 The high degree of selectivity observed is due to these substrate/catalyst
interactions, and while excellent with polar functional groups, selectivity is not retained for alkyl
and aryl derivatives.
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Table 3.1. Rhodium catalyzed asymmetric hydrogenation route to 1,4-benzodioxanes23

Analogous with the methodology by Xamu Zhang, a similar hydrogenation
methodology was reported around the same time detailing an iridium catalyzed asymmetric
hydrogenation technique (Table 3.2).24 This work, by the group of Wanbin Zhang, also utilized
prochiral 2-aryl 1,4-benzodioxine substrates. Using a torpos biphenyl phosphine-oxazoline
(BiphPHOX) ligand bearing a tetrakis(3,5-bis(trifluoromethyl)phenyl)borate (BArF) counter
anion, they showed the conversion of substrates to chiral 2-aryl 1,4-benzodioxanes in high yield
and moderate selectivity. By use of the ionic Ir/BiphPHOX/BArF catalytic system, the
methodology is applicable predominantly to non-polar functionalized substrates, as can be seen
from the substrate scope. The researches extended the scope to a single alkyl substrate, 2ethyl, and a drastic loss in selectivity was observed.
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Table 3.2. Iridium catalyzed asymmetric hydrogenation route to 1,4-benzodioxanes24

The above examples showcase different routes and invoke elegant chemistries to
access the core motif. However, each method suffers from a limitation in its scope of
substitution at C2. While numerous palladium-based techniques are known, they suffer from the
necessity for advanced substrates, and yield a narrow range of products. More recently, both
rhodium and iridium-based hydrogenation methods have been reported. These methodologies
show great promise in yielding enantiomerically pure products, however there use of catalytic
systems, including ligands, have narrowed their general applicability. This leaves a field where
there still exists a need for a general catalytic system which can furnish the desired chirality at
C2 of the 1,4-benzodioxane structure.

3.5. Project design

The aim of this project is to develop a synthetic methodology which allows formation of
enantiomerically pure 1,4-benzodioxanes. In particular, it is our goal to identify a general
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catalytic system which tolerates a broad scope of substituents at the C2 position. Building on
the previous work that has been conducted in this area, we propose to start with prochiral 2substituted 1,4-benzodioxines (Scheme 3.4).23,24 By asymmetric hydrogenation reaction
employing an Ir based catalyst system using bidentate chiral phosphine ligands we hope to
provide highly enantiomerically enriched products displaying alkyl, aryl, heteroaryl, and carbonyl
functionality at C2.

Scheme 3.4. General transformation from prochiral starting material

Where previous methodologies fell short, we hope the choice of Ir as the transition
metal coupled with neutral phosphine ligands will eliminate unwanted substrate coordination
and allow for a broadened substrate scope.

Synthesis of substrates for the project is envisioned to start from a common 2-bromo
1,4-benzodioxine intermediate. As the goal is to evaluate broad diversification at C2, it is
imperative that we can access the substrates in a simple manner. To do so, we will employ Pd
catalyzed Suzuki, Negishi, Kumada, and Carbonylation reactions to install aryl, heteroaryl, alkyl,
and carbonyl functionality.

3.6. Results and discussion

With the aim to begin with 2-substituted benzodioxine substrates, the first task was
synthesis of the common 2-bromo benzodioxine starting material (Scheme 3.5). This synthesis
commenced with the alkylation of catechol (and ortho methyl ester derivative) with allylbromide.
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Isomerization to the bis vinylic compounds (LV and LVI) was followed by RCM using Grela
nitro-aryl RCM catalyst to give unsubstituted 1,4-benozdioxine. Remarkably, the RCM reaction
was enacted using 150-300 ppm catalyst loading. Treatment with NBS, followed by E2
elimination via base addition gave rise to the desired 2-bromo 1,4-benzodioxine intermediates
3.1 and 3.2.

Scheme 3.5. Synthesis of 2-bromo 1,4-benzodioxine starting material

With access to the intended starting material, it was then necessary to test for a
catalytic system which would be appropriate for the asymmetric transformation. To this end, it
was theorized that if good enantioselectivity could be observed for a simple 2-alkyl derivative, as
a system had yet to be reported for, then the selectivity would likely extend to other substituents
at the C2 position. Thus, as a proof of concept, the 2-cyclopropyl ortho methylester derivative
(3.3) was screened against more than 20 commercially available bidentate phosphine ligands
using Ir[COD]Cl2 as the Ir source (Table 3.3). Reactions for ligand screening were conducted at
1 mol% Ir loading, 3 mol% ligand loading, 600psi H2, in THF/MeOH/AcOH at 50 oC for 24hrs.
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Table 3.3. Ligand screen on 2-cyclopropyl test substrate29

Results of the screen against commercially available ligands were lackluster. All
ligands provided less than excellent enantioselectivites (<90:10 er), and full conversion to
product (3.4) was not observed in any case. In light of these results, it was thought that the bisdihydrobenzooxaphosphole (BIBOP) type ligands could provide a better selectivity, as previous
studies had shown the ligands to provide a deep chiral pocket as well as steric tunability for
enatioinduction.25 As the steric bulk increased on the BIBOP ligand a general trend of increased
yield and enantioselectivity was observed (Table 3.4). Best results were found with the 2,6dimethoxyphenyl-substituted ligand (LXI). Displaying a 97:3 er and an isolated yield of 98%, this
ligand was selected to carry out the subsequent substrate scope studies.
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Table 3.4. Screen of BIBOP bidentate phosphine ligands on 2-cyclopropyl test substrate29

Having identified a viable catalytic system, attention turned to the synthesis of
substrates for the hydrogenation reaction. Firstly, a series of 2-alkyl substituted substrates (3.53.9) were synthesized via Negishi and/or Kumada coupling reactions (Table 3.5).
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Table 3.5. Synthesis of alkyl substrates for asymmetric hydrogenation

Difficulties in the synthesis of 2-alkyl derivatives limited the scope mostly to cyclic alkyl
compounds. Observed in many cases was the competing dehalogenation rather than alkyl
coupling (Figure 3.9). The non-polar nature of the products added the difficulty as desired
products would co elute with the dehalogenated product. This problem was particularly
troublesome in the synthesis of 2-ethyl derivative (3.5). As this was a valuable substrate to
compare to previous methodologies, efforts to separate the compounds were optimized and
pure 3.5 was obtained through analytical supercritical fluid chromatography.
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Figure 3.9. 2-ethyl substrate purification by analytical supercritical fluid chromatography

With alkyl substrates in hand, hydrogenation reactions were conducted (Table 3.6). We were
delighted to find that enantioselectivities were maintained to a high degree to yield compounds
3.10-3.3.14.
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Table 3.6. Asymmetric hydrogenation of 2-alkyl substrates

Cyclopropyl analog (3.6) gave similar selectivity, 94:6 er in 92% yield, as its methyl
ester derivative displayed in the initial test reaction. Additionally, the 4,6, and 7 member ring
derivatives (3.7-3.9) were transformed with excellent enantioselectivities as well (93:7-95:7 er).
For the 2-ethyl compound which presented itself as a benchmark for the methodology, a slightly
lower er was observed, 90:10. This was less than we had hoped, but represented a significant
improvement over the previously reported method, 74:26 er.24

Pleased with the selectivity on the challenging alkyl substrates we then turned our
attention to aryl and heteroaryl substrates. Synthesis of which was more easily obtained than
alkyls through Suzuki coupling procedures (Table 3.7).
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Table 3.7. Synthesis of 2-aryl and 2-heteroaryl substrates

Aryl/heteroaryl substrates were then subjected to hydrogenation conditions to obtain
the reduced, chiral products (3.37-3.54, Table 3.8). Selectivity and yields for this series were
excellent. The lowest observed selectivity was that of substrate (2.30) with a 94:6 er. For more
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sterically encumbered substrates such as dibenzofuran (2.35), dibenzothiophene (2.36), and
trimethoxyphenyl (2.28), er of >99:1 was observed. Importantly, many of the heterocyclic
derivatives, which have a high pharmaceutical relevance, were obtained in >98:2 er.
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Table 3.8. Asymmetric hydrogenation of 2-aryl and 2-heteroaryl substrates

174

Having confirmed selectivity across alkyl and aryl/heteroaryl substrates, it was then
desired to determine if the methodology could extend to benzodioxanes with polar coordinating
groups at C2. Synthesis of a series of substrates was then carried out from the 2-bromo
intermediates (Table 3.9). Pd catalyzed conditions, under CO atmosphere (50 psi), in the
presence of amine or alcohol (1.5 eq.) gave the corresponding 2-amide/ester compounds,
including a direct doxazosin precursor (2.54-2.61).

Table 3.9. Synthesis of 2-caboxyl substrates

Subjecting amide/ester substrates to hydrogenation conditions gave exciting results
(Table 3.10). Again, selectivity of >99:1 er was observed for the double methyl ester compound
(3.54). Single methyl ester compound (3.55) showed slightly lower selectivity of 95:5 er.
Pyrrolidine (3.56), morpholine (3.59), piperidine (3.60), phenylpiperazine(3.57), and
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tetrahydroisoquinoline (3.58) derivatives also displayed great to excellent selectivity (from 93:798:2). Of note, tetrhydroisoquinoline derivative (3.58) was reduced and isolated as a mixture of
two rotamers. More interesting yet, when analyzing specific rotation of the products, it was
found that the opposite stereochemistry was observed compared to the previous alkyl and aryl
series. A computation study was then initiated to gain understanding of the underlying
mechanism of stereoinduction leading to the observed products.

Table 3.10. Asymmetric hydrogenation of 2-carboxyl substrates

Previous studies on Ir-calalyzed hydrogenations suggest reduction occurs via
stepwise protonation-hydride transfer mechanism (Figure 3.10).27
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Figure 3.10. Proposed mechanism for hydrogenation by Iridium catalyst26

*Figure reproduced for use in this thesis with permission of publisher (The Royal Society of Chemistry)

In this model, protonation is thought to be the enantiodetermining step. Calculated
energy of the separated ion pair is much higher than the energy of the transition states for the
protonation or subsequent hydride transfer. This supports that facial selectivity is established by
the iridium catalyst during protonation, since transfer the opposite face is highly unfavorable
energetically. To better understand selectivity, this key protonation step was further analyzed. It
was found that protonation occurs via a Markovnikov process at C2, and this selectivity was
confirmed for both faces of the benzodioxine. This finding allows for the same model to be used
across our range of substrates. Proposed mechanisms for coordinating and non-coordinating
substrates are shown in figure 3.11.
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Figure 3.11. Proposed mechanism for coordinating and non-coordinating substrates26

*Figure reproduced for use in this thesis with permission of publisher (The Royal Society of Chemistry)

It was thought that different confirmations within these proposed mechanisms results
in the change in selectivity observed. Testing this idea, computation models were conducted on
the non-coordinating 2-methyl derivative and the coordinating 2-carboxymethyl derivative
(Figure 3.12). Analysis of route A protonation of 2-methyl derivative shows that the reaction
takes place on face A of the benzodioxine. Computational values predicted an 80:20 er whereas
the observed er was 90:10.

178

Figure 3.12. Computational analysis of non-coordinating 2-methyl substrate transition state26

*Figure reproduced for use in this thesis with permission of publisher (The Royal Society of Chemistry)

Analysis of route B protonation of 2-carboxymethyl derivative gave opposite selectivity,
with a computationally predicted er of 7:93 (Figure 3.13). This was in close agreement with the
experimentally observed 5:95 er for this compound.
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Figure 3.13. Computational analysis of coordinating carboxymethyl substrate transition state26

*Figure reproduced for use in this thesis with permission of publisher (The Royal Society of Chemistry)

3.7. Conclusion

We have demonstrated the development of a catalytic system, Ir/BIDIME-dimer, which
displays excellent enantioselectivity (>99:1) in asymmetric hydrogenation reactions to access a
broad range of chiral 2-substitiuted 1,4-benzodioxanes. Substrate scope was shown to tolerate
alky, aryl, heteroaryl, and polar carboxy (amide/ester) substrates with retained selectivity. This
represents a significant improvement over previously known methods. Complimentary
computation studies confirm that enantioselectivity is determined in the protonation step, and
that polar coordinating substrates (amides/esters) interact with the metal center to flip facial
selectivity and give opposite stereochemistry at the new chiral center.

180

3.8. Experimental
Synthesis of 2-alkyl substrates
GP7: General procedure for synthesis of 2-alkyl 1,4-benzodioxine substrates
A representative procedure is given for the synthesis of 2-aryl- or 2-heteroaryl-substituted 1,4Benzodioxines; Compound 3.8: To a suspension of methyl 2-bromo-1,4-benzodioxine-5carboxylate SI-2 (5.00 g, 18.4 mmol, 1 eq.) and t-Bu3PHBF4 (321 mg, 1.10 mmol, 0.06 eq.) in
THF (30 mL), Pd(OAc)2 (207 mg, 0.922 mmol, 0.05 eq.) and a solution of ZnBr2 (~30 wt%
solution, 2.49 g, 11.1 mmol, 0.6 eq.) was added. Cyclopropylmagnesium bromide (59.0 mL, 0.5
M in THF, 29.5 mmol, 1.6 eq.) was added dropwise over 1 h using a syringe pump while
maintaining the temperature at 20–25 °C. Reaction was monitored by HPLC. Once starting
material was consumed (total reaction time within 2 h), reaction was quenched with water (10
mL) and saturated aqueous ammonium chloride solution (50 mL) was added. The organic
layer was extracted with EtOAc (3 × 50 mL). The combined organic extracts were dried over
MgSO4, filtered through a short pad of silica gel, followed by copious EtOAc washes, and
concentrated in vacuo. Purification by column chromatography (elution gradient from 0–5%
EtOAc in hexanes) yielded compound 3.8 as a white solid (230 mg, 32% yield)

H NMR (500 MHz, CDCl3): δ 6.80–6.76 (multiple peaks, 2H), 6.65–6.59 (multiple peaks, 2H),
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5.69 (s,1H), 1.91-1.66 (multiple peaks, 6H), 1.31–1.13 (multiple peaks, 5H); 13C NMR (126 MHz,
CDCl3): δ 143.2, 142.8, 142.4, 123.6, 123.5, 120.7, 116.0, 115.7, 38.4, 29.6, 26.0, 25.6; HRMS
(DART): m/z calcd for C14H17O2 [M+H]+ 217.12231, found 217.12216
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Compound 3.9 was prepared according to GP7 with 2-bromo-1,4-benzodioxine (1.00 g, 4.69
mmol, 1 eq.) and cycloheptylmagnesium bromide (3.8 mL, 2.0 M in Et2O, 7.5 mmol, 1.6 eq.).
Purification by column chromatography using hexanes yielded as a colorless liquid (202 mg,
19%yield); 1H NMR (500 MHz, CDCl3): δ 6.80–6.75 (multiple peaks, 2H), 6.66–6.59 (multiple
peaks, 2H), 5.73 (s, 1H), 2.05 (m, 1H), 1.85-1.40 (multiple peaks, 12H); 13C NMR (126 MHz,
CDCl3): δ 143.2, 143.1, 142.8, 123.6, 123.5, 120.4, 116.0, 115.7, 40.3, 31.5, 28.3, 26.4; HRMS
(DART): m/z calcd for C15H19O2 [M+H]+ 231.13796 , found 231.13808.
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Synthesis of 2-aryl or 2-heteroaryl substrates
GP8: General procedure for Suzuki coupling reactions
A representative procedure is given for the synthesis of 2-aryl- or 2-heteroaryl-substituted 1,4benzodioxines: Compound 2.28; A 20 mL tube was charged with 2-bromo-1,4-benzodioxine
(700 mg, 3.29 mmol, 1 eq.), (3,4,5-trimethoxyphenyl)boronic acid (836 mg, 3.94 mmol, 1.2 eq.),
Pd2dba3 (75.2 mg, 0.0822 mmol, 0.025 eq.), cataCXium A (88.4 mg, 0.246 mmol, 0.075 eq.),
Cs2CO3 (3.21 g, 9.86 mmol, 3 eq.), and 1,4-dioxane (14 mL). The tube was sealed and heated
to 85 °C for 14 h. The reaction was diluted with EtOAc, filtered through a short pad of Celite,
followed by EtOAc washes, and concentrated in vacuo. Purification by column chromatography
(elution gradient from 0–10% EtOAc in hexanes) yielded compound 2.28 as an off-white solid
(615 mg, 62% yield).

H NMR (500 MHz, CDCl3): δ 6.90–6.81 (multiple peaks, 3H), 6.71 (m, 1H), 6.68 (s, 2H), 6.39
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(s, 1H), 3.89 (s, 6H), 3.86 (s, 3H); 13C NMR (126 MHz, CDCl3): δ 153.3, 142.7, 142.1, 138.3,
136.7, 126.9, 124.2, 124.1, 123.1, 116.4, 116.0, 100.8, 60.9, 56.2; HRMS (DART): m/z calcd for
C17H17O5 [M+H]+ 301.10705, found 301.10716.
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Compound 3.19 was prepared according to GP8 with methyl 2-bromo-1,4-benzodioxine-5carboxylate (1.00 g, 3.69 mmol, 1 eq.) and (6-(trifluoromethyl)pyridin-3-yl)boronic acid (916 mg,
4.80 mmol, 1.3 eq.). Purification by column chromatography (elution gradient from 0–20%
EtOAc in hexanes) yielded a white solid (842 mg, 68% yield); 1H NMR (500 MHz, CDCl3): δ
8.80 (d, J = 1.5 Hz, 1H), 7.92 (dd, J = 8.2, 1.7 Hz, 1H), 7.68 (d, J = 8.2 Hz, 1H), 7.45 (dd, J =
1.9/7.7 Hz, 1H), 7.00–6.94 (m, 2H), 6.77 (s, 1H), 3.90 (s, 3H); 13C NMR (125 MHz, CDCl3): δ
164.8, 147.4, 144.5, 142.7, 142.0, 133.9, 131.3, 129.6, 126.7, 125.8, 123.9, 121.4, 120.3, 120.2,
119.4, 52.4; HRMS (DART): m/z calcd for C16H11O4NF3 [M+H]+ 338.06347, found 338.06309.
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Synthesis of 2-carboxyl substrates
GP9: General procedure for the synthesis of 2-amide-1,4-benzodioxine substrates
A representative procedure is given for the synthesis of 2-carboxyl-substituted 1,4benzodioxines: Compound 3.56. A reaction tube was charged with Pd(OAc)2 (52.8 mg, 0.235
mmol, 0.05 eq.), Xantphos (203.53 mg, 0.35 mmol, 0.075 eq.), 2-bromo-1,4-benzodioxine (1.00
g, 4.69 mmol, 1 eq.), Na2CO3 (1.49 g, 14.1 mmol, 3 eq.), pyrrolidine (501 mg, 7.04 mmol, 1.5
eq.), and toluene (4 mL). The reaction was heated to 80 °C under CO (50 psi) for 12 h in
Biotage Endeavor reactor. The reaction was then diluted with EtOAc (20 mL), filtered through a
short pad of Celite, concentrated in vacuo, and purified by column chromatography (elution
gradient 10–20% EtOAc in hexanes) yielded 3.56 as a colorless solid (481 mg, 44% yield).

H NMR (500 MHz, CDCl3): δ 6.87–6.84 (multiple peaks, 2H), 6.78 (s, 1H), 6.71–6.66 (multiple
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peaks, 2H), 3.72 (br s, 2H), 3.54 (br s, 2H), 1.91 (br s, 2H), 1.88 (br s, 2H). 13C NMR (126 MHz,
CDCl3): δ 160.5, 142.2, 141.6, 133.4, 133.0, 124.8, 124.6, 116.5, 116.2, 47.7, 47.2, 26.6, 23.5;
HRMS (DART): m/z calcd for C13H14O3N [M+H]+ 232.09682, found 232.09684.
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Compound 3.60 was prepared according to GP9 with 2-bromo-1,4-benzodioxine (426 mg, 2.00
mmol, 1 eq.) and piperidine (255 mg, 3.00 mmol, 1.5 eq.). Purification by column
chromatography (elution gradient 10–20% EtOAc in hexanes) yielded a yellow oil (234 mg, 48%
yield); 1H NMR (500 MHz, CDCl3): δ 6.88–6.85 (multiple peaks, 2H), 6.71–6.67 (multiple peaks,
2H), 6.54 (s, 1H), 3.56 (m, 4H), 1.70–1.58 (multiple peaks, 6H); 13C NMR (126 MHz, CDCl3): δ
161.5, 142.1, 141.7, 133.2, 131.9, 124.7, 124.6, 116.5, 116.4, 45.9, 26.1, 24.6; HRMS (DART):
m/z calcd. for C14H16O3N [M+H]+ 246.11247, found 246.11253
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Compound 3.59 was prepared according to GP9 with 2-bromo-1,4-benzodioxine (1.00 g, 4.69
mmol, 1 eq.) and morpholine (613 mg, 7.04 mmol, 1.5 eq.). Purification by column
chromatography (elution gradient 10–30% EtOAc in hexanes) yielded a colorless solid (409 mg,
37% yield); 1H NMR (500 MHz, CDCl3) δ 6.89–6.86 (multiple peaks, 2H), 6.73–6.66 (multiple
peaks, 2H), 6.64 (s, 1H), 3.73–3.66 (multiple peaks, 8H); 13C NMR (126 MHz, CDCl3) δ 161.6,
141.8, 141.5, 133.1, 132.7, 124.94, 124.88, 116.6, 116.3, 66.9, 42.3; HRMS (DART): m/z calcd
for C13H14O4N [M+H]+ 248.09173, found 248.09180.
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Compound 3.57 was prepared according to GP9 with 2-bromo-1,4-benzodioxine (500mg,
2.35mmol, 1 eq.) and 1-phenylpiperazine (571 mg, 3.52 mmol,1.5 eq.). Purification by column
chromatography (elution gradient 10–25% EtOAc in hexanes) yielded the an off white solid (500
mg, 17% yield); 1H NMR (500 MHz, CDCl3) δ 7.29 (t, J = 7.8 Hz, 2H), 6.96–6.86 (multiple peaks,
5H), 6.73–6.69 (multiple peaks, 2H), 6.65 (s, 1H), 3.82 (t, J = 5.0 Hz, 4H), 3.23 (t, J = 5.0 Hz,
4H); 13C NMR (126 MHz, CDCl3) δ 161.6, 150.9, 141.9, 141.6, 133.0, 132.8, 129.3, 124.92,
124.85, 120.6, 116.7, 116.6, 116.4, 49.7, 44.6; HRMS (HESI): m/z calcd for C19H19O3N2 [M+H]+
323.13902, found 323.13881.
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Compound 3.58 was prepared according to GP9 with 2-bromo-1,4-benzodioxine (1.00 g, 4.69
mmol, 1 eq.) and tetrahydroisoquinoline (938 mg, 7.04 mmol, 1.5 eq.). Purification by column
chromatography (elution gradient 10–20% EtOAc in hexanes) yielded a colorless solid (283 mg,
21% yield); 1H NMR (500 MHz, CDCl3) δ 7.23–7.11 (multiple peaks, 4H), 6.91–6.86 (m, 2H),
6.74–6.70 (m, 2H), 6.65 (s, 1H), 4.76 (s, 2H), 3.86 (t, J = 5.8 Hz, 2H), 2.96 (t, J = 5.8 Hz, 2H);
C NMR (126 MHz, CDCl3) δ 161.0, 141.0, 140.6, 133.4, 132.0, 131.8, 131.7, 127.7, 125.7,
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124.4, 124.3, 123.9, 123.8, 115.5, 115.4, 45.6, 42.2, 28.0; HRMS (DART): m/z calcd for
C18H16O3N [M+H]+ 294.11247, found 294.11248.
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Compound 3.61 was prepared according to GP9 with 2-bromo-1,4-benzodioxine (1.00 g, 4.69
mmol, 1 eq.) and 4-amino-6,7-dimethoxy-2-piperazinyl-chinazolin (318.27mg, 1.1mmol, 1 eq.).
Purification by column chromatography (elution gradient 10–20% EtOAc in hexanes) yielded a
colorless solid (283 mg, 21% yield); 1H NMR (500 MHz, CDCl3) δ 6.92 (s, 1H), 6.88 (multiple
peaks, 2H), 6.82 (s, 1H), 6.71 (m, 2H), 6.65 (s, 1H), 5.22 (s, 2H), 3.97 (s, 3H). 3.93 (s, 3H), 3.97
(s, 3H), 3.93 (s, 3H), 3.91 (m, 4H), 3.73 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 161.7, 160.5,
158.5, 155.2, 149.8, 146.0, 141.9, 141.5, 132.8, 132.8, 124.9, 124.8, 116.5, 116.4, 105.8, 102.9,
101.1, 56.1, 56.0, 44.1, 29.6; HRMS (DART): m/z calcd for C23H23N5O5 [M+H]+ 450.17331,
found 450.17340
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A reaction tube containing methyl 2-bromo-1,4-benzodioxine-5-carboxylate (500 mg, 1.84 mmol,
1 eq.), Pd(OAc)2 (10.4 mg, 0.0461 mmol, 0.025 eq.), cataCXium A (49.6 mg, 0.138 mmol, 0.075
eq.) in MeOH (3 mL) was heated to 80 °C under CO (100 psi) for 16 h in Biotage Endeavor
reactor. At the end of the reaction, the reaction was concentrated in vacuo and extracted with
EtOAc (30 mL). The combined EtOAc extracts were concentrated in vacuo. Purification by
column chromatography (elution gradient 10–20% EtOAc in hexanes) yielded compound 3.54
as a white solid (310 mg, 67% yield); 1H NMR (500 MHz, CDCl3) δ 7.38 (dd, J = Hz, 1H), 7.01
(s, 1H), 6.97–6.90 (multiple peaks, 2H), 3.87 (s, 3H), 3.82 (s, 3H); 13C NMR (126 MHz, CDCl3) δ
164.6, 161.2, 142.8, 140.9, 135.6, 129.3, 126.4, 124.6, 120.6, 119.7, 52.4, 52.2; HRMS (DART):
m/z calcd for C12H11O6 [M+H]+ 251.05501, found 251.05514
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Reductions of 2-substituted 1,4-benzodioxine substrates
GP10: General procedure for asymmetric hydrogenations
A representative procedure is given for the asymmetric reduction of 2-substituted 1,4benzodioxines: A catalyst solution was prepared in a vial by mixing [Ir(cod)Cl]2 (1.3 mg, 0.0020
mmol, 0.01 eq.) and ligand LXI (4.3 mg, 91.6 wt%, 0.0060 mmol, 0.03 eq.) in THF (0.3 mL) for 5
min. 2-substituted benzodioxine substrate (0.200 mmol, 1 eq.), MeOH (0.3 mL), and AcOH
(0.46 mL, 8.0 mmol, 40 eq.) were added to the vial. The mixture was purged with N2 three times,
followed by H2 three times. The reaction was heated to 50 °C or 70 °C under 600 psi H2 and
stirred for 24 h. Upon completion, the reactor was vented and purged with N2 twice. The
reaction was concentrated in vacuo, loaded onto silica gel cartridge, and purified by column
chromatography. Enantiomeric ratios were determined by chiral SFC or chiral HPLC.

Compound 3.14 was prepared according to GP10 with substrate 3.5 (16.2 mg, 0.200 mmol, 1
eq.) at 25 °C. Conversion (>98%) to product was determined by HPLC. Due to the volatility of
the compound, only conversion is provided. NMR spectra were obtained after filtration through
silica gel pad using hexanes as eluent; 1H NMR (500 MHz, CDCl3): δ 6.89–6.80 (multiple peaks,
4H), 4.24 (dd, J = 2.0/11.2 Hz, 1H), 4.03 (m, 1H), 3.88 (dd, J = 8.0/11.2 Hz, 1H), 1.78–1.57
(multiple peaks, 2H), 1.07 (t, J = 7.6 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ 143.5, 143.3,
121.4, 121.1, 117.3, 117.0, 74.3, 67.8, 24.2, 9.4; The enantiomeric excess was determined by
chiral HPLC on CHIRALCEL OJ-3 column, 4.6 mm ID x150 mm L, 3 um particle size. The
compounds were eluted with 100% heptane. Column temperature 20 ºC; Flow rate 1.3 mL/min;
UV detection at 220 nm; tR= 5.67 min (major), 6.56 min (major); er 90:10
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Compound 3.18 was prepared according to GP10 with substrate 3.9 (52.0 mg, 0.227 mmol, 1
eq.) at 50 °C. Purification by column chromatography (elution gradient 0–2% EtOAc in hexanes)
yielded a colorless oil (49.8 mg, 95% yield); 1H NMR (500 MHz, CDCl3): δ 6.88–6.77 (multiple
peaks, 4H), 4.27 (m, 1H), 3.98–3.89 (multiple peaks, 2H), 1.91–1.42 (multiple peaks, 12H), 1.34
(m, 1H); 13C NMR (126 MHz, CDCl3): δ 143.9, 143.5, 121.3, 121.0, 117.3, 116.8, 77.3, 66.2,
40.5, 29.7, 29.2, 28.5, 28.4, 26.7, 26.5; HRMS (DART): m/z calcd for C15H21O2 [M+H]+
233.15361, found 233.15382; The enantiomeric excess was determined by chiral SFC on
Phenomenex Lux Cellulose-3 column, 4.6 mm ID x 100 mm L, 5 um particle size. The
compounds were eluted with CO2 (mobile phase A) and methanol (mobile phase B) using a
gradient. The gradient used was 1%B to 3%B in 3 min, 3%B to 50%B in 5 min,
hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 minutes). Column temperature
35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV detection at 220 nm; tR= 1.31 min
(minor), 1.42 min (major); er 93.2:6.8
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Compound 3.37 was prepared according to GP10 with substrate 3.19 (67.5 mg, 0.200 mmol, 1
eq.) at 70 °C. Purification by column chromatography (15% EtOAc in hexanes) yielded a white
solid (quantitative yield); 1H NMR (500 MHz, CDCl3): δ 8.80 (s, 1H), 7.97 (dd, J = 8.3/1.7 Hz,
1H), 7.77 (d, J = 8.1 Hz, 1H), 7.50 (dd, J = 1.4/7.8 Hz, 1H), 7.17 (dd, J = 1.4/8.1 Hz, 1H), 6.95 (t,
J = 7.9 Hz, 1H), 5.34 (dd, J = 1.9/8.5 Hz, 1H), 4.59 (dd, J = 2.4/11.6 Hz, 1H), 4.11 (dd, J =
8.5/11.6 Hz, 1H), 3.91 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 165.7, 148.7, 148.2, 143.5, 143.2,
135.5, 135.0, 124.6, 121.6, 121.3, 121.0, 120.6, 120.2, 72.1, 68.7, 52.2; HRMS (DART): m/z
calcd for C16H13O4NF3 [M+H]+ 340.07912, found 340.07913; The enantiomeric excess was
determined by chiral SFC on Phenomenex Lux Cellulose-4 column, 4.6 mm ID x 100 mm L, 5
um particle size. The compounds were eluted with CO2 (mobile phase A) and methanol (mobile
phase B) using a gradient. The gradient used was 1%B to 3%B in 3 min, 3%B to 50%B in 5 min,
hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 minutes). Column temperature
35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV detection at 220 nm; tR= 5.06 min
(minor), 5.35 min (major); er 99.1:0.9
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Compound 3.46 was prepared according to GP10 with substrate 3.28 (60.1 mg, 0.200 mmol, 1
eq.) at 50 °C. Purification by column chromatography (elution gradient 0–10% EtOAc in
hexanes) yielded a white solid (54.2 mg, 90% yield); 1H NMR (500 MHz, CDCl3): δ 7.00 (m, 1H),
6.94 (m, 1H), 6.91–6.87 (multiple peaks, 2H), 6.64 (s, 2H), 5.05 (dd, J = 2.2/9.0 Hz, 1H), 4.35
(dd, J = 2.2/11.4 Hz, 1H), 4.03 (dd, J = 9.0/11.4 Hz, 1H), 3.89 (s, 6H), 3.86 (s, 3H); 13C NMR
(126 MHz, CDCl3): δ 153.6, 143.8, 143.0, 148.4, 142.0, 121.7, 121.6, 117.6, 117.2, 103.6, 75.2,
69.4, 60.9, 56.2; HRMS (DART): m/z calcd for C17H19O5 [M+H]+ 303.12270, found 303.12278;
The enantiomeric excess was determined by chiral SFC on ChromegaChiral CCA column, 4.6
mm ID x 100 mm L, 5 um particle size. The compounds were eluted with CO2 (mobile phase A)
and methanol (mobile phase B) using a gradient. The gradient used was 1% B to 3%B in 3 min,
3%B to 50%B in 5 min, hold at 50% B for 1 min, then to 1% B in 1 min (analysis time 10
minutes). Column temperature 35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV
detection at 220 nm; tR= 3.98 min (minor), 4.33 min (major); er 99.2:0.8
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Compound 3.39 was prepared according to GP10 with substrate 3.21 (53.9 mg, 0.200 mmol, 1
eq.), 2 mol % [Ir(cod)Cl]2 and 6 mol % ligand at 70 °C. Purification by column chromatography
(60% EtOAc in hexanes) yielded a white solid (45.9 mg, 85% yield); 1H NMR (500 MHz, CDCl3):
δ 8.69 (s, 1H), 8.66 (d, J = 4.8 Hz, 1H), 7.76 (d, J = 7.9 Hz, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.38
(dd, J = 4.8/7.9 Hz, 1H), 7.15 (d, J = 7.9 Hz, 1H), 6.93 (t, J = 7.9 Hz, 1H), 5.23 (d, J = 7.4 Hz,
1H), 4.56 (dd, J = 1.9/11.5 Hz, 1H), 4.09 (dd, J = 9.1/11.5 Hz, 1H), 3.91 (s, 3H); 13C NMR (126
MHz, CDCl3): δ 165.9, 150.3, 148.1, 144.0, 143.3, 134.1, 131.7, 124.3, 123.7, 121.6, 120.8,
120.1, 72.7, 69.1, 52.1; HRMS (DART): m/z calcd for C15H14O4N [M+H]+ 272.09173, found
272.09174; The enantiomeric excess was determined by chiral SFC on Phenomenex Lux
Cellulose-3 column, 4.6 mm ID x 100 mm L, 5 um particle size. The compounds were eluted
with CO2 (mobile phase A) and methanol (mobile phase B) using a gradient. The gradient used
was 1%B to 3%B in 3 min, 3%B to 50%B in 5 min, hold at 50%B for 1 min, then to 1%B in 1 min
(analysis time 10 minutes). Column temperature 35 ºC; SFC back pressure 150 bar; Flow rate
3.0 mL/min; UV detection at 220 nm; tR= 4.57 min (minor), 4.16 min (major); er 99.0:1.0
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Compound 3.44 was prepared according to GP10 substrate 3.26 (48.4 mg, 0.200 mmol, 1
equiv), 2 mol % [Ir(cod)Cl]2 and 6 mol % ligand at 50 °C. Purification by column chromatography
(15% EtOAc in hexanes) yielded a white solid (24.4 mg, 50% yield); 1H NMR (500 MHz, CDCl3):
δ 8.58 (s, 2H), 6.98–6.88 (multiple peaks, 4H), 5.15 (dd, J = 2.1/8.3 Hz, 1H), 4.36 (dd, J =
2.1/11.5 Hz, 1H), 4.10 (dd, J = 8.3/11.5 Hz, 1H), 4.04 (s, 3H); 13C NMR (126 MHz, CDCl3): δ
166.0, 158.0, 143.1, 142.7, 123.5, 122.1, 122.0, 117.5, 117.3, 71.1, 68.3, 55.2; HRMS (DART):
m/z calcd for C13H13O3N2 [M+H]+ 245.09207, found 245.09225; The enantiomeric excess was
determined by chiral SFC on Phenomenex Lux Cellulose-3 column, 4.6 mm ID x 100 mm L, 5
um particle size. The compounds were eluted with CO2 (mobile phase A) and methanol (mobile
phase B) using a gradient. The gradient used was 1%B to 3%B in 3 min, 3%B to 50%B in 5 min,
hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 minutes). Column temperature
35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV detection at 220 nm; tR= 3.10 min
(minor), 3.67 min (major); er 97.7:2.3
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Compound 3.62 was prepared according to GP10 with substrate 3.54 (50.0 mg, 0.200 mmol, 1
equiv) at 50 °C. Purification by column chromatography (20% EtOAc in hexanes) yielded a
colorless oil (49.1 mg, 97% yield). 1H NMR (500 MHz, CDCl3): δ 7.44 (dd, J = 1.0/8.0 Hz, 1H),
7.17 (dd, J = 1.0/8.0 Hz, 1H), 6.91 (t, J = 8.0 Hz, 1H), 4.87 (dd, J = 3.0/5.1 Hz, 1H), 4.52–4.43
(multiple peaks, 2H), 3.88(s, 3H), 3.82 (s, 3H); 13C NMR (126 MHz, CDCl3): δ 167.9, 165.7,
143.4, 142.7, 124.3, 121.5, 121.1, 120.0, 71.5, 65.0, 52.9, 52.1; HRMS (DART): m/z calcd for
C12H13O6 [M+H]+ 253.07066, found 253.07074; The enantiomeric excess was determined by
chiral HPLC on Phenomenex Lux Cellulose-3 column, 4.6 mm ID x 150 mm L, 3 um particle
size. The compounds were eluted with 0.1% (v/v) HClO4 in water (mobile phase A) and
acetonitrile (mobile phase B) using an isocratic condition 80% A/20% B. Column temperature 25
ºC; Flow rate 1.5 mL/min; UV detection at 220 nm; tR= 12.7 min (minor), 11.3 min (major); er
99.9:0.1
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Compound 3.63 was prepared according to GP10 with substrate 3.55 (38.4 mg, 0.200 mmol, 1
equiv) at 50 °C. Purification by column chromatography (elution gradient 5–15% EtOAc in
hexanes) yielded a white solid (36.8 mg, 95% yield); 1H NMR (500 MHz, CDCl3): δ 7.00 (m, 1H),
6.92–6.86 (multiple peaks, 3H), 4.85 (t, J = 3.9 Hz, 1H), 4.39 (d, J = 3.9 Hz, 2H), 3.82 (s, 3H);
C NMR (126 MHz, CDCl3): δ 168.5, 142.9, 142.3, 122.2, 121.9, 117.4, 117.3, 72.0, 64.9, 52.8;
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HRMS (HESI): m/z calcd for C10H10O4 [M+H]+ 194.05736, found 194.05742; The enantiomeric
excess was determined by chiral SFC on Phenomenex Lux Cellulose-2 column, 4.6 mm ID x
100 mm L, 5 um particle size. The compounds were eluted with CO2 (mobile phase A) and
methanol (mobile phase B) using a gradient. The gradient used was 1%B to 3%B in 3 min, 3%B
to 50%B in 5 min, hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 minutes).
Column temperature 35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV detection at
220 nm; tR= 2.91 min (minor), 2.36 min (major); er 95.4:4.6
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Compound 3.14 was prepared according to GP10 with substrate 3.56 (46.3 mg, 0.200 mmol, 1
eq.) at 50 °C. Purification by column chromatography (elution gradient 10–30% EtOAc in
hexanes) yielded a colorless oil (43.3 mg, 93% yield). 1H NMR (500 MHz, CDCl3): δ 6.95–6.83
(multiple peaks, 4H), 4.76 (dd, J = 2.5/8.1 Hz, 1H), 4.47 (dd, J = 2.5/11.7 Hz, 1H), 4.33 (dd, J =
8.1/11.7 Hz, 1H), 3.76 (m, 1H), 3.62–3.52 (multiple peaks, 3H), 2.07–1.85 (multiple peaks, 4H);
C NMR (126 MHz, CDCl3): δ 165.0, 143.3, 142.8, 122.0, 121.5, 117.3, 117.3, 72.3, 65.1, 46.7,
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46.4, 26.3, 23.8; HRMS (DART): m/z calcd for C13H16O3N [M+H]+ 234.11247, found 234.11250;
The enantiomeric excess was determined by chiral SFC on ChromegaChiral CCC column, 4.6
mm ID x 100 mm L, 5 um particle size. The compounds were eluted with CO2 (mobile phase A)
and methanol (mobile phase B) using a gradient. The gradient used was 1%B to 3%B in 3 min,
3%B to 50%B in 5 min, hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10
minutes). Column temperature 35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV
detection at 220 nm; tR= 6.78 min (minor), 5.33 min (major); er 92.8:7.2
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Compound 3.67 was prepared according to GP10 with substrate 3.59 (49.5 mg, 0.200 mmol, 1
equiv) at 50 °C. Purification by column chromatography (elution gradient 10–30% EtOAc in
hexanes) yielded a colorless oil (46.5 mg, 93% yield); 1H NMR (500 MHz, CDCl3): δ 6.93–6.83
(multiple peaks, 4H), 4.81 (dd, J = 2.4/8.0 Hz, 1H), 4.49 (dd, J = 2.5/11.8 Hz, 1H), 4.34 (dd, J =
8.0/11.8 Hz, 1H), 3.83–3.67 (multiple peaks, 6H), 3.63–3.54 (multiple peaks, 2H); 13C NMR (126
MHz, CDCl3): δ 165.0, 143.3, 142.4, 122.4, 121.6, 117.5, 117.2, 70.6, 66.84, 66.77, 65.1, 46.3,
42.5; HRMS (DART): m/z calcd for C13H16O4N [M+H]+ 250.10738, found 250.10742; The
enantiomeric excess was determined by chiral SFC on Phenomenex Lux Cellulose-4 column,
4.6 mm ID x 100 mm L, 5 um particle size. The compounds were eluted with CO2 (mobile
phase A) and methanol (mobile phase B) using a gradient. The gradient used was 1%B to 3%B
in 3 min, 3%B to 50%B in 5 min, hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10
minutes). Column temperature 35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV
detection at 220 nm; tR= 5.74 min (minor), 5.08 min (major); er 98.2:1.8
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Compound 3.68 was prepared according to GP10 with substrate 3.60 (49.1 mg, 0.200 mmol, 1
eq.) at 50 °C. Purification by column chromatography (elution gradient 5–20% EtOAc in
hexanes) yielded a colorless oil (44.4 mg, 90% yield); 1H NMR (500 MHz, CDCl3): δ 6.93–6.83
(multiple peaks, 4H), 4.83 (dd, J = 2.5/8.2 Hz, 1H), 4.48 (dd, J = 2.5/12.0 Hz, 1H), 4.31 (dd, J =
8.2/12.0 Hz, 1H), 3.75–3.66 (multiple peaks, 2H), 3.53–3.44 (multiple peaks, 2H), 1.76–1.58
(multiple peaks, 6H); 13C NMR (126 MHz, CDCl3): δ 164.6, 143.4, 142.8, 122.1, 121.4, 117.3,
117.3, 70.7, 65.4, 46.8, 43.2, 26.6, 25.5, 24.5; HRMS (DART): m/z calcd for C14H18O3N [M+H]+
248.12812, found 248.12821; The enantiomeric excess was determined by chiral SFC on
Phenomenex Lux Cellulose-2 column, 4.6 mm ID x 100 mm L, 5 um particle size. The
compounds were eluted with CO2 (mobile phase A) and methanol (mobile phase B) using a
gradient. The gradient used was 1%B to 3%B in 3 min, 3%B to 50%B in 5 min,
hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 minutes). Column temperature
35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV detection at 220 nm; tR= 7.15 min
(minor), 5.20 min (major); er 97.5:2.5
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Compound 3.66 was prepared according to GP10 with substrate 3.58 (58.7 mg, 0.200 mmol, 1
equiv) at 50 °C. Purification by column chromatography (elution gradient 5–20% EtOAc in
hexanes) yielded a tan oil (48.5 mg, 82% yield) as a pair of rotamers (3:2); 1H NMR (600.04
MHz, DMSO-d6): δ 7.23–7.17 (m, 4H, rotamer 1+2), 6.96-6.91 (m, 0.6H, rotamer 1),
6.91-6.82 (m, 3.4H, rotamer 1+2), 5.33 (dd, J = 2.4/6.4 Hz, 0.4H, rotamer 2), 5.30 (dd, J =
2.3/6.4 Hz, 0.6H, rotamer 1), 4.86 (d, J = 16.3 Hz, 0.4H, rotamer 2), 4.81 (d, J = 16.3 Hz, 0.4H,
rotamer 2), 4.68 (d, J = 16.8 Hz, 0.6H, rotamer 1), 4.59 (d, J = 16.8 Hz, 0.6H, rotamer 1), 4.444.39 (m, 1H, rotamer 1+2), 4.24-4.18 (m, 1H, rotamer 1+2), 3.93-3.87 (m, 0.6H, rotamer 2),
3.83-3.77 (m, 0.6H, rotamer 2), 3.75-3.65 (m, 0.8H, rotamer 1), 2.94 (t, J = 6.0 Hz, 1.2H,
rotamer 2), 2.81 (t, J = 6.0 Hz, 0.8H, rotamer 1); 13C NMR (150.88 MHz, DMSO-d6): δ rotamer
1: 165.3, 143.0, 142.8, 134.3, 132.9, 128.5, 126.5, 126.5, 126.2, 121.5, 121.4, 117.0, 116.9,
69.8, 64.7, 43.9, 42.7, 28.8; rotamer 2: 165.2, 142.9, 142.8, 134.6, 133.3, 128.5, 126.6, 126.2,
126.2, 121.4, 121.4, 117.0, 116.8, 69.8, 64.6, 46.3, 40.0, 27.6. HRMS (DART): m/z calcd for
C18H18O3N [M+H]+ 296.12812, found 296.12814; The enantiomeric excess was determined by
chiral SFC on Phenomenex Lux Cellulose-3 column, 4.6 mm ID x 100 mm L, 5 um particle size.
The compounds were eluted with CO2 (mobile phase A) and methanol (mobile phase B) using a
gradient. The gradient used was 1%B to 3%B in 3 min, 3%B to 50%B in 5 min,
hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 minutes). Column temperature
35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV detection at 220 nm; tR= 4.93 min
(minor), 5.47 min (major); er 97.5:2.5
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Compound 3.65 was prepared according to GP10 with substrate 3.57 (64.5 mg, 0.200 mmol, 1
equiv) at 50 °C. Purification by column chromatography (elution gradient 5–15% EtOAc in
hexanes) yielded a colorless oil (54.6 mg, 84% yield); 1H NMR (500 MHz, CDCl3): δ 7.30 (m,
2H), 6.97–6.83 (multiple peaks, 7H), 4.88 (dd, J = 2.5/8.1 Hz, 1H), 4.52 (dd, J = 2.5/11.9 Hz,
1H), 4.36 (dd, J = 8.1/11.9 Hz, 1H), 3.98–3.90 (multiple peaks, 2H), 3.80–3.67 (multiple peaks,
2H), 3.32–3.12 (multiple peaks,4H); 13C NMR (126 MHz, CDCl3): δ 164.9, 150.9, 143.3, 142.5,
129.3, 122.3, 121.6, 120.8, 117.5, 117.3, 116.8, 70.7, 65.2, 50.0, 49.3, 45.7, 42.1; HRMS
(HESI): m/z calcd for C19H21O3N2 [M+H]+ 325.15467, found 325.15435; The enantiomeric
excess was determined by chiral SFC on ChromegaChiral CCC column, 4.6 mm ID x
100 mm L, 5 um particle size. The compounds were eluted with CO2 (mobile phase A) and
methanol (mobile phase B) using a gradient. The gradient used was 1%B to 3%B in 3 min, 3%B
to 50%B in 5 min, hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 minutes).
Column temperature 35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV detection at
220 nm; tR= 7.48 min (minor), 6.63 min (major); er 98.0:2.0
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